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A B S T R A C T
A high yielding synthesis of the acyclic precursor of the peni­
cillins, 6— (L—a—aminoadipyl)—L—cysteinyl—D—valine (LLD-ACV) was devel­
oped. Using this synthesis the isotopically enriched ACV peptides,
S-(DL-a—aminoadipyl)—L—cysteinyl—D— (3R)— [4-13C]—'valine and &—(L—12 - 
aminoadipyl)—L— [3-13c]—cysteinyl-D— [ 1SN]—valine were prepared. In 
an extension to this work the tetrapeptide, <5— (L—a—aminoadipyl)—L— 
cysteinyl—D—valylglycine (LLD-ACVG) was prepared.
A putative intermediate in the biosynthesis of isopenicillin N,
Af— [ 6— (L—a—aminoadipyl)—L—cysteinyl ]—A/—hydroxy—D—valine (LLD-AC( N-OH) V), 
was synthesised from Af—hydroxy—D—valine benzyl ester.
A cell-free system capable of converting <5— (L—a—aminoadipyl )—L— 
cysteinyl—D—valine to isopenicillin N was obtained from cultures of 
the cephalosporin producing fungus Cephalosporium acremonium CW19.
The cell-free system was used to test the importance of the above 
synthesised compounds in penicillin biosynthesis. A/— [ 6— (l—<*—amino­
adipyl )—L—cysteinyl ]-W—hydroxy—D—valine was shown not to be a sub­
strate for the enzyme "isopenicillin N synthetase" but to be a 
potent inhibitor of the LLD-ACV to isopenicillin N conversion. The
tetrapeptide, <S— (L—a—aminoadipyl )—L—cysteinyl—D—valylglycine, was 
found to be a weak inhibitor of this conversion.
The isotopically enriched ACV peptides were used to confirm the 
stereochemistry of the valine C3 centre in biosynthesised 6— (L—a— 
aminoadipyl)—L—cysteinyl—D—valine and to allow preliminary 13C n.m.r. 




























N -  [ S-( a— a m i n oadipyl) cysteinyl ]— /V-hydroxy valine 
<5— (a— ami n o a d i p y l ) cysteinylvaline
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N O T E S
1 21. The penam and cephem ring systems are numbered non-systematic- 








The abbreviated nomenclature and numbering of 6-lactam anti-
3biotics is discussed in detail by Brown
2. The synthesis and reactivity of B-lactams (azetidin-2-ones)
and the general chemistry of the 6-lactam antibiotics is introduced
only where relevant and is not fully reviewed. Excellent reviews 
4-23are available
I N T R O D U C T I O N
1
1 B I O L O G I C A L L Y  A C T I V E L A C T A M S :
D I S C O V E R Y  A N D  D R U G  D E V E L O P M E N T
1.1 THE PENICILLINS 17, 19-21, 24-28
In 1929 Alexander Fleming published a report in which he
described the "inhibitory, bactericidal and bacteriolytic properties" 
of "penicillin". A contaminating mould, on a Staphylococcus-seeded 
plate, lysed the surrounding Staphylococcus colonies. Fleming tent­
atively identified this mould as Peni ci 11 ium rubrum and noted that 
the filtrate, from seven day old nutrient broth cultures of P. rubrum 
had bactericidal properties. Fleming gave this active filtrate the 
name "penicillin" and made a number of important observations. 
"Penicillin" was found to be unstable at room temperature, to kill 
only growing staphylococci and to have negligible toxicity in animals 
and man (or, as Fleming noted, to be "no more toxic than the nutrient 
broth itself").
It was not until late 1937 that Florey and Chain, at Oxford, 
further investigated the lytic properties of "penicillin". Their 
initial assumption, based on Fleming's observations, that the active 
principle was a mould lysozyme was quickly dispelled. The active 
principle rapidly diffused through cellophane membranes indicating 
a low molecular weight compound. Early attempts to purify the 
compound were hampered by the small quantities of material produced, 
the elaborate purification procedure used, and the chemical instab­
ility of the material. Nevertheless by 1941 the value of penicillin 
in the treatment of infectious diseases had been successfully demon—
The economic problems faced by Britain during the war led to the 
establishment of a joint Anglo-American research and development
programme aimed at improving the fermentation yield of penicillin and
25elucidating its molecular structure
Coghill and co-workers at the Northern Regional Research Labora-
32-tories in Illinois were instrumental in securing the first objective 
All previous research had been carried out with surface cultures of 
PeniciIlium notatuin- The isolation of high producing mutants of 
Penici 11ium chrysogenum (from X-ray irradiation) which could be grown 
in submerged, aerated cultures, greatly increased the yield of peni­
cillin. The use of corn steep liquor in the culture medium, in place 
of the less readily available yeast extract,had an important impact on 
the structural studies taking place in both Britain and America.
36Apart from the low purity of the initially available penicillin ’
it soon became apparent that British and American scientists were not
studying the same compound. Inconsistent analytical and degradative
results were obtained in different laboratories. Eventually, however,
the degradative, synthetic and spectroscopic studies began to bear 
25 26 38fruit ’ ’ . The volume of work undertaken during this period
is difficult to summarize and only the degradative pathways important 
to the assignment of the penicillin structure are shown (Figure 1).
The discrepancy between the British and American results lay 
solely in the carboxylic acids isolated upon hydrolysis of the penillo- 
aldehydes (RC0NHCH2CH0 in Figure 1). In America phenylacetic acid 
was obtained, and at Oxford 2-hexenoic acid. Exhaustive as these 
studies were the available data allowed three possible structures; a 
fused B-lactam-thiazolidin® structure (l), a thiazolidine—oxazolone 




F I G U R E  1
'c o 2h
c o 2h /S




Although penicillin lacked the basic characteristics expected of
the thiazolidine-oxazolone (2) this was for some time the structure
most favoured by chemists. Evidence for the correct fused 8-lactam-
25thiazolidine structure (1) was obtained by workers at Merck who 
prepared a monocyclic 6-lactam (4) by Raney nickel desulphurization 
of penicillin G. (See Figure 2 )
CO, H
Finally, in 1945, X-ray chrystallographic analysis of penicillin
25provided conclusive proof of the structure and confirmed the rela­
tive stereochemical configuration of the asymmetric centres in the 
molecule. The structures of various penicillins, isolated and 
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F I G U R E  2
All the penicillins are side-chain acyl derivatives of a parent 
nucleus, 6-aminopenicillanic acid (6-APA) (6).
6
The production of penicillin G in corn steep liquor fermentations
39was due to the presence of 2-phenylethylamine . Supplementation of
the fermentation medium with phenylacetic acid further improved the
35yield of penicillin G . Subsequently more than one hundred different
penicillins were made by adding suitable side-chain precursors to the 
25 40—43culture medium ’ . Despite the large number of "biosynthetic"
penicillins, this method is of limited utility. Only derivatives of
44monosubstituted acetic acids are produced and, even then, not all
monosubstituted acetic acids are incorporated as some prove toxic to
the mould or are otherwise metabolized. Penicillin G and penicillin V
(5, R=PhOCH2— ) are the only therapeutically useful penicillins obtained 
45in this fashion
In 1957 workers at the Beecham Research Laboratories isolated
small amounts of 6-aminopenicillanic acid (6-APA) 47 (6) and
48 49isopenicillin N ’ (7) from the culture fluid of P . chrysogenum,
grown in the absence of side-chain precursors.
7
The action of bacterial, fungal or mammalian penicillin acylases
on penicillin G or penicillin V allowed efficient production of 
50-556-APA and thus the potential of 6-APA as a precursor for the
synthesis of penicillins with unnatural side-chains was quickly
realised. Chemical methods for producing 6-APA were developed
,  ̂ 20, 55, 56later
The availability of 6-APA allowed the chemical introduction of an
17 20 57almost infinite variety of acyl side-chains ’ ’ designed to
improve the characteristics of penicillin. These "semi-synthetic"
58penicillins display increased acid stability , allowing oral adminis-
58-79tration of the drug, and improved resistance to pencillinase enzymes
/ 4-u • • i -i • 59-61 , . 65-67 , . . ...(e.g. methicillin (8) and oxacillin (9) ). Acids or






Unlike penicillin G the "semi-synthetic" penicillins show activity 
against many gram-negative bacteria ^  ^  including Pseudomonas
aeruginosa, indole-positive Proteus, Serratia, Providentia and
r .. , . . 93-103 , . .... 80-85 . . ._.. 93-96L i t r o b a c t e r  species (e.g. ampicillm (10), carbemcillm
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Only an extremely small number of chemical modifications to the
basic acylated 6-aminopenicillanic acid structure (5) afford compounds
with useful anti-bacterial activity The most important
105examples are mecillinam (13) which is active against gram-negative
bacteria and penicillins in which the carboxyl group has been replaced
K C 4- +- I T  • -1- 106, 107 , .by a 5—tetrazolyl moiety (14) .
10
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1.2 THE CEPHALOSPORINS 19, 28, 108-110
Around the time that the structure of penicillin was being 
confirmed, Brotzu, in Sardinia, was studying the microbial flora of 
seawater near a sewage outlet. His search for antibiotic producing 
organisms led to the isolation of a fungus, similar to Cephalosporium 
acremonium, which inhibited the growth of both gram-positive and gram- 
negative bacteria. The filtrate from a particular strain of this 
fungus, grown in glucose-starch medium, was biologically active. A 
more active concentrate, obtained by ethanol precipitation of inactive 
materials, was used in the successful treatment of typhoid, paratyphoid 
A and B and brucellosis.
IllThis work was published in 1948 and in August or September
of that year a culture of the organism was sent to Florey at Oxford 
for further study.
C. acremonium, grown in submerged aerated cultures, was filtered 
and the filtrate extracted with butyl acetate. Following counter- 
current distribution, one major and four minor antibiotics were iso­
lated. The major component, cephalosporin P!, inhibited only certain
2_  115gram-positive bacteria and was, therefore, not responsible for
the wide spectrum antibiotic activity observed by Brotzu. Cephalos­







The culture filtrate, after butyl acetate extraction, contained
113 114an antibiotic substance ’ some 2-6 times more active than
penicillin G against gram-negative organisms. A partially purified 
sample of this material, called cephalosporin N, was obtained after
119charcoal and alumina chromatography and countercurrent distribution
The material was sufficiently pure to establish a molecular formula,
and to allow degradative analyses. Acid hydrolysis produced D-a-
120aminoadipic acid, D-penicillamine and C02 • The penillic acid
(16) was obtained after treatment with dilute acid (pH 2.7) and this,
along with other degradative results, confirmed the penicillin
121 121 structure (17). Cephalosporin N was identical to synnematin B ’







During purification of the penillic acid (16) by ion-exchange
chromatography, a new material, cephalosporin C, was isolated in 
123 124minute amounts ’ . Although cephalosporin C showed only about
10% of the activity of penicillin N against a variety of organisms, 
its resistance to penicillinase hydrolysis aroused immediate interest. 
Mice infected with penicillin-resistant staphylococci were effectively 
treated using this new antibiotic and, in the hope that more powerful 
antibacterial compounds could be produced, semi-synthetically 
(as had happened with the penicillins), research was undertaken to 
establish the structure of cephalosporin C.
127Initial degradative results suggested a similarity to
penicillin N. D-a- aminoadipic acid was obtained upon hydrolysis,
the infra-red spectrum showed a strong B-lactam carbonyl absorption
and valine was isolated after Raney nickel desulphurization and
hydrolysis. However, penicillamine was not detected, the isolated
valine was racemic and n.m.r. spectroscopy indicated the absence of
the gem dimethyl groups characteristic of the penicillins. Based on
109 128these and other results ’ , Abraham and Newton proposed the
129fused 6-lactam—dihydrothiazine structure (18) for cephalosporin C
130 131This structure accounted for the UV absorption maximum at 260nm ’
132and subsequently was confirmed by X-ray analysis
13





To parallel the work undertaken on the penicillins, 7-amino- 




7-ACA had not been detected in the culture fluid of cephalosporin
C producing organisms, and attempts to remove the D-a-aminoadipyl side-
133—138chain enzymically proved unsuccessful . 7-ACA could be pro-
126 139duced by hydrolysis or acidolysis of cephalosporin C but only
in poor to moderate yields.
The first practical preparation of 7-ACA involved imine formation 
2and hydrolysis (Figure 3). The diazonium salt, generated in the 
presence of nitrosyl chloride and formic acid, is attacked intra- 
molecularly by the amide carbonyl with elimination of nitrogen.
The resultant imine is readily hydrolysed to afford 7-ACA in 40-50% 
overall yield.
A variety of methods for the preparation of 7-ACA, using this
55 140general strategy, have been introduced ’ . Reaction of ¿V,
AH?hthaloylcephalosporin C dibenzhydryl ester with phosphorus
pentachloride and methanol affords an imino ether, from which 7-ACA
141can be obtained in over 80% yield . Further improvements in
yield are achieved using the trimethylsilyl ester derivatives of
142cephalosporin C or /V, /V—phthaloylcephalosporin C
15










F I G U R E  3
More potent antibiotics could now be prepared by acylation of
7-ACA. However, a problem for the pharmaceutical industry was the
supply of cephalosporin C. Even the most efficient industrial strains
of C. acremonium produced cephalosporin C in only small amounts and,
143until recently , its extraction and purification had been time- 
consuming and wasteful.
A possible solution to this problem lay in the chemical conver­
sion of cheap, available penicillin V or penicillin G to cephalosporin 
144C derivatives . The conversion of the penam to the cephem nucleus
involves a Pummerer reaction on penicillin V (S)—sulphoxide methyl
ester, to give 7—phenoxyacetamido—3'—deacetoxycephalosporanic acid 
145-148methyl ester (20). Use of pyridine-phosphate buffers in
149 150dioxane ’ allowed conversions in the order of 90% (Figure 4).
This rearrangement involves a thermal ring opening of the peni­
cillin sulphoxide, with subsequent re-closure of the intermediate
-i . . , 21, 144, 145 _.sulphenic acid (Figure 5).
16
Selective oxidation of 7—phenoxyacetamido—3' —deacetoxycephalos-
151poranic acid methyl ester (20), or better the 2, 2, 2-trichloroethyl
152ester , can produce the 3'—acetoxy derivatives (21).
As acylase enzymes can remove the phenoxymethyl side-chain 134, 
a steady supply of 7-ACA and analogues became available for semi­
synthetic studies. Chemical acylation of 7-ACA did indeed lead to
the production of cephalosporins with improved antibacterial charac-
, . , . 58, 153teristics
The ready displacement of the 3' acetoxy group by N and S
17





_C pyridine phosphate 
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nucleophiles had been accidentally achieved in early experiments 154
As a result, the potential number and variety of cephalosporin 
analogues increased dramatically and led to the development
of a large number of therapeutically useful cephalosporins 155-157
. . ,  ̂ 109, 158-162The first commercial cephalosporin was cephalothm
(Figure 6) which possesses a broad spectrum of activity and stability
. n ■ 109, 162-168to staphylococcal penicillinase. Cephalondme , with
similar characteristics, was patented in 1965, followed by cefamandole
169-171 . 172-174 . . . .and more recently cefotaxime which is resistant to
g-lactamase hydrolysis (Figure 6). Research on the cephalosporins
175 176continues today. Ceftazidime ’ (Figure 6), a broad spectrum
antibiotic active against Pseudomonas spp and with good 3—lactamase 
stability has recently been introduced by Glaxo.
All the clinical cephalosporins mentioned above lack oral activity
and have to be administered by injection. While this is generally
true of the cephalosporins, cephalexin 162, 168, 177-181 , cefadroxil
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As with the penicillins, only acylation of 7B-aminocephalosporanic 
acid (19) produces biologically important compounds. Epimerization 
at the 7 position or introduction of other chemical groupings generally 
results in the loss of antibiotic activity.
Greater scope for variety exists at the 3 position where a sub­
stituted methylene is not essential for activity. Directly bonded
methoxy, chloro or bromo derivatives can show enhanced antibacterial
_ 188-190 n 189, 191activity and clinical potential, e.g. cefaclor
(Figure 6). Key intermediates in the synthesis of these compounds
188-190 192-197are the 3—methylenecephams ’ (22) which are conveniently
prepared from penicillin sulphoxides.
22
A most promising recent development has been the synthesis of
i v, i • 198-200 , . ^  -1-oxacephalosponns which are some 4-10 times more active
than their cephalosporin analogues. 1-oxacephalosporins, and others,
have become known as "New Generation" B-lactam antibiotics. They
display exceptional activity against many gram-negative organisms,
including E. c o h , K lebsiella , Enterobacter, Serratia, Providencia, 
Citrobacter and Proteus spp.
2 0 1 , 2021.3 THE CEPHAMYCINS
The discovery of the cephalosporin B-lactam antibiotics and
scattered literature reports of various penicillin producing organ- 
26 203isms ’ prompted the major drug companies to undertake extensive
screening programmes to identify novel 3-lactam antibiotics and to 
isolate high producing strains of the known antibiotics.
From an initial total of 1852 cultures, workers at Lilly Research
Laboratories selected two strains of Streptorryces, S. lipmanii and a
204new strain S. clavuligerus, foe further study . Three new anti­
biotics were obtained from the culture media following chromatographic 
separation and purification over charcoal, ion-exchange resin,
Sephadex G-25, silica and microcrystalline cellulose. The physical- 
chemical properties of all three substances were similar to those of 
cephalosporin C. Acid hydrolysis produced D-a-aminoadipic acid, the 
UV spectra showed absorption maxima around 260nm and the i.r. spectra 
indicated the presence of 8-lactam carbonyls. High resolution mass 
spectral analysis of /V-acyl, dimethyl ester derivatives and n.m.r. 
studies on the parent systems confirmed the structures to be
7a-methoxycephalosporin C, O-carbamoyldeacetylcephalosporin C and
2050-carbamoyl-7a-methoxydeacetylcephalosporin C (cephamycin C)
(Figure 7). Both cultures also produced penicillin N.
At the same time, Merck scientists isolated and characterized
the antibiotics cephamycin A, B and C from Streptorryces spp. 206-209
(Figure 7). Characterization of the cephamycins was followed by 
210-218  ̂ _reports of other naturally occurring cephalosporin deriva­
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F I G U R E  7
24
The 7ot-methoxy function of the cephamycins greatly increases the
220stability of these antibiotics to g-lactamase hydrolysis 
Although the natural cephamycins are not particularly potent anti­
microbial agents they possess a slightly expanded spectrum of activity 
and significant effort has been expended in the synthesis of more 
potent analogues.
221 222 223Side-chain cleavage ’ and exchange of the naturally
occurring cephamycins has been carried out, but a more viable route
to side-chain modified cephamycins has been direct 7a—méthoxylation 
224-229of cephalosporins . A number of modified cephamycins have
, , 155, 221, 223, 230 _  . ^been prepared and are active against many cephalos­
porin resistant strains of Enterobacter> Klebsiella> Proteus morganii
(24) are the only semi-synthetic cephamycins undergoing clinical eval­
uation .
and S e r r â t i a ■ As yet cefoxitin 156, 231-233 (23) and cefotetan 234, 235
I
H O H
/ C H 3
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c o 2h
23
/ C H 3




Shionogi scientists have combined the advantages of a 7a-methoxy 
group and a 1-oxacephem nucleus in the synthesis of a highly effective
cephamycin analogue, moxalactam 155, 157, 200, 236-238 (25) .
'CH<












1.4 OTHER NATURALLY OCCURRING 6-LACTAM ANTIBIOTICS
In recent years whole new families of B-lactam antibiotics have 
been isolated. Extensive screening programmes, using "super-sensi­
tive" bioassay methods, have facilitated these discoveries and, though
only a brief discussion is included here, a comprehensive review is 
199available
1.4.1 The Clavulanates
One of the first families of new B-lactam antibiotics to be dis­
covered were the clavams of which clavulanic acid (26) is the most





Although only a weak antibiotic, clavulanic acid is a potent, 
irreversible inhibitor of many B-lactamases. Against penicillin 
resistant Staphylococcus aureus, the MIC value for ampicillin is 
reduced twenty-five thousand fold in the presence of 5 Mg/ml of 
sodium clavulanate. These results have prompted the development of 
a clavulanic acid-amoxycillin "cocktail" for the treatment of peni­
cillin resistant infections.
The biosynthesis of clavulanic acid is quite different from that
of the penicillins and cephalosporins (see Section 3). Both glycerol
241and a-amino-6-hydroxyvalerate are efficiently incorporated (Figure 8).
c h 2oh OH c o 2h
O
c h 2o h ■> +
c h 2o h
c = c h 2
n h 2 n h 2
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1.4.2 The Nocardacins
The nocardacins, isolated from DJocardis uniform!s subsP •
tsu y a m en en s is , were the first monocyclic 3-lactam antibiotics
(Figure 9). Nocardacins possess activity against only gram-negative
bacteria, especially P. aeruginosa, Proteus and Neisseria, with nocar-
dacin A being the most potent. Surprisingly the in vivo  protection
of mice from experimental infections was much greater than the in vitro
results suggested. It is believed that the bacterial cell wall is
modified by the nocardacin antibiotic in such a manner as to enhance
199the sensitivity of the bacterium to phagocytosis . It is interest-
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The biosynthetic origin of the nocardacins has been studied 244, 245 
and appears to involve a peptidal intermediate. L-methionine,
L-serine and L-p-hydroxyphenylglycine are all precursors (Figure 10).
Ring closure of serinyl peptides to B-lactams has been achieved













































By far the largest group of new 6-lactam antibiotics are the 
carbapenems. Over forty naturally occurring derivatives are known. 
Carbapen—2—em 3-carboxylic acid (28), the parent nucleus for all the





The more highly functionalised members of this group have almost
all been isolated from Streptonyces spp. and are structurally very
199similar, bearing substituents at the C2 and C6 positions (Figures
11-16).
In thienamycin and related compounds (Figures 11 and 12) the
6-lactam ring substituents are trans orientated. This previously
unknown stereochemistry and the R configuration of the hydroxyethyl
side-chain are responsible for the 6-lactamase stability of these 
267compounds
In general carbapenems are effective 6-lactamase inhibitors and/ 
or powerful antibiotics. Thienamycin is perhaps the most potent 
wide-spectrum antibiotic known. Gram-positive and gram—negative 
organisms, resistant or otherwise to ampicillin and cephalothin,
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anaerobic B a c t e r o i d e s are all extremely sensitive to thienamycin and





Results in man unfortunately are much less satisfactory due to 
renal metabolism of the compounds. A mammalian enzyme, dehydro­
peptidase I, rapidly hydrolyses the 8-lactam ring of carbapenem anti-
N— formimidoyl thienamycin (29) has therefore required co-administra­
tion of a dehydropeptidase I inhibitor.
Few biosynthetic results have been reported for the carbapenems
though the apparent precursors of thienamycin are glutamic acid,
cysteine and acetate. In contrast numerous total or partial syntheses
of carbapenems and their precursors have been reported. The various
270synthetic strategies employed have been reviewed
biotics 269 Therapeutic evaluation of Merck's semi-synthetic
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1.4.4 The Monobactams
The most recently discovered family of B-lactam antibiotics, the
monobactams 271-277 , have been isolated from bacteria. The mono-
bactams are monocyclic and possess a novel sulphamate grouping 
(Figure 17).
The antibacterial activity of the natural monobactams is restricted 
to gram-negative organisms and is much less than that of ampicillin. 
However, as with the cephamycins, the 3a-methoxy group confers 8-lacta­
mase stability. A highly potent, totally synthetic analogue, azthreo- 
278 279nara ’ (30), has been prepared and is undergoing clinical trials.
Azthreonam is specifically active against aerobic gram-negative bacteria 
including Pseudomonas aeruginosa. The 4a-methyl group of azthreonam
270
protects the antibiotic from 8-lactamase hydrolysis
No biosynthetic studies on the monobactams have been published 
though the amino-acids, alanine, glutamic acid, phenylalanine and/or
serine may form the 8-lactam ring, in a manner analogous to nocardacin 
biosynthesis, and that the immediate precursor may be a peptide as in 
the biosynthesis of penicillins, cephalosporins and nocardacins.
30













As illustrated in this section the last decade has seen an 
explosive increase in the number of "non-classical" B-lactam anti­
biotics. Not only are their structures diverse but their natural 
sources have descended the evolutionary ladder from fungi to actino- 
mycetes to bacteria. There seems little doubt that many other 
B-lactam compounds are present in nature and wait only to be dis­
covered.
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2. B A C T E R I C I D A L  M O D E  O F  A C T I O N
Although most studies have employed penicillins, all B-lactam
antibiotics are bactericidal because they interfere with bacterial
,, , . .. . 20, 58, 280-282cell wall biosynthesis
283—286The bacterial cell wall contains many materials including
teichoic acid, lipopolysaccharide and peptidoglycan , a multi­
ply cross-linked macromolecule which gives the cell rigidity and shape 
and protects the delicate semi-permeable cytoplasmic membrane from the 
potentially destructive high internal osmotic pressure.
The structure of peptidoglycan has been determined and, though 
differing in detail from species to species, can generally be repre­
sented by the Staphylococcus aureus structure proposed by Wise and 
289 290Park ’ (Figure 18). A polysaccharide backbone of alternating
8—1, 4—linked, D-hV—acetylglucosamine and A/-acetylmuramic acid moieties
is cross-linked by peptide chains bound tothemuramic acid carboxyls.
This cross-linking is accomplished by attack of a — (Gly)s chain on
the terminal D-ala—D—ala residue of a neighbouring pentapeptide,
291 292forming a new gly—D—ala bond and displacing D—alanine ’ (Figure 19)
The enzymes responsible for the final cross-linking of the pep-
289 293 294tide chains are inhibited by 8-lactam antibiotics ’ ’
Transpeptidases, D—alanine carboxypeptidases and endopeptidases are 
all inhibited, reversibly or irreversibly, by acylation at or near 
their active sites Ring strain, in bicyclic systems, or
electron withdrawal in the monobactams, activates the 8-lactam ring 
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B-lactam treatment of bacterial cells results in reduced cross-
linking and a weakening of the cell wall. A point may be reached
where the internal osmotic pressure ruptures the cytoplasmic membrane
299and the cell lyses. As indicated by Rolinson , however, cell 
lysis is not essential for loss of cell viability. The impaired 
strength of the cell wall may place an additional strain on the cyto­
plasmic membrane, damaging its semi-permeable character and ultimately 
causing the death of the organism.
Why some bacteria should be more resistant to B-lactam anti­
biotics than others is a complex question. The various factors which 
may contribute to resistance have been discussed .
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3. T H E  B I O S Y N T H E S I S  O F  P E N I C I L L I N S ,
C E P H A L O S P O R I N S  A N D  C E P H A M Y C I N S
It is convenient to discuss the biosynthesis of penicillins, 
cephalosporins and cephamycins in one section, as the biosynthetic 
pathways which lead to these natural products share a number of 
common intermediates.
Although studies on the biosynthesis of the B-lactam antibiotics 
have been continuous over the past forty years, most of the import­
ant observations have been made in the last ten years. Present
knowledge of B-lactam biosynthesis is summarized in Figure 20.
... . .. . .. .. 215, 301-306Various review articles are available
3.1 AMINO-ACID PRECURSORS
3.1.1 L—a—Aminoadipic Acid
A requirement for a-aminoadipic acid might be assumed from the 
structures of isopenicillin N, penicillin N, the cephalosporins and 
the cephamycins, but not necessarily for the solvent soluble penici­
llins. The fact that lysine inhibition of penicillin G synthesis
could be reversed by addition of a-aminoadipic acid to the culture 
307medium suggests however that a-aminoadipic acid is an essential
*
precursor of the solvent soluble penicillins . Studies with lysine
* In fungi a-aminoadipic acid is a precursor of lysine . In
the presence of lysine, feedback inhibition of homocitrate syn-300thetase prevents the production of a-aminoadipic acid . In 
Streptorryces spp. a-aminoadipic acid is synthesised from lysine^10.
44
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auxotrophs of P. chrysogenum have confirmed this requirement
Likewise, lysine auxotrophs of C. acremonium produce antibiotics
312only when grown in the presence of a-aminoadipic acid
DL— [l— 1 l*C ]-a— aminoadipic acid labelled cephalosporin C and although
the a-aminoadipyl side-chain of penicillin N and the cephalosporins
has the D-configuration L-a—aminoadipic acid was more efficiently 
313incorporated than the D—isomer. The a-aminoadipyl side-chain of
cephamycin C, produced by S. clavuligerus, is also derived from
, 314 a-aminoadipic acid
L-Cysteine
The bicyclic nuclei of the penicillins and cephalosporins could 
conceivably be formed from cysteine and valine (Figure 21).
Radiolabelled cysteine was shown to be incorporated into peni-
315 qcillin G in P. chrysogenum , into cephalosporin C in C. acremonium ~
314and into cephamycin C in S. clavuligerus . The complete skeleton
of cysteine is incorporated intact into penicillin G.
DL—[3-ll*C, 1SN, 3 s S]—cysteine was effectively incorporated without 
315loss of label . L-cysteine has been shown to be a more efficient
317precursor of penicillin G than the D-isomer which is presumably
isomerized before incorporation.
The pivotal position cysteine occupies in the primary metabolism
of sulphur in fungi explains many of the misleading results obtained
in earlier studies. The ability of various Pénicillium  and Cepha-
losporium species to utilize sulphate or methionine depends largely
301, 318on the primary metabolic control of each species . Thus
the extremely efficient incorporation of sulphur from [35S]-methionine
46
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into cephalosporins in C. acremonium is due to the rapid assimilation 
of methionine by the mycelia and its rapid conversion to cysteine 
within the cell.
3.1.3 L-Valine
319-321The D-penicillamine fragment of penicillins and the
316 3212,3-dehydrovaline fragment of cephalosporin C ’ and cepha-
314mycin C are derived from L-valine. Radiolabelled L-valine was
319 320incorporated more efficiently into penicillin G ’ than D-
valine and although both isomers were equally effective precursors
in a high producing strain of P. chrysogenum results from feeding
D— [2-3H]-valine, L— [U— "C, 15N]-valine and D— [U— 11*C , 1SN ]—■valine
322 323indicate that D-valine is not incorporated directly ’
323 324Prior isomerization of D-valine to L-valine probably occurs ’
Similar results have been observed in C. acremonium
47
As with L-cysteine the valine skeleton is incorporated intact.
The 1 l*C/15N ratios remained essentially the same in biosynthetised
324penicillin G as in the substrates, L— [1— l‘*C, l5N]-valine and
L— [U— ‘-C, 15N]-valine 323.
3.2 THE TRIPEPTIDE INTERMEDIATE, 6— (L-g—AMINOADIPYL)—L—CYSTEINYL—D—VALINE
The isolation of 6— (a—aminoadipyl) cysteinylvaline from the
325mycelia of P■ chrysogenum and its obvious structural similarity 
to penicillin N led Arnstein and Morris to propose this tripeptide as 
a biosynthetic intermediate (Figure 22).
The stereochemistry of the P • chrysogenum tripeptide was later 
2 2 0 328established as 6— (L—a-aminoadipyl)—L—cysteinyl—D—valine
(LLD-ACV) (34) and shown to be identical to material isolated from
329 330C. acremonium . ACV has a ls o  been is o la te d  from  S. clavuligerus
331and from the cephalosporin producing fungus Paecilorryces persi cinus
LLD-ACV is the only optical isomer of ACV to have been detected though
related tri- and tetra-peptides of undefined stereochemistry are known 
329, 331, 332
The omnipresence of ACV in B-lactam producing fungi and actino- 
mycetes strongly supports its role as an intermediate in penicillin 
and cephalosporin biosynthesis. This is discussed further in section
3.3 (page 51).
3.2.1 Biosynthesis of 6— (L-ct-Aminoadipyl )-L—Cysteinyl—D—Valine (LLD-ACV)
The biosynthesis of LLD-ACV has been studied in broken cell 
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302 333results ’ from radiolabelled feeding experiments using the
C. acrem onium system suggest that LLD-ACV is synthesised from 
6— (L-a—aminoadipyl)-L-cysteine and L-valine. No LLD-ACV was 
detected in this system when 6— (D—a—aminoadipyl)—L—cysteine,
L—cysteinyl-L-valine or L—cysteinyl—D—valine were tested as pre­
cursors, nor was any production observed from the constituent amino-
acids. Isolation of 6— (L-«—aminoadipyl)—L—cysteine from the mycelium
306of S. clavuligerus supports the conclusion that LLD-ACV is bio­
synthesised from the /V~terminal end, as is the case in glutathione
334biosynthesis
Apparently contradictory results have been obtained with whole
335 336P. chrysogenum cells ’ . L— [2— 3 h ]—cysteinyl—L—[u—1 1’ C] —valine was
incorporated into penicillin G with the same 3H: 1 **C ratio as the di­
peptide. Subsequent experiments suggested that the most likely course
of events involved hydrolysis of the dipeptide and construction of
336penicillin G from the liberated amino-acids . Whole C. acremonium
cells assimilate only amino-acids and not preformed dipeptides or tri- 
337peptides . A cell free system from P . chrysogenum has been re-
338ported to synthesise LLD-ACV from the component amino-acids, but
has not been used to study the direction in which this synthesis 
occurs.
LLD-ACV appears to be synthesised, at least by Cephalosporium 
spp., from the/V-terminal end (Figure 23).
Nothing is known about the enzyme "ACV synthetase", except that
333it may be membrane bound , and little is known about the activated
forms of the amino-acids used by the enzyme. An a-aminoadipic acid
339— AMP ligase has been isolated from P. chrysogenum and the AMP 
derivative of L—a—aminoadipic acid may well be the activated form of 
this amino-acid.
Elimination of one carboxyl oxygen atom from L—[ 1 802 ]—valine
340occurred during incorporation into penicillin V in P. chrysogenum
This finding is consistent with the involvement of an enzyme bound
form of valine, for example as a thioester, though not necessarily
341 3 4 2at the stage of LLD-ACV synthesis. However, recent results
have shown that the loss of 180 does not occur during cyclization of
LLD-ACV to isopenicillin N (see Section 3.3).
Another interesting question, which remains as yet unanswered,
49
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is the point at which L-valine is isomerized to the D-valine residue 
of LLD-ACV. Is L-valine converted to D-valine then coupled with 
6— (L—a— aminoadipyl)—L—cysteine or is L-valine first coupled to pro­
duce an LLL-tripeptide which is isomerized to LLD-ACV? Abraham has
304suggested that this latter alternative is unlikely since synthetic
LLL-ACV is not converted to isopenicillin N (see Section 3.3).
Tritium from the C2 but not the C3 position of L-valine was lost
343 3 4 4during the synthesis of LLD-ACV in C. acremonium ' • Any
mechanism which isomerizes the valine C2 chiral centre and involves
an intramolecular hydride shift from C3 to C2 (or C2 to C3) is thus
precluded, as is the intermediacy of a free 2, 3 dehydrovaline species.
3 4 5 3 4 6A supportive observation ’ has been made with P . chrysogenum
cultures. No incorporation of tritium into penicillin V was detected 
when either DL— [3— 3H ]—valine or L— [3— 3H ]—valine was added to the cul­
ture medium.
51
3.3 OXIDATIVE CYCLIZATION OF LLD-ACV TO ISOPENICILLIN N
The tripeptide LLD-ACV does not enter the intact mycelium of
302 215C. acremonium or S. clavuligerus . Until the development of
cell-free systems capable of converting LLD-ACV to isopenicillin N,
evidence for the intermediacy of LLD-ACV in the biosynthesis of the
8-lactam antibiotics was primarily circumstantial. A lysine auxo-
troph of C. acremonium produced neither LLD-ACV nor antibiotics when
grown in the presence of lysine, but produced both when grown in the
312presence of a-aminoadipic acid . DL— [U— 11*C ]—valine, when fed to
a C. acremonium culture, rapidly labelled this tripeptide immediately
321prior to antibiotic production
52
Conversion of LLD-ACV to isopenicillin N has now been demon-
347strated in cell-free preparations derived from P. chrysogenum ,
r  _  • 328, 348-354  ̂ c , 330, 355, 356C. acremonium and b. clavullgerus ’ ’
328 35VA lysed protoplast system from C. acremonium C91 ’ , in
the presence of ATP, phosphoenalpyruvate and pyruvate kinase, convert­
ed 6— (L-a-aminoadipyl)-L-cysteinyl-D— [4,4'-3H]—valine into a substance 
which co-chromatographed with penicillin N and yielded tritium labell­
ed penicillaminic acid following performic acid oxidation. Penici­
llin N was the only penicillin then known to be produced by Cepha- 
losporium spp. and was assumed to be the product. However, the
electrophoretic and chromatographic separations used could not have
348distinguished penicillin N from isopenicillin N. Subsequently 
the antibiotic was identified as isopenicillin N on the basis of the 
behaviour of the a-aminoadipic acid, obtained by hydrolysis, towards 
L-amino-acid oxidase.
349 350The same conclusion was reached by Demain and co-workers ’
using protoplast lysates and active sonicates from an antibiotic-
negative mutant, C. acremonium M—0198, blocked prior to LLD-ACV
synthesis. Their cell-free preparations converted LLD-ACV to an
antibiotic which was completely destroyed by penicillinase. The
different bactericidal spectrum of the product from that of penicillin
N (see Section 1.2) suggested that the product was isopenicillin N.
Isolation of the biosynthesised material, chiral derivatization and
h.p.l.c. comparison with authentic samples, has since confirmed 
354this assignment . Isopenicillin N has been detected in mycelial
n 352 J „ . 358extracts from C . acremonium and S. tokunonensi s
A cell-free system capable of cyclising LLD-ACV to isopenicillin
53
N has been obtained by grinding the mycelia of C. acremonium C91 in a 
352Dyno-Mill . A partially purified preparation allowed an 85% con­
version of LLD-ACV to isopenicillin N and has been used to study this
351 353ring closure by direct 13C and ‘H n.m.r. observation ’
Incubation of radiolabelled LLD-ACV with a protoplast lysate of
P. chrysogenum produced isopenicillin N, identified as its penicilloic 
347acid . A number of methods to produce active cell-free extracts
355from S. clavuligerus have been reported . Sonication proved not 
only to be the simplest method tested but also gave the most active 
preparations. Using this system LLD-ACV was converted to an anti­
biotic which appeared, on the basis of its activity against a variety
of gram-positive and gram-negative organisms, to be a mixture of iso-
355penicillin N and penicillin N . Analysis by h.p.l.c. could not 
separate the two isomers but confirmed that reduction in tripeptide 
concentration, in the incubation mixture, was matched by an equal 
increase in penicillin concentration it has been shown
that P. chrysogenum mutants incapable of producing LLD-ACV are also 
incapable of producing penicillins. These results confirm the con­
clusion that the LLD-tripeptide is an obligatory intermediate in 
penicillin biosynthesis (Figure 24).
3.3.1 "Isopenicillin N Synthetase"
In the 3-lactam producing fungi and Streptonyces the enzyme 
responsible for converting LLD-ACV to isopenicillin N would appear 
to be soluble and not membrane bound, despite the increased activity 
observed in the presence of Triton X-100. Molecular oxygen, ferrous 
ions and a reducing agent, preferably dithiothreitol (DTT) but also 
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arate are required and other ions particularly Zn2+ are inhibitory.
The enzyme has a molecular weight of approximately 32,000 a.m.u. and
is stable at -20°C in tris—HC1 buffer at pH7*0 for up to three 
350, 352, 355months
328 348 351LLD-ACV is converted intact into isopenicillin N ’ ’
No label was lost from double-labelled material and no label was 
incorporated in the product when unlabelled LLD-ACV was incubated 
in the presence of DL— [4,4'-3H]-valine.
To gain an insight on the active site of isopenicillin N synthe­
tase various structural analogues and optical isomers of LLD-ACV have 
been synthesised and tested as substrates or inhibitors 828 ’ 8^2, 360 
(Figure 25).
55












* Inhibition is defined as the decrease (%) in the 
bioactivity generated after 30 min.
A=6— (a—aminoadipic acid); Ab=a—aminobutyric acid; 
Al=alanine; C=cysteine; G=6—glutamic acid; I=iso- 
leucine; Is=alloisoleucine; S=serine; V=valine.
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The enzyme, though not totally substrate specific, tolerates 
only minor changes in the D-valine residue. The cysteinyl and 
<5-linked L—a—aminoadipyl residues are apparently essential for 
activity and may play a vital role in binding the tripeptide to the 
active site. It is possible that the L—a—aminoadipyl side-chain 
co-ordinates to, or bonds ionically with, some point on the enzyme 
surface and that the free thiol group of LLD-ACV forms a disulphide
i7 341 342bond with the enzyme. 0 n.m.r. studies ’ have shown that
no thioesters, esters or amidines can be directly involved in bind­
ing LLD-ACV to the active site of the enzyme.
3.3.2 Mechanism of Formation of Isopenicillin N
As soon as ACV was muted as a possible precursor of the peni­
cillin nucleus speculation arose on the mechanism by which this
cyclization could occur. No intermediates have ever been isolated
351or detected by C n.m.r. spectroscopy . One major approach to 
elucidating the mechanism has involved the feeding of specifically 
labelled amino-acids and peptides. Results from such studies have 
proven valuable in examining the validity of various proposed mecha­
nisms by comparing the predicted results with those obtained. 
Alternatively, putative intermediates have been synthesised and fed 
to cell-free systems or model reactions used to exemplify a potential 
mechanism. It has been generally assumed that cyclization occurs in 
two steps and that the 6-lactam ring is formed first (Figure 26, path
A). Although no experimental evidence exists to support these ass­
umptions the alternative sequence of bond formation (Figure 26, path
361B) appears unlikely on the basis of recent feeding studies . A 
concerted closure of both 3-lactam and thiazolidine rings remains a 
possibility (Figure 26, path C).
Oxidation of cysteine and intramolecular attack by the valine 
nitrogen provides an attractive mechanism for the closure of the 
8-lactam ring (Figure 27).
The 2,3 dehydrocysteine species (42) is not an intermediate.
Tritium from DL-[2— 3H]-cystine was retained in the penicillin G, 
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363 , _Bycroft confirmed that tritium from L— [2 — H, U— 1 CJ—cystine was
incorporated without loss and that the 3H from the isolated penicillin
G was located solely at the C6 position. Model reactions in which
2,3 dehydrocysteinyl intermediates were generated also failed to pro-
3 0 4
duce B-lactam products . As expected only one of the cysteine C3
tritia was retained in the penicillin V isolated when L— [3,3,31 ,3’ — 3H„,
U— 1 l4C]-cystine was fed to a culture of P . c h r y s o g e n u m ^ ^  ■ Experi-
365 368ments with stereospecifically tritiated cysteines have shown
that ring closure occurs with loss of the 3—pro-S hydrogen and hence
with retention of configuration at cysteine C3 (Figure 28).
58
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Although these results do not necessarily preclude the inter­
mediacy of the thioaldehyde tautomer (43), oxidation of LLD-ACV to a 
thioaldehyde intermediate would have to proceed by a mechanism diff­
erent from the known microbial oxidation of alcohols to aldehydes
369which generally occur with loss of the pro-R hydrogen . Results
370 371from chemical model studies ’ suggest that thioaldehydes are
not intermediates. Chemically generated thioaldehydes enolized, 
polymerized or cyclized to a y-lactam structure but did not produce
B-lactams. Unfortunately the model compounds tested all possessed a
2,3 dehydrovaline residue, then thought to be involved in thiazolidine 
ring closure. This is now known not to be the case and the reduced 
nucleophilicity of the valine nitrogen, due to amide and enamine reso­
nance, may be the reason no 8-lactam formation was observed. Conse­
quently the thioaldehyde species (43) remains a possible, if unlikely,
intermediate. In a formal reversion of the proposed mechanism the
372thioaldehyde (45) was produced from the monocyclic 8-lactam (44)
(Figure 29).
Alternatively, hydroxylation at cysteine C3 could activate this 
position to nucleophilic attack. <5 — ( L—a—aminoadipyl )—L—3—hydroxy— 
cysteinyl—D—valine would be highly unstable but might exist long 
enough as an enzyme bound species for ring closure to occur (Figure 
30) .
The overall process of ring closure proceeds with retention of
365—368configuration at cysteine C3 . As nucleophilic attack by the
amide lone pair would involve inversion at the carbon centre, hydroxy­
lations must also proceed with inversion. Most hydroxylations at
373aliphatic carbon, however, proceed with retention of configuration
305and although a few exceptions have been reported this unusual
stereochemical requirement must cast doubt on the intermediacy of a
3-hydroxylated species. Other thioaldehyde equivalents, for example,
—OR, —SR or S-Enzyme (for 0-Enzyme in Figure 30) are valid alterna-
374 375tives. Model studies ’ , with related systems, have provided
chemical analogy for ring closure (Figure 31).
376Oxidation may occur at the valine nitrogen . Hydroxamic 




























c o 2c h 3
F I G U R E  31
377 378isms and a hydroxamic acid has been postulated as a possible
intermediate (Figure 32). A model chemical reaction has been des-
378cribed which supports this hypothesis (Figure 33).
379The cyclic orthothioamide (46) has also been proposed as a 
possible intermediate .
All the model reactions described above involve internal pro­
tection of the thiol and dehydration of the acyl side-chain. De-
341 342hydrated species such as these are now known ’ not to be
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No label was lost from the isopenicillin N isolated after incubation 
of 6— (L— [1 ,1 ,6— 1 70/ 1 80 ]—a—aminoadipyl)—L—cysteinyl-D-valine with a 
cell-free extract from C. acrem onium • In a complementary experiment
addition of 1 7 0 / 1 8 0 water to the incubation mixture did not label 
isopenicillin N. These results eliminate the intermediacy of 
cyclic structures such as 46, but do not necessarily preclude an 
acyclic hydroxamic acid or a thioaldehyde equivalent as intermediates.
380Baldwin has proposed a radical mechanism for B-lactam forma­
tion. Isothiazolidinones, readily obtained from cysteinyl peptides 
381 382’ , may be substrates for an oxygenase enzyme. The generated
carbon radical could then rearrange to the more stable sulphur radi­
cal, trapped as a symmetric or asymmetric disulphide (Figure 34).
383However, model reactions in which isothiazolidinonyl rad­
icals were almost certainly produced did not yield detectable quan­
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mechanism is not involved in penicillin biosynthesis. B-lactams
have been obtained, in small amounts, by treatment of a simple amide
384with di— t—butylperoxide (Figure 35) but radical treatment of
stereospecifically labelled /V— 1~butyldihydrocinnamamide resulted in
385complete loss of stereochemistry . The previously mentioned 
stereochemical constraints on B-lactam formation appear therefore 
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In 1980 Adriaens 347 claimed to have detected an intermediate in
the cell-free conversion of LLD-ACV to isopenicillin N. The material, 
known as compound Y, was not isolated but assigned the monocyclic 
B-lactam structure (40, Figure 26) on the basis of radiolabelling 
studies and comparison with a synthetic sample. Compound Y retained 
only one of the tritia from L— [3— 3H 2]—cysteine, but retained the val­
ine C2, C3 and C4 hydrogens. The monocyclic B-lactam was reportedly 
synthesised (though details of this synthesis have not yet appeared 
in the literature) and was found to co-elute with compound Y from a
cation-exchange column. These results are at variance with the
386 387reported syntheses ’ of 1— (D—carboxy—2—methylpropyl)—3—L—
(6—L—a—aminoadipamido)—4—L—mercaptoazetidin—2—one (40). This
material is now known to be extremely unstable particularly at alka­
line pH. No mention was made of this instability in the original 
paper and indeed the monocyclic B-lactam was claimed to be stable 
to the alkaline isolation procedures used.
Compound Y could not be the more stable disulphide (47) as
extracted materials were reportedly stored overnight at pH8-2 in the
presence of excess DTT; conditions known to destroy the disulphide 
386 Whatever the structure of compound Y, it is unlikely that it 
was the monocyclic B-lactam (40).
47
c o 2h
A speculative possibility is that compound Y might be the 
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Structure 48, while not an intermediate, fits the known radio-
labelling results and analogous structures have been obtained from
372, 388monocyclic B-lactams v ia thioaldehydes (Figure 36)
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Perhaps the putative intermediate was a thioaldehyde, trapped as 
the thiazole (48) and subsequently shown to be the same as a re­
arranged product from the authentic monocyclic 8-lactam (40).
Baldwin has shown that compound 40 does open to an unstable thio- 
386aldehyde . If such speculation is justified Adriaens' observa­
tions lend as much support to a thioaldehyde (or equivalent) inter­
mediate as to the monocyclic structure.
The fused thiazoline-azetidinone (49), an internally protected
form of the monocyclic species (40), was originally proposed by 
389Cooper as a possible biosynthetic intermediate. Nuclear mag-
341, 342netic resonance studies and feeding experiments with a cell-
390free extract from C. acrem onium have, however, eliminated 49 as 
a possible intermediate.
Incubation of the synthetic disulphide (47) with cell-free 
extracts of P . chrysogenum and C. acrem onium in the presence and
absence of DTT yielded no detectable quantities of isopenicillin N
386, 387 . . .These results cannot be inferred to eliminate the mono-
cyclic 8-lactam (40) as an intermediate, as the material undoubtedly 
decomposed rapidly in the test solutions. It is still possible 
that 40 exists transiently as an enzyme bound species. In conclus­
ion, initial closure of the penicillin N4-C5 bond has still to be 
demonstrated.
Even if the monocyclic B-lactam is an intermediate the mechan­
ism of its formation is unknown. A thioaldehyde, thioaldehyde
38 5equivalent, hydroxamic acid or organonometallic species could
be involved and each of these proposals remains viable.
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For a long time a2,3 dehydrovaline species (50) was assumed to be
362involved in thiazolidine ring formation
c o 2h
50
Addition of the thiol across the double bond would effect ring
closure and could readily explain the stereochemical inversion of
L-valine to the D-penicillamine fragment of penicillins. This early
assumption was challenged when ACV was found to already possess a
371 391D-valine residue and model reactions ’ completely failed to
yield penicillins.
Tritium was retained in the penicillins isolated after incuba­
tion of 6— (L—a—aminoadipyl)—L—cysteinyl—D—[2— 3H]—valine and
<S— (L— o-aminoadipyl)-L—cysteinyl-D— [2— 3H, 1— 1 “c]—valine with cell-free
n 328 n 7 347extracts from C. a c r e m o n i u m  and P. c h r y s o g e n u m  . Such
results are inconsistent with a free 2,3 dehydrovaline intermediate
and also eliminate the intermediacy of an imine containing species 








DL— [4,4'-2H6]—valine was fed to C. a c r e m o n i u m  and P. c h r y s o g e n u m
392 393and the isolated penicillins shown ’ by mass spectral analysis
to have retained all six deuterium atoms. The diastereoisomeric 
methyl groups of penicillin G were not labelled when D20 was added 
to a P. c h r y s o g e n u m  culture Consequently no 3,4 dehydrovaline
intermediates are involved in penicillin biosynthesis.
The conversion of <5— (L-a-aminoadipyl)— L—cysteinyl-D— [ 2 , 4 , 4 2H7
— valine to isopenicillin N in a cell-free system from C. a c r e m o n i u m ,
395proceeded without loss of deuterium , as evinced from 2H n.m.r.
spectroscopy of the product, thus confirming earlier conclusions.
396The tripeptide (52) was recently synthesised and found not to be 








The stereochemical fate of the prochiral methyl groups of valine 
has been studied by several groups. Stereospecifically labelled 
precursors have been synthesised and fed and the biosynthesised peni­
cillin V or penicillin N analysed by n.m.r. spectroscopy. Unfortun­
ately the nomenclature used in this area is confusing and frequently
397incorrect. The correct nomenclature , and not necessarily the 
nomenclature used in the original literature, is used throughout the 
following discussion.
The 3-methyl group of penicillin V was labelled when (2RS,3S)—
398[4— 1 3C ]—valine was fed to P . chrysogen u m  and in complementary
experiments (2S,3R)— [4— 1 3C]—valine labelled the a-methyl of penicill-
399 400in N and penicillin V (Figure 37).
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Incorporation of valine into the bicyclic penicillin structure 
proceeds with overall retention of configuration at valine C3.
LLD-ACV, occurred with retention of configuration. Isolation of 
chirally labelled LLD-ACV as its sulphonic acid (ACyaV) later con-
8-lactam-negative mutant, C. acremonium N2 , only the low field methyl 
group of LLD-ACyaV was labelled. Hydrolysis of the purified tri-
For all labelling results to be self-consistent the conversion 
of LLD-ACV to isopenicillin N must occur with retention of configura­
tion at valine C3.
The incubation of chirally labelled LLD-ACV with a cell-free 
system and analysis of the synthesised isopenicillin N has not been 
reported. However, tripeptides related to LLD-ACV have been studied
Tritium studies 344 suggested that the first step, production of
firmed this When (2S,3R) — [4— 1 3c ] —valine was fed to the
peptide gave (2R,3R) — [4— 1 3c]—valine '̂ ''"(Figure 38).
353, 360 and produce the isopenicillin N analogues expected on the
basis of the preceding stereochemical arguments.
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Tetrapeptides containing a 3-hydroxyvaline residue have been
329 331isolated from C. acremonium and Paeci 1 orryces persicinus
305It was proposed that nucleophilic displacement of hydroxide 
by sulphur could effect ring closure (Figure 39).
74
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For overall retention of configuration at C2 (C3 of valine), 
hydroxylation would have to proceed with inversion of configuration.
As previously mentioned, however, hydroxylation at aliphatic carbon
373generally proceeds with retention of configuration and this pro-
402posai appears unlikely. An alternative mechanism would satisfy
the stereochemical requirements of the ring closure reaction, but
3ô 1recent feeding studies have shown that ô-(L-a—aminoadipyl)—L— 
cysteinyl—3—hydroxy—D—valine is not incorporated into isopenicillin N.
403Baldwin has suggested that the 3—hydroxyvaline peptides are 
shunt products. The radical (53) generated by hydroxylase activity 
might be intramolecularly trapped to give isopenicillin N (Figure 40). 
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403A model reaction has been reported but this mechanism can
only be acceptable and in agreement with the known stereochemical
facts if bond formation is shown to be much faster than valine C2-C3
404bond rotation. A radical intermediate (54) has been proposed 
in the photochemical formation of a penam from an azetidin—2—one 
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At present is it not possible to say how LLD-ACV is converted to 
isopenicillin N. Many mechanisms have been eliminated and others 
appear unlikely, but no details are known as to the actual mechanism 
of ring closure. All intermediates may be enzyme bound, in which 
case a full understanding of the problem will require quantities of 
pure isopenicillin N synthetase. This enzyme appears fairly stable 
but its isolation has not yet been reported.
Isopenicillin N is the last common intermediate in the bio­
synthesis of the penicillins, cephalosporins and cephamycins. At 
this point the pathway branches to give the solvent soluble penicill­
ins in Penici11ium spp. and the cephalosporins in Cephalosporium and 
Streptorryces spp.
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3.4 THE SOLVENT SOLUBLE PENICILLINS
The absolute requirement for L— o-aminoadipic acid in the bio-
307synthesis of penicillins , and the presence of 6-(L— cr-aminoadipyl)
—L—cysteinyl—D—valine but not cysteinylvaline peptides in the mycelium
325of P . chrysogen u m  , suggests that isopenicillin N is a precursor
of the solvent soluble penicillins. It was unclear whether 6—amino-
46 47penicillanic acid (6—APA) (6), found in the culture medium ’ ,
was an intermediate in this process.
Isopenicillin N and 6—APA were not taken up by intact mycelia
and an active cell-free preparation was required. Such a system
405was reported in 1975 and shown to catalyse the conversion of
tritium labelled isopenicillin N and phenylacetyl-CoA to penicillin 
G. 6—APA but not penicillin N also gave penicillin G under ident­
ical conditions.
The inter-relationship of isopenicillin N, 6—APA and the solvent
306soluble penicillins is now more clearly understood . Isopenici­
llin N is an obligate intermediate in the biosynthesis of the penic­
illins, but under the influence of various enzymes is hydrolysed to 
6—APA. 6—APA is subsequently acylated to give, for example, penic­
illin G. Four classes of enzyme have been identified: isopenicill­
in N amidolyase, acyl—CoA:6—APA acyltransferase, monosubstituted 
acetic acid:CoA ligase and penicillin acylase (Figure 41).
As enzymes A and B are probably closely associated within the 
cell very little free 6—APA is observed.
A Isopenicillin N
B 6-APA + Acyl-CoA
C_ RCC^H + Coenzyme A 
D 6-APA + RC09H
isopenicillin M ^ 
amidolyase
acyl-CoA : 6-APA ^ 
x acyltransferase
monosubstituted 




6-APA + I-a-amino- 
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3.4.1 Isopenicillin N Amidolyase
306Abraham and co-workers have partially purified an enzyme
from P . ch rysogen u m  which hydrolyses isopenicillin N to 6—APA and
L—a—aminoadipic acid. Cell-free extracts from P . ch rysogen u m  were
347observed to catalyse an acyltransfer reaction between labelled 
isopenicillin N and unlabelled 6—APA. Both results are consistent 
with the presence of an isopenicillin N amidolyase.
3*4.2 Acyl—CoA:6—APA Acyltransferase
The enzymic conversion of 6-APA and phenyacetyl—CoA to penicillin
G has already been mentioned a purified acyltransferase
synthesised penicillins from the coenzyme A derivatives of various
monosubstituted acetic acids. 6—APA acyltransferase activity has
407also been implied from radiolabelling studies
Monosubstituted Acetic Acid: Coenzyme A Ligase
A coenzyme A ligase has been demonstrated in extracts from
408 409P. chrysogenum • The partially purified enzyme was found to
condense coenzyme A with phenylacetic acid, phenoxyacetic acid and
other monosubstituted acetic acids.
Penicillin Acylase
Penicillin acylases have previously been considered in the hydro­
lysis of penicillins to 6—APA (Section 1.1). The reverse reaction,
formation of penicillin G from 6—APA and phenylacetic acid, has been 
410observed in extracts from P. chrysogenum.
411 412Studies with bacterial penicillin acylases ’ have suggest­
ed that this class of enzyme plays only a minor role in penicillin 
biosynthesis, and that enzymes A, B and C produce almost all the 
solvent soluble penicillins.
PENICILLIN N BIOSYNTHESIS
The conversion of isopenicillin N to penicillin N has been
413demonstrated in a cell-free extract from C. acremonium. Incuba­
tion of isopenicillin N produced a penicillinase sensitive material 
which, when bioassayed against Salmonella typhi , proved to be peni­
cillin N. The epimerase responsible is a soluble enzyme which 
appears to be extremely labile; only 15% of the activity remained 
after storage for 24 hours at —20°C.
Deacetoxycephalosporin C is produced from penicillin N (see
349 414 415Section 3.6). LLD-ACV ’ or isopenicillin N have been
converted to cephalosporins by fresh cell-free extracts, presumably
via penicillin N. This ability was lost following overnight storage
at —80°C. In repeated experiments using old cell-free extracts
LLD-ACV was converted to only isopenicillin N, even though the sys­
tems remained capable of transforming penicillin N to deacetoxycepha- 
416losporin C . Further evidence of epimerase activity has been
355 356provided using a S. clavuligerus cell-free preparation ’
Incubation of LLD-ACV and cofactors produced a mixture of isopenic­
illin N and penicillin N.
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3.6 OXIDATIVE RING EXPANSION OF PENICILLIN N
As all cephalosporin producing species produce penicillin N, a
possible precursor-substrate relationship has always been accepted.
321Early experiments suggested this was not the case. However, the
failure to isolate penicillin N negative — cephalosporin positive
organisms when penicillin N positive — cephalosporin negative mutants 
312were known , is readily explained if penicillin N is a precursor 
of the cephalosporins.
Incubation of penicillin N with cell-free extracts from C.
acremonium produced a penicillinase resistant, B-lactamase sensitive
_  216, 416-419 . , , , , , 216, 419antibiotic identified by h.p.l.c. and paper
416electrophoresis, paper chromatography and t.l.c. as deacetoxy-
cephalosporin C (35). Penicillin G and 6—APA were not substrates 
for the ring expansion enzyme.
The mechanism of ring expansion is unknown but published labell­
ing experiments eliminate a number of possibilities. Thus C4, C41 
deuterated valines, fed to C. acremonium, labelled cephalosporin C
in the C2 and C3' positions with only the expected loss of two 
343 393deuterium atoms ’ . Neither position was labelled when the
81
incubation was repeated in 80% D20 with unlabelled valine as sub-
393 398strate . (2RS,3S)—[4—13C]-valine labelled cephalosporin C
399at C2 while (2S,3R)-[4-13C]—valine labelled the C3' position.
Given the established labelling pattern of penicillins (Figure 37) 
the overall penicillin N-cephalosporin C conversion is believed to 
proceed as shown in Figure 42.
Thus the formation of deacetoxycephalosporin C does not involve 
the intermediacy of a free A2 cephem or oxidation of a penicillin N 
methyl group to an aldehyde.
108The penicillin N sulphoxide (55) was proposed as an inter­
mediate on the basis of analogy with the chemical conversion of pen­
icillins to cephalosporins (Section 1.2). However, the 6-sulphoxide 
of penicillin N (55) and S-acetoxymethylpenicillin N (56) have been 
tested in a cell-free system from C. acremonium and are not inter­
mediates
Optimal ring expansion activity in cell-free systems requires
high aeration, an energy generating system, ferrous ions and ascorbic
417 418 420 417acid ’ ’ . The enzyme was inhibited by potassium cyanide ,
420zinc ions and copper ions , and appeared to be an oxygenase. When
421partially purified the enzyme had properties similar to those of
a 2—oxoglutarate—linked dioxygenase (Figure 43).
In this case penicillin N is the reduced substrate, SH, and the
product, a hydroxylated species, may well be 8 -hydroxymethylpenicillin
N (57). B-hydroxymethylpenicillin N has not yet been synthesised and 
380tested as a substrate for the ring expansion enzyme.
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SH + 02+ 2-oxoglutarate 
dioxygenase
V
SOH + succinic acid + C02
SH = reduced substrate 
SOH = oxidised substrate
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3.6.1 Mechanism of Ring Expansion
306A popular proposal for penicillin N ring expansion is out­
lined in Figure 44. Displacement of hydroxide or an activated 
form of hydroxide would give the 8-episulphonium ion which could 
rearrange to a tertiary carbonium ion. Loss of H+ or addition and 
trans-elimination of H2O would yield deacetoxycephalosporin C (35).
84
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The isomeric alcohol (58) has been isolated from Q. acrem oniuin  
and could arise by addition of H20 to the more hindered B-face of the 






422Chemical studies support this mechanism (Figure 45) but
423recently published experiments are inconsistent with the propos­
al as it stands. Chiral [4— 3H,2H, *H ]—methyl valines were fed to 
C. acrem onium and the biosynthesised cephalosporin C analysed by 3H 
n.m.r. spectroscopy. A mixture of C2 epimers was obtained (Figure 
46) .
These results imply that at some point during the ring expansion 
reaction an achiral intermediate is formed which is independent of 
the chiral methyl valine precursor. Complete or partial randomiza­
tion of label could be explained, but the consistent excess of 61 
over 62, irrespective of which valine (59 or 60) was tested, is 
difficult to account for and no mechanistic explanation of these 
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Further work is required to prove or disprove the proposed
biosynthetic pathway (Figure 44) although some modification to this
scheme appears essential. The intermediacy of the 3-exomethylene-
cepham (63) in the conversion of penicillin N to deacetoxycephalos-
216 424 425porin C has been discussed ’ ’ . Results indicate that
the exomethylene compound is not an intermediate, but under certain
425conditions can be converted to deacetylcephalosporin C (36).
-C H . 
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3.7 THE CEPHALOSPORINS AND CEPHAMYCINS
In some C. acremonium mutants deacetoxycephalosporin C
is the final biosynthetic product, but in most 0-lactam producing 
Cephalosporium and Streptonyces species additional oxidation, acyla- 
tion and substitution reactions produce a wide variety of antibiotics 
(see Figure 7).
3.7.1 Functionalization at C3'
428 429A substrate specific dioxygenase present in C. acremonium ’
429 423and S. clavuligerus stereospecifically hydroxylates deacetoxy­
cephalosporin C to give deacetylcephalosporin C (36). The newly
430 431introduced hydroxyl group is derived from molecular oxygen ’
Acylation of deacetylcephalosporin C yields a number of deriva­
tives. An acetyl-CoA:deacetylcephalosporin C O-acetyltransferase
427 ~has been purified from extracts of C. acremonium and found to
catalyse the formation of cephalosporin C. A 3-hydroxmethylceph-
432 4333-em:O-carbamoyltransferase, from S. clavuligerus ’ , produced
O-carbamoyldeacetylcephalosporin C from deacetylcephalosporin C and
cephamycin C from 7a-methoxydeacetylcephalosporin C. Cephamycins
A and B and compound C—2801X (Figure 7) may arise by acylation of a
deacetylcephalosporin or by non-enzymic displacement of carbamate
212from cephamycin C. The C3' thiol substituted cephalosporins ’
214 426’ may be formed by displacement of acetate from cephalosporin
C. This may be enzymic, as in the biosynthesis of cysteine from
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435Studies with a cell-free system from S. clavuligerus have
shown that the methoxy substituent is introduced in two steps. A
4312-oxoglutarate-linked dioxygenase incorporates molecular oxygen
into O-carbamoyldeacetylcephalosporin C. The resultant alcohol is
rapidly methylated to give cephamycin C. The methyl donor is
S-adenosylmethionine Cephalosporin C was likewise converted
to 7a-methoxycephalosporin C but neither deacetoxycephalosporin C
435nor deacetylcephalosporin C were substrates for this enzyme 
(Figure 20).
3.7.3 Miscellaneous Reactions
A number of modifications to the D—a—aminoadipyl side-chain of 
the cephalosporins have been observed. Some C ep h a losp oriu m  strains
430  437
oxidatively deaminate and decarboxylate the side-chain ’ while
438others accumulate /V-acetylated derivatives . These compounds are 
not involved in cephalosporin biosynthesis.
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3.8 ADDENDUM
Such is the current interest in 6-lactam biosynthesis that since 
this manuscript was prepared several relevant publications have 
appeared in the literature.
Using model systems Easton and co-workers have studied the ring
closure of the 6-lactam and thiazolidine rings of penicillin. The
isothiazolidinone (65) was converted to the monocyclic 6-lactam (66)
439when treated with phenyl lithium . Presumably the amide amion 
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The mechanism of ring closure is similar to the model thioalde- 
hyde equivalents previously discussed (see Figure 31). The analag- 
ous in  v i v o  reaction could be tested by feeding the peptide deriva­
tive (68) to a cell-free system capable of converting LLD-ACV to 
isopenicillin N.
68
Using conditions similar to those reported by Baldwin 384, 385
radical ring closure of a simple amide (69) to a 3-lactam was 
440achieved . However, treatment of the biosynthetic model (70) 
in an identical manner completely failed to produce any S-lactam 
materials (Figure 48).
The stereochemical problems of radical 3-lactam formation have
been discussed in Section 3.3.2 and this latest publication offers
385little new to contradict Baldwin's original conclusion that a
radical mechanism is highly unlikely in  v i v o .
In contrast a proposal 403 for the radical closure of the
92
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thiazolidine ring of penicillins remains a possibility (Figure 40).
441Easton subjected /V-benzoylvaline methyl ester to radical chlorin­
ation conditions. /V—benzoyl—3—chlorovaline methyl ester was isolated
as the major product (Figure 49), suggesting (perhaps not surprising­
ly) that hydrogen abstraction from the tertiary valine C3 position is
most favoured. These results, together with the model studies dis- 
403cussed earlier , provide chemical evidence to support an in  v i v o  
closure of the thiazolidine ring by a radical mechanism.
442 443In two communications from Baldwin and Abraham ’ a highly
444purified sample of the single enzyme isopenicillin N synthetase 
(molecular weight 37,000 a.m.u.) was used to investigate the mechan­
ism of penicillin formation. Incubation of the modified substrate, 
a— (L—a—aminoadipyl)—L—cysteinyl-D— (a—aminobutyric) acid, with this
enzyme, in the presence of FeS0„, DTT, ascorbic acid, catalase and
445oxygen , afforded two 6-lactam products in a 3:1 ratio (Figure 50).
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360One product was identified as the penicillin (71) reported previously 
and the second material as the cepham (72) of undefined stereochemistry 
(Figure 50). The tripeptide, 6— (L—a—aminoadipyl)—L—cysteinyl—D— 
valine, gave only one product, isopenicillin N, when incubated with 
the pure enzyme.
To study the mechanism of thiazolidine ring closure the asymmet­
rically labelled substrates (73 and 74) were incubated with iso­
penicillin N synthetase. In both cases the penicillin (75) was the 
only penicillin isolated (Figure 51).
The authors conclude that these results strongly support a 







73 R1 = D ; R2 = CEj
74 R1 = CEL, ; R2 = D —  ;>
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penicillin biosynthesis. Indeed if a simple assumption is made all 
the results can be readily explained. With the normal substrate 
LLD-ACV the valine isopropyl group is contained and sterically con­
tained within a hydrophobic pocket at the active site of the synthe­
tase enzyme. The time course of events is not known, but probably 
the 3-lactam ring is first formed and the radical intermediate (76) 
then generated by hydrogen abstraction from the most reactive tertiary 
position. The isopropyl radical is sterically prevented from rotating
96
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and closes to isopenicillin N with retention of configuration at the 
valine C3 centre (see Section 3.3.2) (Figure 52).
With the modified substrate 6— (L—a—aminoadipyl)—L—cysteinyl—D—
(a—aminobutyric) acid there is greater rotational freedom within 
the hydrophobic pocket. Any of the methyl or methylene hydrogens 
can, in a suitable conformation, present themselves to the radical 
initiator on the enzyme surface and be abstracted. With the stereo- 
specifically deuterated tripeptides (73 and 74) a substantial kinetic 
isotope effect results in abstraction of hydrogen only from the 
a-aminobutyric acid C3 carbon (Figure 53). The radical (77) is 
free to rotate and adopts, presumably, the most stable conformation 
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The observed 3:1 ratio of penam to cepham (Figure 50) is remark­
ably similar to that which would be calculated on the basis of random 
hydrogen abstraction from the a-aminobutyric acid C3 and C4 positions 
In the radical chlorination of propane the relative reactivity of a 
secondary hydrogen to a primary hydrogens is 4:1. From the statisti­
cal 2:3 ratio of "abstractable" hydrogen on 79 and the 4:1 reactivity 
ratio mentioned above, a final 2*7:1 ratio of products (71:72) can be 
calculated for totally random hydrogen abstraction. This is very 
close to the observed ratio and suggests that the a-aminobutyric acid 
residue of <5— (L-a—aminoadipyl)— L—cysteinyl—D— (a—aminobutyric) acid is 
rotationally free and not conformationally constrained within the 
hydrophobic pocket of the synthetase enzyme.
More work is required to confirm a radical mechanism, and in 
this respect an in  v i v o  e.s.r. study might prove interesting.
446In a recent communication the alcohol (80) was isolated
following incubation of cephalosporin C with a cell-free system 
prepared from S. c l a v u l i g e r u s. The isolated intermediate was 
identical, by mass and lH n.m.r. spectral analysis, to a synthetic 
sample of 80. The cell-free system converted 7a-hydroxycephalos- 
porin C (80) to 7a-methoxycephalosporin C (37) in the presence of 
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4. S Y N T H E T I C  T A R G E T S
In order to study the problem of isopenicillin N biosynthesis,
two complementary approaches were proposed. The first was the syn-
378thesis of the putative intermediate (81) (described in section
4.4), and to test this as a substrate, and the second was the syn­
thesis of specifically 13C, 15N — labelled LLD-ACV (82). Direct 
in  v i v o  13C n.m.r. observation of the cyclization of LLD-ACV to iso­
penicillin N (Section 3.3) could yield information on possible inter­
mediates, particularly if these intermediates could be "trapped" by 
lowering the reaction temperature and reducing the rate of"intermed­
iate" turnover. The problems associated with such cryoenzymological
447studies are discussed in detail elsewhere . It was hoped that a
coupling would be observed in intermediates possessing the
B-lactam ring and in the biosynthesised isopenicillin N. While the
448magnitude of one bond 13C— l5N J values is dependent on geometry , 
a coupling of ca 7*0Hz between N4—C5 of penicillin G has been

















A pre-requisite for both approaches to this problem was the 
availability of a cell-free system capable of converting LLD-ACV to 
isopenicillin N (see Section 3.3).
In addition it was desired to synthesise <5— (L—a—aminoadipyl)—L— 
cysteinyl—D—valylglycine (LLD-ACVG) (83). A tetrapeptide with pro­
bably this sequence of amino-acids, but of undefined stereochemistry,
329has been isolated from the mycelia of C ep h a losp oriu m  spp. . The 
significance of ACVG in penicillin biosynthesis has never been invest­
igated .
When this work was started the literature syntheses of LLD-ACV 
328, 449, 450 involved construction of the tripeptide from the
C-terminal or valine end. As the target molecule (82) was to be 
labelled in the cysteine and valine residues, an alternative approach, 
construction from the /V-terminal residue, appeared to be the most 
economical. A synthesis of LLD-ACV from the /V-terminal residue has








Peptide synthesis is in theory fairly straightforward. In 
practice, however, the problems associated with the protection, de­
protection and coupling of amino-acids are complex, and these aspects
strategy for the synthesis of LLD-ACV (34) and LLD-ACVG (83) is out­
lined in Figure 54.
A successful synthesis of LLD-ACV by this route requires that 
the R 3 ester be selectively removed while the R, R 1 and R 2 protective 
groups are retained. In the synthesis of LLD-ACVG, R 3 and R 4 have 
to be selectively removed in the presence of R, R 1 and R2. To opti­
mize the final yield of LLD-ACV (34) and LLD-ACVG (83) it would be
desirable if all the protective groups were removed in one deprotect-
465ion step. The final synthesis of LLD-ACV and LLD-ACVG which
satisfied all these conditions is outlined in Figure 55.
have been discussed in detail in many publications 452-464 The
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4.1 THE SYNTHESIS OF 5— (L—a—AMINOADIPYL)—L—CYSTEINYL—D—VALINE
The protected L-a—aminoadipic acid (84) (R=PhCH202C— , R‘=4-N02C6-
H„CH2— ) was the derivative chosen for this work. Treatment of
4-06A/—benzyloxycarbonyl—L-a—aminoadipic acid with 4-nitrobenzyl-
bromide and triethylamine afforded a mixture of the 1— and 6— (4—nitro- 
benzyl) esters, which could be separated by column chromatography.
The desired 1— (4—nitrobenzyl) isomer (84) was isolated in 50% yield 
and the 6— (4—nitrobenzyl) isomer (91) in 24% yield. The mass 
spectra of the two derivatives were quite different and enabled the 
products to be readily distinguished. Fragmentation ions at m/z 
250 and 206 in the spectrum of 84 arise by cleavage a to the amino- 
group and are characteristic of this derivative.
91
S~benzyl—L—cysteine (R2=PhCH2— ) is commercially available. A 
number of ester protective groups were tested before the benzhydryl 
ester derivative (85) (R3=Ph2CH— ) was finally selected. The methyl
ester of S-benzyl-L—cysteine could be readily prepared in 90% yield 
by briefly refluxing the amino-acid in HC1 saturated methanol.
However attempts to selectively remove the methyl ester from synthes­
ised /V-benzyloxycarbonyl—l— (4—nitrobenzyl)—6— (L-a-aminoadipyl)—S—
467benzyl—L—cysteine methyl ester (92) using an excess of Lil in DMF
468or in refluxing pyridine were unsuccessful.
106
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469 470Since its introduction by Woodward ’ the 2,2,2—trichloro-
ethyl group has found extensive use in peptide synthesis as a pro­
tective group for carboxylate residues. Although the 2,2,2—trich- 
loroethyl ester of A/—benzyloxycarbonyl —S~benzyl-L-cysteine 2 ,2 ,2— 
trichloroethyl ester was rapidly and selectively removed at room
temperature using Zn/HOAc, the 2,2,2—trichloroethyl esters of S~ben­
zyl— L—cysteine and D-valine could be prepared in only poor yield.
In contrast treatment of either amino-acid with 1* 5 equivalents
of diphenyldiazomethane in DMF afforded the corresponding benzhydryl
471esters in high yield . Purification of the amino-acid benzhydryl
esters as their 4—toluenesulphonic acid salts proved difficult due to
the considerable quantities of crystalline acetophenone azine (93)
471produced as a by-product during the reaction . However, it
proved possible to use the crude benzhydryl esters in the coupling
reactions (Figure 55) and to remove the contaminating acetophenone
azine by column chromatography of the reaction mixture. Using
472dicyclohexylcarbodiimide and 1 -hydroxybenzotriazole , coupling
of 84 and 85 proceeded in high yield to afford N—benzyloxycarbonyl—
1— (4—nitrobenzyl)— 6—(L—a—aminoadipyl)—S—benzyl-L—cysteine benzhydryl 
ester (8 6 ).
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To determine the optimum conditions for the selective removal 
of the benzhydryl ester small quantities of this dipeptide were sub­
jected to various acidolytic conditions. Treatment with several
different concentrations of HBr—nitromethane failed to selectively
473remove the benzhydryl ester, but treatmentwith 0*2N HCl-nitromethane 
afforded only one product. Reaction of this product with diazomethane 
yielded material chromatographically identical with /V-benzyloxycarbonyl 
—1— (4—nitrobenzyl)—5— (L—a—aminoadipyl)—S~benzyl—L—cysteine methyl ester 





Condensation of /V—benzyloxycarbony1— 1— (4—nitrobenzyl)—5—
(L-a—aminoadipyl)—L—cysteine (94) with crude D-valine benzhydryl 
ester using dicyclohexylcarbodiimide and 1—hydroxybenzotriazole 
afforded fully protected LLD-ACV (87). The lH and l3C n.m.r. 
spectra were fully consistent with the assigned structure. Only 
three a-carbon resonances were observed confirming that the material 
was one diastereoisomer and that no significant racemization had 
occurred during the coupling reactions.
474Sodium-liquid ammonia reduction of fully protected LLD-ACV
(87) cleanly removed all the protective groups to yield the tripeptide
(34), which was isolated as its mercaptide and regenerated by passing
a stream of hydrogen sulphide through an aqueous suspension of the
mercaptide. However, the material obtained by freeze drying the
475resultant solution was shown by Ellman's procedure (using 5,5'-
dithiobis (2-nitrobenzoic acid) as test reagent) to be a 3:1 mixture 
of monomer (34) and dimer (8 8 ). Furthermore elemental analysis of 
the isolated peptide showed that it contained ca 4% inorganic con­
taminants .
To overcome the problem of inhomogeneity the crude product from 
the sodium-liquid ammonia reduction was oxidized by passing air
450through a weakly basic aqueous solution. The resultant disulphide
(8 8 ) was isolated in near quantitative yield by cation-exchange
chromatography on Biorad AG50WX2 resin. The product obtained after
freeze drying the ninhydrin-positive eluate from the ion-exchange
column was shown to be homogeneous by paper electrophoresis, t.l.c.
and h.p.l.c. (using a p-Bondapak-NH2 column with H20:Ac0H (99*6:0*4)
as eluant and UV detection at 214nm and 254nm). The 13C n.m.r.
spectrum of 8 8 showed ten distinct resonances and was similar to 
451that described for the monomer (34) except for the cysteinyl C3
which resonated at 38*5 p.p.m. The cysteinyl C3 resonance of the
451monomeric tripeptide is observed at 26*1 p.p.m. . These results
476are in agreement with the reported shifts of cystine C3 at 44*6
p.p.m. and cysteine C3 at 28*2 p.p.m.
Evidence from lH n.m.r. experiments confirmed that quantitative 
reduction of the disulphide to LLD-ACV (34) could be achieved using 
dithiothreitol (DTT) in neutral or slightly basic aqueous solution.
The chemical shift of the cysteine 3H,2H and valine 3H protons are
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quite distinct in the monomer and dimer. Thus a solution of 88 
and a five fold excess of DTT in D20 was stable and contained none 
of the monomeric species. When the solution was adjusted to neutral 
or weakly basic pH the lH n.m.r. spectrum indicated complete reduct­
ion to the monomer (34). Reduction occurred quantitatively and 
virtually immediately (at least in the 30 sec or so necessary to 
adjust the pH and return the sample to the probe).
The overall yield of LLD-ACV (8 8 ) from S-benzyl—L—cysteine was 
40% and from D-valine, 62%.
4.2 THE SYNTHESIS OF IS0T0PICALLY ENRICHED ACV PEPTIDES
4.2.1 The Synthesis of 5— (DL-ct—Aminoadipyl)—L—Cysteinyl—D— (3R) — [4— 1 3C ]—Valine
With a satisfactory synthesis of LLD-ACV now available the syn­
thesis of isotopically enriched species was undertaken.
As discussed in Section 3.3 the stereochemical fate of the valine
C3 centre was of importance in elucidating the mechanism of thiazoli-
401dine ring formation. It has recently been shown that (2S,3R)—
[4— 1 3C]—■valine is incorporated into LLD-ACV (isolated as its sul- 
phonic acid, LLD-ACyaV, 95) apparently without racemization of the 
valine C3 centre. Hydrolysis of the sulphonic acid (95) afforded 
D-valine enriched at the 3—pro—R methyl carbon. Assignment of the 
position of enrichment in the biosynthesised peptide was based on 
comparison of the 13C n.m.r. spectra of the sulphonic acid and the 
D-valine from hydrolysis with the 13C n.m.r. spectrum of authentic
401*The correct stereochemical assignments and not those reported 
earlier (on the basis of Aberhart's incorrect assignments 400) are 
used throughout the following discussion.
110
(2R,3R)— [4— 1 3C]—valine. To confirm the stereospecificity of valine
incorporation it was necessary to prepare the sulphonic acid (96) 
enriched specifically at the 3—pro-R methyl carbon.
111
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95 R = CH3
96 R = i3CH3
Coupling of /V-benzyloxycarbonyl- 1 — (4—nitrobenzyl)— 6— (DL—a—amino-
adipyl)—S—benzyl—L—cysteine and D-valine benzhydryl ester enriched
with synthetic (2R,3R)— [4— 1 3C]—valine benzhydryl ester afforded fully
protected LLD-ACV. The (2R,3R)— [4— 1 3c ] —valine required for this
400synthesis had previously been prepared in this laboratory as a
by-product in the preparation of (2S,3R)— [4— 1 3C]—valine. The 
D-valine isotopomer was diluted with D-valine to an enrichment of 
ca 2 atom%. The material was converted to its benzhydryl ester and 
coupled as previously described.
The fully protected LLD-ACV so obtained was deprotected and the
product oxidized with performic acid to afford <5— (DL—a—aminoadipyl) —
L—cysteicyl—D— (3R)—[4— 1 3C]—valine (96). The 13C n.m.r. spectrum was
identical to that of unlabelled LLD-ACyaV (95) prepared in an anala- 
gous manner (Figure 56). The intensity of the signal at 18*7 p.p.m. 
was greater (2 *1 ±0 *1 x natural abundance) than that of the diastereo- 
isomeric methyl group at 17*0 p.p.m. The results were in complete 
agreement with those previously published and confirmed the stereo- 
specificity of valine incorporation (Figure 38).
4.2.2 The Synthesis of 6— (L-q-Aminoadipyl)—L— [3— 1 3C]—Cysteinyl-D— [1 5N]—'Valine 
The 1 3C, l5N-labelled LLD-ACV (82) was synthesised as its di­
sulphide using the procedures developed for the synthesis of 8 8 .
Commercially available DL—[1 5N]—valine (95 atom% 1 5N) was
477resolved using standard methods . The labelled amino-acid was 
refluxed in a mixture of acetic acid and acetic anhydride to afford 
the IV -acetyl derivative which was not isolated. Treatment of the 
crude product with hog kidney acylase I yielded L— [1 5N]—valine and 
A/'-acetyl—D— [ 1 5N]—valine which were separated by cation-exchange 
chromatography. The /V—acetyl—D— [1 5N]—valine was refluxed in con­
centrated aqueous HC1 to obtain the required starting material,
D— [1 5N]—valine (Figure 57).
The lH n.m.r. spectrum of the D—[ 1 5 N]—valine hydrochloride salt 
displayed a three bond N-H coupling of 3»3Hz with the C3 proton but 
no two bond N-H coupling. A 1 of 6 ’OHz was evident from the 13C 
n.m.r. spectrum of the hydrochloride salt. A coupling of ca3’OHz 
has been reported for L—[2—l3C, l5N]—valine but the magnitude of 
the coupling constants may depend on the pH at which the spectra are 






90MHz broad-band proton decoupled n.m.r. spectrum 
of (a) 5-(L-a-aminoadipyl)-L-cysteicyl-D-valine 
(sweep ’width 20kHz, number of scans 80808) and 
(b) 6-(DL-a-aminoadipyl)-L-cysteicyl-D-(3R)-[4- ^c] - 
valine (sweep width 20kHz, number of scans 49800).
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the range 0-2Hz) is known to decrease with decreasing pH.
S—benzyl—L— [3— 1 3C]—cysteine is not commercially available and
had to be synthesised. DL— [3— 1 3C]—serine is commercially available
and could have been converted to S—benzyl—DL— [3— 1 3C]—cysteine by the
479method of Wood and Middlesworth (Figure 58). A more attractive
route to the labelled amino-acid, however, was one based on Upson 
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What was effectively a two step synthesis of S~benzyl—DL—cysteine 
could prove extremely economical if the relatively inexpensive [1 3C]— 
paraformaldehyde could substitute for the paraformaldehyde equivalent 
CD2 (0Ac) 2 employed by Upson and Hruby. The highly volatile diacetoxy 
—[2H2]—methane was presumably used in their synthesis as it could be 
easily prepared from the readily available dibromo— [2H2]—methane.
The reaction of unlabelled paraformaldehyde, dimethylamine and 
diethyl acetamidomalonate afforded a low yield of diethyl acetamido- 
dimethylaminomethylmalonate. However, by varying the reaction con­
ditions, time, temperature and pH of the aqueous suspension, an 
acceptable 67% yield of product was obtained. The yield of diethyl 
acetamidodimethylaminomethylmalonate from a series of trial experi­
ments was found to vary greatly and depend on the purity of the
starting materials. The optimum pH of the reaction was the weakly
481acidic catalytic condition of the Mannich Reaction
The remaining steps from diethyl acetamidodimethylaminomethyl-
malonate to S~benzyl—DL—cysteine were carried out as previously
described (Figure 59). Resolution of the racemic S-benzyl—
cysteine was found to be more difficult than had been anticipated.
477The literature procedure , involving N— acétylation and enzymic 
deacetylation of the L-isomer, afforded only moderate yields of 
L—cysteine. The refluxing Ac0H/Ac20 conditions used to acylate 
5—benzyl—DL—cysteine were found to cause decomposition. Maintain­
ing the temperature of the reaction below 60°C allowed /V-acetylation 
without decomposition and, as observed with S-benzyl—L—cysteine, 
without racemization of the chiral centre of the amino-acid.
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Despite careful attention to the optimum conditions derived
from trial reactions, when the synthesis was repeated using [1 3C]—
paraformaldehyde the final yield of product dropped considerably.
This was presumably due to an impurity in the [1 3C]—paraformaldehyde
which was used as supplied by the manufacturer and was not resublimed.
[1 3C]—paraformaldehyde has also been used for the preparation of
dimethoxy— [1 3C ]—methane in this laboratory. While yields of 90-95%,
based on technical grade paraformaldehyde, are generally possible in
this reaction, yields from [1 3C]-paraformaldehyde are typically 60-70%.
482The source of the impurity is not known
S—benzyl—L— [3— 1 3C ]—cysteine was finally obtained by treating
S—benzyl—DL— [3— 1 3C ]—cysteine with Ac0H/Ac20 at 60°C and resolving 
the resultant racemic /V—acetyl amino-acid with hog kidney acylase I.
The mixture of S~benzyl—L— [3— 1 3C ]—cysteine and A/-acetyl—S-benzyl—D—
[3— 1 3C ]—cysteine was separated by cation-exchange chromatography 
(Figure 60).
Only one resonance at 36*73 p.p.m. was observed in the 13C n.m.r. 
spectrum of 5 —benzyl—L— [3— 13C]—cysteine sodium salt. A number of 
1 3C-H couplings could be determined from the n.m.r. spectrum.
The cysteine 3H protons formed the AB of an ABMX multiplet with
couplings of 140*7 and 140*3 Hz. A two bond 1 3C-H coupling of 
4*8Hz to the cysteine 2H proton and a three-bond1 3C-H coupling of 
3*8Hz to the methylene protons of the 5—benzyl group were also 
observed. The 3H n.m.r. spectrum indicated a 13C enrichment at 
cysteine 30 of _> 90%.
With D— [1 5N ]—valine and S-benzyl-L-[3-1 3C]-cysteine now avail­
able the synthesis of 6— (L—a-aminoadipyl)—L— [3— 1 3C]—cysteinyl—D— 
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described for the unenriched tripeptide (Section 4.1). The 1 3C 
n.m.r. spectrum of the isolated disulphide (97) displayed one reson­
ance at 39*176 and in the lH n.m.r. spectrum a lJ coupling ofCH
193*9Hz was observed for the cysteine 3H protons. All the amide 
protons exchanged in the D20 solution and no 1 SN-H doublet was
observed- However, in the fully protected species, /V-benzyloxy-
carbonyl—1— (4—nitrobenzyl) — <5— (L—a—aminoadipyl J-S-benzyl-L-I^S- 1 3C ]
—cysteinyl—D— [1 SN ]—valine benzhydryl ester, a lJ of 91«3Hz wasNH
observed. The free [l3C, 1 5 N]—tripeptide dimer (97) displayed a 
base peak, (M+H) ion at m/z 729 in its FAB mass spectrum.
A related tripeptide, 6 — (L-a-aminoadipyl)-L—[ 3— 1 3 C]—cysteinyl 
—D—[ 3—1 3C,1 5 N]—valine has been synthesised
CONH 




4.3 THE SYNTHESIS OF <S-(L—a—AMINOADIPYL )—L—CYSTEINYL—D—VALYLGLYCINE
The nature of the protective groups used in the synthesis of 
LLD-ACV (Figure 55) was deliberately designed to allow easy access 
to the protected tetrapeptide (89). Thus treatment of 87 with 0*2N 
HCl-nitromethane selectively removed the benzhydryl ester yielding 
/V—benzyloxycarbony1—1— (4—nitrobenzyl)—5 — (L-a—aminoadipyl)— S— benzyl 




98 R = -OH
99 R = -N'
O
*NH
100 R= N NH
ester could not be satisfactorily achieved with dicyclohexylcarbodii-
mide and 1 -hydroxybenzotriazole. The only material isolated from
this reaction was the /V-acyl urea (99). It is possible that the
456activated 0-acyl derivative (1 0 0 ) is sterically hindered to
attack by 1 -hydroxybenzotriazole or the added glycine benzyl ester 
and rearranges to the synthetically useless derivative (99) .
Condensation was achieved in moderate yield using a mixed anhy­
dride method. The acid (98) was treated with ethylchloroformate in 
the presence of pyridine to give the corresponding mixed anhydride 
which was not isolated but reacted in  s i t u  with glycine benzyl ester 
to afford, after preparative t.l.c., the desired product (89) in 46% 
yield (from 87).
The fully protected tetrapeptide (89) was isolated analytically 
pure. The lH n.m.r. spectrum was recorded in CDC13 :CD30D (1:1), as 
89 was poorly soluble in CDC13. Although the presence of a CD3OH 
resonance partially masked the glycine a-protons, the rest of the
spectrum could be readily assigned and was consistent with the de­
sired structure.
Fully protected LLD-ACVG (89) was deprotected as previously 
described for LLD-ACV (87) and isolated as its disulphide (90) after 
cation-exchange chromatography. The material was homogeneous by 
t.l.c. and h.p.l.c. (using a Waters p—Bondapak—NH2 column and H20:
AcOH (99*6:0*4) as eluant). The FAB mass spectrum of 90 displayed 
a (M+H) ion at m/z 839 though the base peak at m/z 421 was of the 
monomer (83). The glycine a-protons resonated as a singlet at 
3*206 in the lH n.m.r. spectrum of 90.
The overall yield of 90 from S—benzyl—L—cysteine was 13% and
from D-valine, 21%.
4.4 THE SYNTHESIS OF N-\ 6 — ( L—a—AMINOADIPYL)—L—CYSTEINYL]-/V—HYDROXY—D—VALINE
Based on the methodology used to synthesise LLD-ACV (8 8 ) it was 
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hydroxy—D—valine (LLD-AC(N-OH)V) (81) would be straightforward (Figure
61). Compound 94 had already been prepared 465 and it seemed likely,
483-485on the basis of literature reports , that this compound would
acylate A/—hydroxy—D—valine benzyl ester (1 0 1 ) exclusively on nitrogen 
to afford protected LLD-AC(N-OH)V (102).
4.4.1 The Synthesis of (V—Hydroxy—D—Valine Benzyl Ester
The synthesis of racemic N—hydroxy—amino-acids has been achieved
486-488 u , , . , . 489 . . . . . .but there is only one brief report in the literature on
the indirect oxidation of amino-acid esters to chiral N—hydroxy-amino-
acid derivatives. The communication describes the oxidation of the
Schiff bases of amino-acid esters to oxaziridines, which, when heated
in hydrochloric acid, afford the corresponding N—hydroxy—amino-acids
(Figure 62) .
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In order to secure a one step deprotection of 102 to LLD-AC 
(N-OH)V (81) (Figure 61) the benzyl ester of D-valine was the deriva­
tive chosen as starting material. D-valine benzyl ester 4-toluene-
490sulphonic acid salt was prepared as described and shown by t.l.c.
to be free of any D-valine 4-toluenesulphonic acid salt. The opti­
cal rotation ([a]D+3*0 (c2 «0 ,ethanol)) of the product was of opposite
491sign but of lower magnitude than that reported for L-valine
benzyl ester 4-toluenesulphonic acid salt ([a] —3»5(c2*0,ethanol)).
The D-valine ester was therefore refluxed in concentrated aqueous 
HC1 and the free amino-acid isolated from solution. The optical 
rotation of this material was identical to that of the commercial 
D-valine used in the synthesis and confirmed that no racemization 
had occurred.
Treatment of D-valine benzyl ester with 4—methoxybenzaldehyde
in benzene afforded the imine (103) in quantitative yield. Oxida-
492tion of the imine with 3—chloroperbenzoic acid gave the oxaziri-
dine (104) which was unstable and adjudged by lH n.m.r. spectroscopy 
to be a complex mixture of diastereoisomeric products. Attempted 
hydrolysis of the crude mixture with 1M or 2M aqueous-methanolic HC1 
afforded the highly crystalline D-valine benzyl ester 4-methoxy- 
benzaldimine IV-oxide (105) (Figure 63). The rearrangement of oxo-
489ziridines to ¿V-oxides in the presence of an acid catalyst is known
492, 493and proceeds v ia  a carbonium ion intermediate ’ . At higher
492-494acid concentrations oxaziridines are successfully hydrolysed 
(Figure 64).
The 4-methoxybenzaldimine derivative (R=4—Me0C6H„- in Figure 64) 
stabilises the carbonium ion allowing hydrolysis to proceed at a 
reasonable rate. Thus treatment of the 3-chloroperbenzoic acid
125
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oxidation products with 3M HC1 in dioxane:H20(1:1) afforded the desired 
material, N— hydroxy—D—■valine benzyl ester hydrochloride salt (106) 
(Figure 63). The overall yield of 106 from D-valine was 50%.
The structure of N—hydroxy—D—•valine benzyl ester hydrochloride 
salt was confirmed from its spectroscopic properties. It is inter­
esting to note that the valine C2 resonance, in the 13C n.m.r. spect­
rum of 101 obtained from 106, was observed at 72*81 p.p.m. This 
compares with a chemical shift of 59*156 for the valine 02 resonance 
of D-valine benzyl ester. Elemental analysis of the hydrochloride 
salt (106) was unsatisfactory and remained unsatisfactory even after 
three successive crystallizations. The free base (101) also yielded 
an unsatisfactory result but the 4-toluenesulphonic acid salt of
A/—hydroxy—D—valine benzyl ester gave a satisfactory elemental analysis.
/V—hydroxy—D—'valine benzyl ester was found to be weakly ninhydrin- 
495positive . This may have been due to disproportionation of the
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The /V—hydroxy—amino-acid (106) did not give a colour reaction
with a 2% ethanolic solution of FeCls. All hydroxamic acids give a
497red or violet colour with ferric chloride in weak acid solution
4.4.2 The Synthesis of A M  <$— ( L—a—Aminoadipyl )—L—Cysteinyl ]-A/—Hydroxy—D—Valine 
Reaction of A/—benzyloxycarbonyl— 1— (4—nitrobenzyl)—6— (L—a—amino- 
adipyl)—S—benzyl—L—cysteine (94) with A/—hydroxy—D—valine benzyl ester
(1 0 1 ), using dicyclohexylcarbodiimide and 1-hydroxybenzotriazole as 
coupling agents, afforded one major product isolated in 74% yield.
This material was FeCl3-negative and on the basis of mass spectro­
scopic evidence appeared to be the 0-acyl derivative (107) rather 




483-485This result was unexpected . However, a search of the
literature uncovered several examples 4 8 8 of 0-acylation of
/V-alkyl hydroxylamines. In a mechanistic study, Jencks '̂<“)<“>’ 
found that the reaction of 4-nitrophenyl benzoate with hydroxylamine 
gave rapid initial 0-acylation. In the presence of excess hydroxy­
lamine this product further reacted to yield benzohydroxamic acid.
O-benzoylhydroxylamine was also converted to the thermodynamically 
more stable benzohydroxamic acid upon heating the pure liquid.
Attempts to rearrange the 0-acyl derivative (107) by refluxing 
the product in EtOH or dioxaneor heating the solid under an argon 
atmosphere failed to produce any FeCl3-positive material. The only 
isolated material was N~benzyloxycarbonyl— 1— (4—nitrobenzyl)— 6— (L—a— 
aminoadipyl)—S—benzyl-L-cysteine (94) possibly obtained by a-proton 
abstraction (Figure 6 6 ) .
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In an attempt to establish conditions which would isomerize
O-acyl derivatives to hydroxamic acids, 0 — (N~benzyloxycarbonyl-S— 
benzyl—L—cysteinyl)-A/~hydroxy—D—valine benzyl ester (108) was syn­
thesised in 90% yield (by the dicyclohexylcarbodiimide/l-hydroxy- 
benzotriazole coupling of A/—benzyloxycarbonyl—S—benzyl—L—cysteine 
and ¿V—hydroxy—D—valine benzyl ester). However, conditions could 
not be found which would transform 108 to the hydroxamic acid. 
Heating 108 in a variety of solvents, in the presence of acid, base, 
FeCl3 and excess /V— hydroxy—D—valine benzyl ester all failed to pro­




In Kolasa and Chimiak's successful synthesis of /V—hydroxy- 
peptidescoupling was achieved using 0 -protected derivatives of 
/V—hydroxy—amino-acid esters. As 0-acylation was evidently readily 
accomplished A/—chloroacetoxy—D—valine benzyl ester (109) was syn­
thesised but could not be successfully coupled with A/—benzyloxy­
carbonyl—S—benzyl—L—cysteine under a variety of conditions. The 
electron withdrawing chloroacetoxy substituent presumably reduces 





A trimethysilyl derivative of A/—hydroxy—D—valine benzyl ester
was prepared by reaction with N ,0 —bis(trimethysilyl)acetamide but
was not characterized. Reaction of the crude material with chloro-
acetic acid and dicyclohexylcarbodiimide in methylene chloride
afforded a mixture of products including a minor FeCl3-positive
component. Attempts to synthesise and isolate the more stable
503t-butyldimethylsilyl derivative were unsuccessful.
Alkylation of A/-hydroxy—D—valine benzyl ester proved equally
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unrewarding. Starting material was recovered when the salt (106)
was treated with trityl chloride or benzyl bromide and triethylamine.
504Treatment with benzyl bromide and silver oxide did yield a new
product, but this was identified as the (V-benzyl derivative (1 1 0 ),
rather than the desired 0-benzyl derivative (1 1 1 ), by comparing the
499shift of the benzyl methylene protons with reported values and
with those calculated from Shoolery's rules. The observed shift of
499the benzyl methylene was 3*876, while examples reported by Chimiak 
for 0-benzyl derivatives fall in the range 4*62-4-906. The calcul­
ated values for R0C//2Ph and R 2NC//2Ph are 4 .44,5 and 3.656 respectively. 
¿V-benzyloxy—D—valine benzyl ester (1 1 1 ) was prepared, though in very 
low yield, following reaction of A/-hydroxy—D—valine benzyl ester with 
sodium hydride and benzyl bromide. The observed benzylation on nit­
rogen, with benzyl bromide and silver oxide, and on oxygen, with
sodium hydride and benzyl bromide, is in complete agreement with
505theoretical predictions for the alkylation of hydroxylamine
OH
n o  i n
As direct 0-protection of /V—hydroxy—D—valine benzyl ester 
appeared impracticable, attention was focused on the coupling re­
action in the hope that certain conditions would favour A/— rather 
than 0 — acylation. The active 4-nitrophenyl esters, ethoxycarbonyl
mixed anhydrides or acid chloride derivatives of A/—benzyloxycarbonyl—
1— (4—nitrobenzyl)— 6— (L—a—aminoadipyl) —S—benzyl—L—cysteine (78) and 
A/—benzyloxycarbonyl-^—benzyl—L—cysteine did not react with N—hydroxy—
D—valine benzyl ester (101) to yield hydroxamic acids. No FeCl3- 
positive materials were detected by t.l.c. of the reaction mixtures.
Treatment of -benzyloxycarbonyl-5 -benzyl—L—cysteine and 
/V—hydroxy—D—valine benzyl ester with dicyclohexylc-arbodiimide in DMF 
gave a mixture of products, one of which was FeCl3-positive. 
Chromatography on silica gel afforded A/ — (A/—'benzyloxycarbonyl-£— 
benzyl—L-cysteinyl)-A/,A/'—dicyclohexylurea (1 1 2 ) isolated in 33% 







The hydroxamic acid (113) decomposed rapidly upon crystalliza­
tion but an analytically pure sample was obtained. This material 
gave a strong red colour with ethanolic FeCl3 and absorbed at 1670cm 1
in the i.r. spectrum. Absorption in the range 1670-1640 cm 1 has 
484been reported for hydroxamic acid carbonyls. A single resonance, 
at7»91<5 in the “H n.m.r. spectrum of 113, readily exchanged with D20 
and was assigned to the hydroxamic acid proton.
In an attempt to reduce /V—acyl urea (112) formation, the dicyclo-
506hexylcarbodiimide coupling was performed in methylene chloride , 
but none of the desired hydroxamic acid (113) was obtained. The 
only successful condition for the formation of 113 was the dicyclo- 
hexylcarbodiimide coupling in DMF.
When identical conditions were used to couple A/—benzyloxycarbonyl 
— 1— (4—nitrobenzyl)— 6— (L—a—aminoadipyl)—S—benzyl—L—cysteine (94) and
A/—hydroxy—D—valine benzyl ester, the only isolated product was N—[N—
benzy loxyca rbo ny l—1 —(4—n it r o b e n z y l)—<5—( L—a—a m in o a d ip y l)— S— b e n zy l—L—
cysteinyl]-iV,/Vdicyclohexylurea (114). No FeCl 3-positive material
was detected. The coupling condition is apparently very sensitive
to the /V-substituent of S—benzyl—L—cysteine. N— t—butoxycarbonyl—S—
be n zy l—L—c y s te in e  lik e w is e  f a i le d  to  condense w ith  /V—hydroxy—D—v a lin e
507m ethy l e s te r  to  g ive  a hydroxam ic a c id
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The successful formation of 113, however, suggested that 
LLD-AC(N-0H)V (81) could be produced by selective deprotection of 
113, coupling of the product with /V—benzyloxycarbonyl —L-d—aminoadipic 
acid 1— (4—nitrobenzyl) ester (84) and deprotection of the result­
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F I G U R E 67
Literature reports ’ ’ confirmed that a benzyloxy-
carbonyl group could be selectively removed in the presence of a 
benzyl ester. However, treatment of the dipeptide derivative (113) 
with various concentrations of HBr in acetic acid or with trifluoro- 
acetic acid gave a mixture of starting material and the three products 
115, 116 and 117. Conditions could not be found which gave predom­
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The desired product (115) was identified by t.l.c. as it gave a
positive colour reaction with ninhydrin but no colour reaction with
5102,6—dichlorophenolindophenol sodium salt . Although 115 could be 
identified, it readily decomposed and could not be isolated by pre­
parative t.l.c.
In a trial reaction the crude mixture of products (113, 115, 116 
and 117) was treated with the ethoxycarbonyl mixed anhydride of /V- 




After 3^h at room temperature the reaction was stopped. An 
analytical t.l.c. of the reaction mixture suggested at least nine 
different materials were present. Fortunately there was only one 
major FeCl3-positive material, and after extensive column chromato­
graphy this was isolated in 12% yield. The product was homogeneous 
by t.l.c. in a variety of solvent systems, but the *H and 13C n.m.r. 
spectra of the material indicated that it was an almost 50:50 mixture 
of two compounds. A small quantity of the mixture was separated by 
reverse phase h.p.l.c. and the lH n.m.r. spectra of the individual
components examined. The least mobile component was FeCl3—positive 
and appeared to be the desired hydroxamic acid tripeptide (1 0 2 ).
The lH n.m.r. spectrum showed two amide NH resonances at 5*54 and 
6«21 p.p.m. and one resonance at 8*34 p.p.m. assigned to the hydrox­
amic acid proton. The lH n.m.r. spectrum of the most mobile com­
ponent contained three amide protons and no hydroxamic acid proton, 
but was otherwise similar to that of 102. It was initially assumed 
that this second component was /V—benzyloxycarbonyl— 1— (4—nitrobenzyl)
— 6— (L—a—aminoadipyl)—S—benzyl—L—cysteinyl—D—valine benzyl ester (119) 
and indeed a subsequent lH n.m.r. spectrum of an authentic sample 
(prepared by coupling benzyloxycarbonyl—1— (4—nitrobenzyl)— 6— (L—a— 
aminoadipyl)—S—benzyl—L—cysteine and D-valine benzyl ester) was 
identical to that of the second component. The isolated LLD-ACV 






It is not entirely clear how the tripeptide (119) was formed in 
the above reaction. The most likely explanation, and one which can 
be inferred from later results, is that /V-benzyloxycarbonyl—S-benzyl— 
L-cysteinyl-D—valine benzyl ester (120) was formed early in the syn­
thesis .
As previously mentioned /V-(/V-benzyloxycarbonyl—S~benzyl—L—
cysteinyl )-/V—hydroxy—D—valine benzyl ester (113) was obtained in
slightly impure form. The impurity (5-10% of the weight) was not
identified but may well have been the dipeptide (120). The minor
peaks in the lH n.m.r. spectrum of crude 113 were consistent with 
451values reported for 1 2 0 , and a synthetic sample of N—benzyloxy-
carbonyl—5—benzyl—L—cysteinyl—D—valine benzyl ester (1 2 0 ) (prepared 
by coupling N—benzyloxycarbonyl—S—benzyl—L—cysteine and D-valine 
benzyl ester) proved inseparable from 113 by analytical t.l.c.




of y\/-hydroxy—D—valine benzyl ester used in the preparation of 113, 
but may have been formed during the coupling reaction by disproport­
ionation of A/-hydroxy—D—valine benzyl ester (Figure 65). In the 
presence of /V-benzyloxycarbonyl—S—benzyl—L—cysteine and dicyclohexyl- 
carbodiimide the dipeptide (1 2 0 ) would be rapidly formed.
The mixture of N—[N—benzyloxycarbonyl—1 — (4—nitrobenzyl ) — 5—
(L—a—aminoadipyl)—S-benzyl—L—cysteinyl ]-/V—hydroxy—D—valine benzyl 
ester (1 0 2 ) and N—benzyloxycarbonyl— 1— (4—nitrobenzyl)— <5— (L—a—amino­
adipyl )— S-benzyl—L-cysteinyl—D—valine benzyl ester (119) could not 
be chromatographically separated except in minute quantities by 
h.p.l.c. Many different solvent systems and stationery phases 
(silica, alumina, polyacrylamide and reverse phase C—18 silica) were 
tested but no separation of the components was observed.
Attention, therefore, was directed to the difference in func­
tionality between the two components. It was hoped that a deriva­
tive of the hydroxamic acid (1 0 2 ) could be found which would allow 
chromatographic separation from the tripeptide (119 ).
The trimethylsilyl ester of the hydroxamic acid (121 ) could be
prepared by treatment of the mixture with /V,0-bis(trimethylsilyl)
acetamide. This derivative, however, was too labile to effect
separation of the mixture, and the t-butlydimethylsilyl ester, which
503would have been more stable , could not be prepared.
Reaction of 102 with acetic anhydride and pyridine afforded the
0-acetyl derivative (1 2 2 ) which was stable and could be separated 
from the LLD-ACV tripeptide (119) by preparative t.l.c. Unfortun­














group were incompatible with other functionalities in the molecule 
and a mixture of unidentified products was obtained. Trifluoro- 
acetic anhydride reacted not only with the hydroxamic acid (1 0 2 ) but 
also with the tripeptide (119) in the mixture. Mild basic hydrolysis 
of the crude products did not lead to recovery of starting materials.
The 2,2,2-trichloroethoxycarbonyl derivative (123) was prepared by 
reaction of the mixture with 2 ,2 ,2-trichloroethylchloroformate in 
pyridine. The product (123), isolated by preparative t.l.c., was 
apparently deprotected using Zn/HOAc, but the hydroxamic acid (102) 
was not recovered from the solution. The free hydroxamic acid may 
have complexed with the zinc.
In an attempt to alkylate the hydroxamic acid (102), the mixture 
of materials was treated with benzyl bromide and triethylamine, but 
after five days at room temperature the starting materials were re­
covered unchanged. Reaction with diazomethane afforded the methyl
473ester (124), but the more versatile diphenylmethyl derivative 
(125) was not obtained from reaction with diphenyldiazomethane.
Finally treatment of the mixture (102 and 119) with benzyl 
bromide and silver oxide in DMF yielded /V— [/V—benzyloxycarbonyl—
1— (4—nitrobenyl)— 6— (L—a—aminoadipyl)—£—benzyl—L—cysteinylj-W—benzy- 
loxy—D—valine benzyl ester (126) which was separated from unchanged 
119 by column chromatography. The structure of the protected spec­
ies (126) was confirmed from its spectroscopic characteristics.
The material was FeCl3-negative as anticipated, and in the lH n.m.r. 
spectrum a new benzyl methylene signal was observed as an AB multi- 
plet centred at 5*066. In the 13C n.m.r. spectrum of 126 the val­
ine C2 resonance was observed at 66*236. Though this is not as
142
significant a downfield shift as observed for A/-hydroxy—D—valine 
benzyl ester (1 0 1 ), the consistent shift of the a-carbon to high 
frequency appears to be indicative of the hydroxamic acid function­
ality . In /V-benzyloxycarbonyl—1— (4—nitrobenzyl)—6— (L-a—aminoadipyl)
—5-benzyl—L—cysteinyl—D—valine benzyl ester (119) the valine a-carbon 
resonates at 57*476.
The derivative (126) was deprotected and isolated using the same 
procedures developed for the synthesis of LLD-ACV (8 8 ). Thus sodium- 
liquid ammonia reduction and air oxidation afforded a crude material 
which was purified by cation-exchange chromatography. Freeze-drying 
the ninhydrin-positive eluate yielded two products. These could be 
separated by preparative electrophoresis and, on the basis of FAB mass 
spectral analysis, were tentatively assigned the monomer and dimer 
structures, 127 and 128 respectively.
Both materials were FeCl3-positive and yielded the same product 
(presumably IV— [6-(L-a—aminoadipyl)—L—cysteicyl]-N — hydroxy—D—valine) 
when oxidized with performic acid. Why the free thiol (127) was 
not completely oxidized to the disulphide (128) on oxygenation of a 
basic aqueous solution of 127 was unclear. The close proximity of 
the strongly acidic hydroxamic acid may decrease the pKb of the sul- 
phydryl group and reduce the rate of disulphide formation.
The lH n.m.r. and 1 3C n.m.r. spectra of 127 and 128 were ex­
tremely complicated and adjusting the pH of the D20 solutions had 
little simplifying effect on the lH n.m.r. spectra. As the mass 
spectra were consistent with the proposed structures, 127 ((M-H) 
ion at m/z 378*1327, Ci i,H2 DNaOyS requires m/z 378*1329) and 128 








attributed to each being a mixture of diastereoisomers. Racemiz- 
ation at one or more chiral centres may have occurred during the 
basic oxidation of the crude product or during the sodium-liquid 
ammonia deprotection of the fully protected species (126), partic­
ularly if a trace of moisture was present.
After eventually succeeding in producing AC(N-OH)V it was dis­
heartening to find that the final product was not optically pure.
It was resolved, therefore, to devise an improved synthesis of LLD- 
AC(N-OH)V (81). The knowledge gained during the above synthesis of 
127 and 128 would help determine the new synthetic route. A more
acid labile ^-protective group than the benzyloxycarbonyl derivative
of 113 was required, yet too great a change in the /V-protective group
might result in failure to synthesise the hydroxamic acid (see page
511134). The 4-methoxybenzyloxycarbonyl derivative seemed ideal and
the proposed synthesis of 81, using this protective group, is outlined 
in Figure 6 8 . In order to test this route, LLD-ACV (119) was synthe­
sised as shown in Figure 69.
/V—4—methoxybenzyloxycarbonyl—5—benzyl—L—cysteine (129) was pre­
pared by reaction of 5-benzyl—L—cysteine with 4—methoxybenzyloxy- 
carbonyl azide under Shotten-Baumann conditions. The product was 
isolated as its dicyclohexylamine salt and fully characterized. The 
free acid (129) readily obtained from the dicyclohexylamine salt was 
coupled with D-valine benzyl ester using dicyclohexylcarbodiimide and
1—hydroxybenzotriazole. The resultant dipeptide derivative (132)
was isolated by column chromatography in near quantitative yield and 
subjected to various acidolytic conditions. It was found that 
removal of the 4—methoxybenzyloxycarbonyl group could be selectively 
achieved using a range of HCl-nitromethane concentrations. In 
practice HC1 saturated nitromethane was employed. The deprotected 
species (133) could be isolated as its hydrochloride salt, but was 
most conveniently isolated as its 4-toluenesulphonic acid salt in 
71% yield. The dicyclohexylcarbodiimide/1—hydroxybenzotriazole 
mediated coupling of the free base (133) and /V—benzyloxycarbonyl—L— 
a-aminoadipic acid l-(4—nitrobenzyl) ester (84), afforded the fully 
protected LLD-ACV tripeptide (119) identical to previously prepared 
material. The overall yield of 119 from 5—benzyl—L-cysteine was 
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F I G U R E  69
Encouraged by this short efficient synthesis of fully protected 
LLD-ACV (119) from the C—terminal end, an analagous route (Figure 6 8 ) 
was used to prepare protected LLD-AC(N-OH)V (102). The first and 
most critical step was the synthesis of the dipeptide hydroxamic acid 
(130). The previously established dicyclohexylcarbodiimide condensation 
of /V— 4 — methoxybenzyloxycarbonyl—S-benzyl—L—cysteine (129) and 
/V-hydroxy—D—valine benzyl ester (101) in DMF, afforded a mixture of 
materials which could be separated, with difficulty, by column chroma­
tography. The major product was /V— (N--4—methoxybenzyloxycarbonyl—S— 
benzyl—L—cysteinyl) -N ,N '~dicyclohexylurea (134) isolated in 22% yield.
The more polar FeCl3-positive material decomposed upon crystallization 
and as a result was obtained in only 8% overall yield.
148
134
It was clear from the *H and 13C n.m.r. spectra that the FeCl3-
positive material was in fact a mixture of 130 and 132. Treatment
504of the mixture with benzyl bromide and silver oxide in distilled
DMF did not give the 0 —benzyl derivative (135) as anticipated. The 
dipeptide (132) was recovered along with two new materials identified 
by !H n.m.r. and mass spectroscopy as 0 —benzyl—2—oxoisovaleric acid 
oxime benzyl ester (136) and /V—benzyl-/V—hydroxy—D—valine benzyl ester 
(1 1 0 ).
149
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The isolated material (110) was identical to that produced dur­
ing attempts to 0 ~benzylate A/—hydroxy—D—valine benzyl ester with 
benzyl bromide and silver oxide (see page 131). Presumably 110 arose 
in this case as in the previous case by reaction of free /V—hydroxy—D— 
valine benzyl ester. How free A/—hydroxy—D—valine benzyl ester came 
to be present in the reaction mixture, and how the minor component 
(136) was produced, is unknown. In contrast, the reaction proceeded 
smoothly and efficiently when repeated in non-distilled DMF to afford 
N —  (/V—■4—methoxybenzyloxycarbonyl—S— benzyl—L—cysteinyl )-A/—benzyloxy—D— 
valine benzyl ester (135) in 6 8% yield.
The only difference between the successful and failed reactions
was that in the failed reaction distilled DMF had been used as sol-
512vent. As DMF is known to decompose to dimethylamine and carbon- 
monoxide during distillation perhaps the following speculative pro­
posal can explain these results.
Initially the benzylation reaction proceeds as expected but 
soon traces of moisture are produced (Figure 70).
Ag2 0 + 2PhCH2 Br + 2R0H
4'
2R0CH2 Ph + 2AgBr + H20 
F I G U R E  70
In the presence of dimethylamine, hydroxide ions would be formed 
and could hydrolyse the hydroxamic acid. Hydroxamic acids are hydro­
lysed to carboxylic acids and hydroxylamines far more readily than 
amides and hydrolysis is almost certainly involved (Figure 71).
151
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F I G U R E  71
The N—hydroxy—D—valine benzyl ester (137, R=H) so obtained 
would react to yield the observed ¿V-benzyl—/V-hydroxy—D—valine benzyl 
ester (110). The water produced from A^benzylation of the free ¿V~ 
hydroxy—D—valine benzyl ester (cf. Figure 70) would be available to 
hydrolyse more of the hydroxamic acid (130) yielding more /V^hydroxy 
—D—valine benzyl ester.
This argument is tenuous, however. As can be seen from Figure 
70, only one mole of water is produced for every two moles of start­
ing material (ROH in Figure 70) consumed. As 130 was completely
hydrolysed extra moisture must have been present in the reaction
512mixture. This is quite likely as it is known that DMF is
notoriously difficult to dry.
The presence of 0—benzyl—2—oxoisovaleric acid oxime benzyl 
ester (136) is difficult to account for. Only 6mg of this material 
was isolated and could possibly have been produced following dispro­
portionation of the A/—hydroxy—D—valine benzyl ester (Figure 65).
The resultant oxime (138) would benzylate under the reaction condi­
tions to afford the observed product (136). Alternatively, the 
0-benzyl species (137, R=PhCH2), obtained by hydrolysis of the fully 
protected derivative (135), may have been oxidized by the silver 
oxide. In a reverse argument to the above, the hydroxylamine (137,
R=H) may have been first oxidized to the oxime (138) then benzylated 





No oxime (138) norD-valine benzyl ester (nor /V—benzyl derivatives 
thereof) were observed, and studies to determine the mechanism of 
this reaction were not undertaken.
As has been mentioned N— (N—4-methoxybenzyloxycarbony1—5—benzyl— 
L—cysteinyl )-/V-benzyloxy—D—valine benzyl ester (135) could be pre­
pared when non-distilled DMF was used as solvent. The resultant 
material (135) was FeCl3—negative, and in the 13C n.m.r. spectrum the 
valine C2 resonance was observed at 65«746and the benzyl methylene 
of the hydroxamate benzyl ester at 79»36<$.
Reaction of /V— (/V—4—methoxybenzyloxycarbonyl—S—benzyl—L—cysteinyl) 
-/V-benzyloxy—D—valine benzyl ester (135) with HC1 saturated nitro- 
methane, followed by a basic aqueous work up, afforded /V— (S'—benzy 1—
L—cysteinyl )-/V—benzyloxy—D—valine benzyl ester (139) as a crystall­
ine solid. The material was ninhydrin-positive and homogeneous by 
t.l.c. A n.m.r. spectrum of 139 confirmed its purity, but when 
coupled with /V—benzyloxycarbonyl—L—a—aminoadipic acid 1— (4—nitro- 
benzyl) ester (84), using dicyclohexycarbodiimide and 1—hydroxy- 
benzotriazole as coupling agents, an inseparable mixture of at least 
seven compounds was obtained.
153
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Fortunately, at the same time as this approach to the synthesis 
of the hydroxamic acid tripeptide (126) was proving unsuccessful, 
conditions were established which gave A/~(Af~4—methoxybenzyloxy- 
carbonyl—S~benzyl-L—cysteinyl)~N—hydroxy—D-valine benzyl ester (130) 
in 2 0% yield and free of any contaminating IV—-4—methoxybenzyloxy- 
carbonyl—5—benzyl—L—cysteinyl—D—valine benzyl ester (132) . Thus a 
solution of /V—4—methoxybenzyloxycarbony1—5—benzyl—L—cysteine in non­
distilled DMF was pre-treated with dicyclohexylcarbodiimide. Some 
five minutes later A'-hydroxy—D—valine benzyl ester hydrochloride 
salt and pyridine were added and the solution stirred overnight. 
Following extensive column chromatography on silica the hydroxamic 
acid dipeptide (130) was isolated analytically pure. The valine 
C2 resonance was observed at 62*866 in the 13C n.m.r. spectrum of 
130, and in the 1H n.m.r. spectrum the hydroxamic acid proton reson­
ated at 7*776.
Deprotection of the hydroxamic acid (130) with HC1 saturated 
nitromethane and coupling of the crude product with the ethoxycar- 
bonyl mixed anhydride (118) afforded, after column chromatography, 
protected LLD-AC(N-0H)V (102) as a crystalline solid in 29% yield.
The material was judged pure by elemental analysis, 3H n.m.r. and 
l3C n.m.r. spectroscopy. The 13C n.m.r. spectrum was assigned on 
the basis of selective decoupling experiments. The valine C2 re­
sonance was again found at high frequency, 63*106, compared with a 
shift of 57*476 for the valine a-carbon in the 13C n.m.r. spectrum 
of IV— benzyloxycarbonyl— 1— (4—nitrobenzyl)—6— (L—a—aminoadipyl ) S ~  
benzyl—L-cysteinyl-D—valine benzyl ester (119). The material (102) 
was FeCl3-positive and exhibited a (M+H) ion, as the base peak (m/z 
829), in its FAB mass spectrum.
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Attempts to deprotect A/— [/V—benzyloxycarbonyl—1— (4—nitrobenzyl)— <5—
(L—a—aminoadipyl)—S—benzyl—L—cysteinyl]-/V—hydroxy—D—valine benzyl ester
(1 0 2 ) by catalytic reduction over charcoal supported palladium failed, 
even when one equivalent of catalyst was used. Sodium-liquid ammonia 
deprotection of 1 0 2 and purification of the crude product by cation- 
exchange chromatography afforded /V— [6— (L—a—aminoadipyl)—L—cysteinyl]
-tV— hydroxy—D—■valine (81) in analytically pure form (Figure 72). The 
product was FeCl3-positive and the lH n.m.r. spectrum could be unam­
biguously assigned by comparison with the lH n.m.r. spectra of other 
derivatives, described previously. The valine a-proton was observed 
as a sharp doublet at 4*666.
The material was identified as the monomer (81) and not the di­
sulphide (140) from its 13C n.m.r. spectrum (Figure 73). The cysteine 
C3 resonance at 25*55<S is characteristic of the free thiol. The
451chemical shift of cysteine C3 in the LLD-ACV monomer (34) is 26*106
465and in the disulphide (8 8 ), 38*496. After exposure to the atmos­
phere for several days the monomer (81) had oxidized to the disulphide 
(140). This was confirmed from subsequent 13C n.m.r. and FAB mass 
spectral analysis; the base peak (M+H) ion at m/z 757 was of the 
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75MHz broad-band proton decoupled 
C n.m.r. spectrum of _N—[5 —(X j—CZ— 
aminoadipyl)-L-cysteinyl]-N-hydroxy- 
D-valine (sweep 'width 15151Hz, 
number of scans 8687).
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The chemical shift of the valine a-carbon in the originally iso­
lated thiol (81) was 66*626. This compares with a shift of 59*306 
451reported for the valine a-carbon of LLD-ACV (34). As already
suggested this downfield shift of the a-carbon may be indicative of 
the hydroxamic acid functionality. The valine C2 chemical shifts 
of various relevant compounds are summarized in Figure 74.
There is at least a 6 p.p.m. downfield shift of the valine 
a-carbon on going from the simple amide to the hydroxamic acid.
The overall yield of LLD-AC(N-OH)V (81) from S—benzyl-L-cysteine 
was 4% and from D-valine, 3%.
4.5 THE SYNTHESIS OF /V-BENZYLOXYCARBONYL— L —a—AMINOADIPIC ACID 1-BENZYL 
ESTER
In the synthesis of the LLD-ACV peptides, and particularly in 
the low yielding synthesis of the hydroxamic acid (81), considerable 
quantities of suitably protected L-a—aminoadipic acid (84) were re­
quired. L-a—aminoadipic acid is commercially available but is 
expensive, and conversion to the desired derivative (84) was effected 
in only 39% yield. Separation of this isomer from the 6— (4—nitro- 
benzyl) isomer (91), produced as a by-product in the synthesis of 
(84), by column chromatography is difficult and restricts the pre­
paration of 84 to a scale of about 7 millimolar.
To overcome the problem of expense and in order to produce large 
quantities of suitably protected L—a—aminoadipic acid, it was hoped to 
oxidize the L-lysine derivative (141) to /V—benzyloxycarbonyl—L—a—amino­
adipic acid 1-benzyl ester (142) (Figure 75). A similar strategy has
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Comparison of the n.m.r. chemical shifts of the 
valine a-carbon of related compounds.
CONH SH
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L-lysine is readily available and very much cheaper (£14 per
kilogram) than L—a~aminoadipic acid (£20 per gram). The /V£—benzyl-
514idene derivative of L-lysine was prepared as described and con­
verted to ¿Va—benzyloxycarbonyl—L—lysine using the improved proced-
515ures of Scott and co-workers . The benzyl ester 4—toluene-
sulphonic acid salt of /Va—benzyloxycarbonyl—L—lysine was obtained
490by standard methods in 92% yield (Figure 76).
The 'H n.m.r. spectrum ofN a—benzyloxycarbonyl—L—lysine benzyl 
ester 4—toluenesulphonic acid salt was consistent with the proposed 
structure. The free base (141), readily obtained from the 4—toluene­
sulphonic acid salt, was ninhydrin positive and exhibited a parent 
ion at m/z 370 in its El mass spectrum.
A solution of 141 int—BuOH: 0*1M aqueous phosphate buffer 
(pH6«0)(l:l) was treated with 2*5 equivalents of bromine. After 
gently heating for 12 hours the starting material was shown, by ana­
lytical t.l.c., to have been consumed. The only product isolated, 
however, was benzoic acid, probably from oxidation of benzyl alcohol 
produced during the reaction.
The use of potassium permanganate did allow direct oxidation of 
the amine (141) to the carboxylic acid (142). When 1*33 equivalents 
of KMnO^ were added to a solution of N®—benzyloxycarbonyl-L—lysine 
benzyl ester in t -BuOH:H20(2:1), buffered with solid CaSO,, , and the 
mixture heated for 40 min a brown precipitate of manganese dioxide 
formed. After filtration, several extractions and column chromato­
graphy of the extracts, the desired derivative N—benzyloxycarbonyl 
—L^x —aminoadipic acid 1-benzyl ester was isolated in 8% yield.
The melting point, optical rotation and lH n.m.r. spectrum of the
161
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F I G U R E  76
L—o-aminoadipic acid derivative (142) were virtually identical to
516those reported by Baldwin , who had previously oxidized 141 to
142 by an indirect three-step process in an overall yield of 22%.
A biomimetic oxidation of a protected lysine derivative to a protect-
517ed L—a—aminoadipic acid derivative has also been reported
The 8% yield of product (142) was disappointingly low but time 
did not allow optimization of the reaction conditions. Considerable 
quantities of unreacted starting material (as much as 50%) could be 
recovered from the reaction mixture which suggested that, if the 
reaction conditions were optimized, direct KMnO,, oxidation of 141 
could provide a feasible synthesis of A/-benzyloxycarbonyl—L—a—amino­
adipic acid 1-benzyl ester (142). Even an 8% yield represents an 
economical approach to the preparation of suitably protected L—a— 
aminoadipic acid. This indirect synthesis of 142 from L-lysine is 
some one hundred times cheaper (with reference to the starting amino- 
acid) than the direct synthesis of 84 from L—a—aminoadipic acid.
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5. C E L L - F R E E  P R E P A R A T I O N  A N D  F E E D I N G
S T U D I E S
5.1 PREPARATION OF AN ACTIVE CELL-FREE SYSTEM
352In 1981 Abraham reported the preparation of a cell-free 
extract from the mechanically ruptured mycelium of C. acremonium 
C91. Using the procedures described in this paper it was possible 
to obtain an active cell-free system from C. acremonium CW19 (Figure 
77) .
518A growth curve was established for C. acremonium CW19. The 
results suggested that the mycelium should be harvested after 72h 
growth; prior to the onset of the stationary phase and cephalosporin 
C production. Centrifugation of the CW19 culture failed to pellet 
the cell mass, possibly due to a carbohydrate gradient, but the mycel­
ium was readily collected by filtration of the growth medium. Mech­
anical grinding of the mycelium, resuspended in morpholinopropane- 
sulphonic acid (MOPS) buffer (50mmol,pH7•2), in a Dyno Mill afforded 
a crude broken-cell system which was weakly active in converting syn­
thetic LLD-ACV to an antibiotic substance (as determined from B. 
subtilus bioassay). However, control experiments indicated a large 
background antibiotic titre, presumably due to intracellular penici­
llins (and cephalosporins) released during cell rupture. This weak 
"synthetase" activity was completely lost after 24h at 0°C.
The crude broken-cell system was treated with ammonium sulphate
352and the 50-80% precipitate dialysed overnight at 4°C. The cell- 
free system obtained in this manner was found to be only slightly
165
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more active in converting LLD-ACV to an antibiotic than the crude 
broken-cell system. When the 50-80% precipitate fraction was immed­
iately de-salted on a Sephadex G25 column, however, the eluate was 
found to be highly active and to contain no detectable quantities of 
penicillins or cephalosporins. The cell-free preparation could be 
stored at -20°C for several weeks without appreciable loss of "synthe­
tase" activity.
2 +Experiments to determine the optimum DTT and Fe concentrations 
352were undertaken . Maximum antibiotic titres were observed for 
DTT concentrations of ca 2mmol and above (some 3-4.x LLD-ACV concentra­
tion) but results from the FeSO,, experiments were inconclusive. The 
antibiotic titre was not greatly dependent on the FeSO,, concentration 
and the optimum concentration varied from one system to another.
Why this should be so is unclear, but the enzyme system is fairly
2 +crude and might already contain small quantities of Fe . Concent­
rations for DTT of 2 mmol and for FeSO., of lmmol were normally used
352in subsequent feeding experiments
5.1.1 Identification of the Antibiotic
352Abraham observed that the cell-free system prepared by
mechanical rupture of the C. a c r e m o n i u m  C91 mycelium produced only 
isopenicillin N. As the epimerase responsible for penicillin N 
biosynthesis is highly labile (see Section 3-5) it was assumed that 
the cell-free system obtained from C. a c r e m o n i u m  CW19 also produced 
only isopenicillin N.
The antibiotic activity produced from LLD-ACV by the CW19 cell- 
free system was completely destroyed when treated with 5 units of
B. c e r e u s  penicillinase. Thus the material is a penicillin, either
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isopenicillin N or penicillin N, and this was further indicated by
derivatization and mass spectral analysis of the antibiotic. LLD-
ACV was incubated with the cell-free system and, using a procedure
342similar to that described by Baldwin , a small quantity of the 




C O 2C H 3
143
The El mass spectrum exhibited a parent ion at m/z 459 and a 
base peak ion at m/z 230 (from a—cleavage of the aminoadipyl amide 
bond). The remainder of the mass spectrum was similar to that
already reported 342 for 143.
354In a recent publication the chiral derivatization of iso­
penicillin N and penicillin N and the h.p.l.c. separation of the
diastereoisomers was described. Treatment of the penicillins with
5192,3,4,6—tetra-0-acetyl—6—D—glucopyranosyl isothiocyanate (GITC) 
(144) afforded the thiourea derivatives 145 and 146 (Figure 78) 
which were efficiently separated by reverse phase h.p.l.c.
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Authentic samples of penicillin N and isopenicillin N would be
required in order to unambiguously identify the penicillin produced
in the cell-free reaction. While the synthesis of both compounds
520-522has been reported , an alternative though related procedure
appeared more attractive. If the penicillin derivative (143) was 
heated in concentrated acid, a-aminoadipic acid could be isolated 
from solution by preparative electrophonesis (cf. Figure 1). The 
chirality of the isolated a-aminoadipic acid would distinguish the 
penicillins (L—a—aminoadipic acid from isopenicillin N and D—a—amino- 
adipic acid from penicillin N) and could be determined from GITC 
derivatization and h.p.l.c. analysis of the amino-acid derivative.
The GITC derivatives of commercial L—a—aminoadipic acid (145,
R= -(CH2)3C02H) and D—a—aminoadipic acid (146, R= -(CH2)3C02H),
523prepared as previously described , were separated by reverse 
phase h.p.l.c. using a Waters y-Bondapak C18 analytical column and 
methanol: lOmmol aqueous phosphate buffer (pH 2*8)(37»5:62*5) as 
eluant. The thiourea group absorbs strongly at 254nm and facili­
tates UV detection of the chiral derivatives. The L-isomer was
523eluted before the D-isomer as has been reported for the GITC
derivatives of eleven other amino-acids. At a flow rate of 0*9ml/ 
min the retention time for the L-isomer was 15*0 min and for the 
D-isomer 19*0 min.
The feasibility of this approach was thus demonstrated, but
unfortunately 143 could not be prepared in quantities sufficient to
establish the chirality of the a-aminoadipyl side-chain. On the
352basis of literature analogy , however, there seems little doubt 
that the penicillin produced is isopenicillin N and not penicillin N.
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Although the cell-free system was fairly crude, conversions of 
LLD-ACV to isopenicillin N in the order of 75% were routinely achieved. 
These results were determined from bioassay at optimum incubation con­
ditions and with Staph, aureus as sensitive organism. An activity
against Staph, aureus for cephalosporin C of 10 units/mg and for iso-
352penicillin N of 80 units/mg was assumed
With an efficient cell-free system available the role of other 
peptides and peptide derivatives in penicillin biosynthesis could be 
investigated.
5.2.1 <5 — (L—ct—Aminoadipyl)—L—Cysteinyl—D—Valylglycine
LLD-ACVG(83) is not a substrate for isopenicillin N synthetase. 
When the tetrapeptide was incubated with the cell-free system in the 
presence of DTT and FeSO,, no antibiotic activity was detected by 
Staph, aureus bioassay. In a concurrent test LLD-ACV (34) was 
efficiently converted to isopenicillin N.
The LLD-ACVG tetrapeptide could be recovered from the incubation 
mixture as its sulphonic acid, 6— (L-a—aminoadipyl)—L—cysteicyl—D— 
valylglycine (LLD-ACyaVG) (147). An equivalent volume of methanol 
was added to the incubation mixture and the precipitated protein 
filtered. The filtrate was oxidized with performic acid and the 
sulphonic acid (147) isolated by cation-exchange chromatography with 
water as eluant.
When LLD-ACV and LLD-ACVG were co-incubated with the cell-free 
system antibiotic production was observed to decrease with increasing 
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(125ug), cell-free preparation (500pl) and various quantities of 
LLD-ACVG (Figure 79). The volume of each flask was adjusted to 
1-Oml with MOPS buffer (50mmol ,pH7*2) and dithiothreitol, to a 
final concentration of 2*5 mmol, and FeSO,,, to a final concentration 
of l'Ommol, added. The mixtures were incubated at 26°C for l/£h 
then bioassayed against S ta ph , a u r e u s (Figure 79).
Graphical interpretation of this data (Figure 80) supports the 
contention that LLD-ACVG is inhibiting the biosynthesis of isopeni­
cillin N. It is not possible to deduce from this graph whether 
the inhibition is competitive or non-competitive, though the close 
structural similarity of LLD-ACVG and LLD-ACV favours competitive 
inhibition. Further kinetic studies were not undertaken as the 
crude nature of the cell-free system and the limitations of the bio­
assay method allow only gross measurements to be made. Nevertheless,
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* The concentration of biosynthesised 
isopenicillin IT was determined from 
the linear In dose - response curve 
from several cephalosporin C stand­
ards. However, the inherent ass- 
352umptions in the calculations 
mean that only the relative values 
and not the absolute values can be 
considered accurate.
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the results suggest that LLD-ACVG is a poor inhibitor. Concentra­
tions of LLD-ACVG double the original concentration of LLD-ACV were 
required to reduce isopenicillin N production by 50%.
The stereochemistry of the ACVG tetrapeptide isolated from
329C. acrem onium is not known but synthetic LLD-ACyaVG (147) has
302been reported to behave slightly differently on paper electro­
phoresis to the sulphonic acid derivative of the isolated ACVG tetra-
302peptide. It is possible that the isolated ACVG tetrapeptide is
a diastereoisomer of LLD-ACVG. However, it has never been rigorous­
ly proven that the isolated tetrapeptide is <5— (a—aminoadipyl)—cystein- 
329ylvalylglycine . A peptide with the same constituent amino acids
but different primary structure, glycyl— 6— (a—aminoadipyl)—cysteinyl-
valine (GACV), has been isolated from the mycelium of the B-lactam
331producing P a e c i l o n y c e s  p e r s i c m u s  P-10 . The role of this tetra­
peptide in penicillin biosynthesis has not been investigated.
It is quite possible that the ACVG and GACV peptides are simple 
shunt products and not relevant to the biosynthesis of the penicillins 
and cephalosporins.
5.2.2 /V- [6~(L—a—Aminoadipyl)—L—Cysteinyl]—fy-Hydroxy—D—'Valine
/V— [6— (L-a-aminoadipyl)-L—cysteinyl]-/V-hydroxy-D—'valine (81) has 
378been proposed as an intermediate in the biosynthesis of isopeni­
cillin N from 6— (L—a—aminoadipyl)—L—cysteinyl—D—valine. It was of
interest, therefore, to test this hypothesis by feeding the synthetic 
hydroxamic acid (140) to the active cell-free system obtained from
C. acremonium CW19. In the presence of DTT and FeSO^ no detectable 
quantities of antibiotic were produced (as observed from Staph, 
aureus bioassay). In the control incubation LLD-ACV was converted
to isopenicillin N though the apparent conversion yield in this ex­
periment was only 20%.
AT_[ 5— (L-a—aminoadipyl )—L—cysteinyl]-AT—hydroxy—D—valine was how­
ever a powerful inhibitor of penicillin synthesis. Various quantit­
ies of LLD-AC(N-0H)V (140) were added to incubation mixtures contain­
ing LLD-ACV (at a final concentration of 350pg/ml), DTT and FeS0<, .
The flasks were aerated on a rotary shaker at 26°C for lh then bio­
assayed against S ta ph , a u reu s (Figure 81).
As the control conversion of LLD-ACV to isopenicillin N was 
disappointingly low the quantitative data may be suspect. However, 
it is apparent that AT— [ 6— (L-ci—aminoadipyl)—L—cysteinyl]-AT—hydroxy—D— 
valine (81) is a potent inhibitor of this conversion. Concentra­
tions of the hydroxamic acid as low as 70pg/ml (0*18mmol) completely 
inhibited "synthetase" activity and, calculated from Figure 81, a 
hydroxamic acid concentration of 17yg/ml (0*04mmol) resulted in a 
50% inhibition of penicillin synthesis. To check that the inhibi­
tion is a property of the tripeptide derivative (81) and not of any 
hydroxamic acid, an analogous set of experiments were performed in 
the presence of various concentrations of acethydroxamic acid 
(Figure 82). Incubation mixtures contained LLD-ACV (lmg/ml)(75pl), 
cell-free preparation (300yl), DTT (0*1M solution)(20P1), FeSOi,
(0*1M solution)(lOpl), acethydroxamic acid and MOPS buffer (50mmol, 
pH7«2) to a final volume of 480pi. Each flask was shaken on a rot­
ary shaker at 150 r.p.m. at 26°C for lh and the incubation mixtures 
bioassayed against S ta ph , a u reu s (Figure 82).
Acethydroxamic acid proved inhibitory, but much higher concen­
trations of this simple hydroxamic acid were required to reduce
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* See note at foot of figure 79.
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isopenicillin N production. Production was halved at a concentra­
tion of 67pg/ml (0*91mmol); a concentration some twenty times greater 
than that required of N—[ 6— (L—a—aminoadipyl)—L—cysteinyl]—/V-hydroxy—D— 
valine (81) to elicit a similar reduction.
Acethydroxamic acid appears to inhibit isopenicillin N synthe­
tase, and may do so by chelation to a metal at the active site of 
the enzyme. Influence at the active site, rather than elsewhere on 
the synthetase enzyme (i.e. competitive rather than non-competitive 
inhibition), can be inferred from the feeding studies with LLD-AC 
(N-OH)V (81). The hydroxamate derivative of LLD-ACV, due to its 
structural similarity with Arnstein's tripeptide (34), may be expect­
ed to bind more strongly to the active site than acethydroxamic acid 
and, as already observed, LLD-AC(N-OH)V inhibits isopenicillin N syn­
thesis at much lower concentrations than acethydroxamic acid. If 
the influence on the enzyme was at some other point on the enzyme
surface and due solely to the hydroxamic acid functionality, or due
2 +to the reduction of available Fe in the incubation mixture, both 
acethydroxamic acid and (V—[ 6 — (L-a—aminoadipyl)—L—cysteinyl] -N — 
hydroxy—D—valine would be equally effective in inhibiting isopeni­
cillin N synthesis.
This inhibition may be due to metal chelation at the active
524-527site of the enzyme. Peptide hydroxamic acids are known to
be powerful active site inhibitors of zinc containing metallopeptid-
528ases, and in a recent publication the hydroxamic derivatives of 
L—amino-acids were shown to be potent inhibitors of A erom onas amino- 
peptidase, a zinc-containing enzyme. Acethydroxamic acid also 
inhibited this enzyme but was a weaker inhibitor than the amino-acid
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derivatives.
2 "t"There is no evidence that Zn is involved in penicillin bio-
synthesis, and indeed zinc ions inhibit isopenicillin N synthetase
(though zinc ions also inhibit Pseudom onas a e r u g in o s a elastase, an
529enzyme which contains zinc at its active site ). Ferrous ions, 
however, are required by the cell-free system and may play a vital 
role at the active site of the synthetase enzyme. The assumption 
that the hydroxamic acid chelates enzyme bound ferrous ions is specu­
lative and the mechanism by which /V— [ <5— (L—°—aminoadipyl)— L—cysteinyl ]
-/V—hydroxy—D—valine inhibits penicillin biosynthesis is not known.
5.2.3 <5— (L—a— Aminoadipyl)—L— [ 3-1 3C ]— Cysteinyl—D— [ 1 SN]-Valine
The double labelled tripeptide, 6— (L—a—aminoadipyl)-L— [3-13C]—
cysteinyl—D— [15N]—valine (97), was prepared in order to study the
530synthesis of isopenicillin N by in  v i v o  13C n.m.r. spectroscopy 
A number of experiments to test the feasibility of this approach con­
cluded that no isopenicillin N was produced when LLD-ACV was incubated
with the cell-free system in a 10mm n.m.r. tube. There is an absol-
445ute requirement for molecular oxygen by the synthetase enzyme
(Section 3.3.1), and poor oxygen diffusion in the n.m.r. tube was 
probably the reason no antibiotic production was observed. A stream 
of oxygen playing on the surface of the incubation mixture in a 10mm 
n.m.r. tube did not improve the situation, and ultimately the labelled 
tripeptide (82) had to be incubated with the cell-free system in the 
normal manner. The incubation mixture (labelled tripeptide (97)
(5mg), DTT(l»6mg), FeS0„(0»lM solution)(50pl) and cell-free extract 
(5ml)) was aerated on a rotary shaker at 26°C and aliquots removed 
at various times. The protein was precipitated by addition of
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acetone and the 13C n.m.r. spectrum of each de-proteinated aliquot
recorded. Further purification of the <5— (L—ct-aminoadipyl)— L— [3-1 3C ]
—cysteinyl-D— [1SN]—valine disulphide (97) improved the quality of the 
390 ,final spectrum (Figure 83).
As expected the C5 of the biosynthesised isopenicillin N was
observed as a doublet centred at 66*9 p.p.m. with a one bond 13C-15N
coupling of 4*4 Hz. The chemical shift of the C5 carbon was very
351close to the value reported by Baldwin , but the observed was
smaller than the one bond N4-C5 coupling in the 13C n.m.r. spectrum
336of 1SN enriched penicillin G
Although aliquots of the incubation mixture were removed at 
short time intervals and the l3C n.m.r. spectra of the deproteinated 
solutions recorded immediately, no new signals from potential mono- 
cyclic B-lactam intermediates were observed. It is possible that 
any intermediates are enzyme-bound and/or present in only low steady
state concentration. In either case no 13C n.m.r. signal would be
, 447 observed
The direct m  v iv o  l3C n.m.r. observation of the cell-free
conversion of <5— (L—a-aminoadipyl) — L-[3-3 3C]— cysteinyl—D— [3-1 3C] —
r i 3 i  351valine to 12,5- C2J-isopenicillin N has been reported . The
incubation was performed in a 25mm n.m.r. tube using a cell-free 
extract of greater activity than available in this laboratory.
There was no mention in the communication of any oxygen diffusion 
problems and no new 13C resonances, assignable to biosynthetic inter­
mediates, were observed.
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50MHz broad-band p ro to n  decoupled spectrum  o f d e p ro te in -  
a ted  in c u b a tio n  m ix tu re  (sweep w id th  6880Hz, number o f 
scans 604 ). a: C5 o f [5-1^C, - i s o p e n ic i l l in  N,
b: c y s te in e  03 o f [ ' ^C,  ' ^ n] - t r ip e p t id e  d im er(9 7 ) , c: 
c y s te in e  03 o f [ 1^C, ^ n] - t r ip e p t id e  monomer(82) . Ho 
l in e  broadening fa c to r  was a p p lie d  d u r in g  tra n s fo rm a tio n  
o f  the  FID .
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valuable in elucidating the mechanism of isopenicillin N biosynthesis 
but pure isopenicillin N synthetase and refined experimental condi­
tions are probably required. The [13C,15N]-labelled tripeptide (82) 
would be an excellent substrate for such experiments as carbon doub­
lets observed in the 13C n.m.r. spectrum of the incubation mixture 
would almost certainly be due to B-lactam species.
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6. E X P E R I M E N T A L
6.1 MATERIALS AND METHODS
Electrophoresis was carried out at 80V/cm on Whatman 3MM paper
531using the apparatus described by Michl , pH 2.1, 3.5 and 6.5
532buffers were prepared as described by Ambler . Merck silica 60 
(70-230 mesh) was used for column chromatography and thin layer 
chromatography (t.l.c.) was carried out on 200 x 200 x 1mm or 
200 x 200 x 0.25mm layers of Merck 60F25, silica. Components were 
visualized by ultraviolet (UV) light, by exposure to iodine vapours 
or by colour reaction with ninhydrin, ferric chloride or 2,6-dich- 
lorophenol indophenol sodium salt. High performance liquid chroma­
tography (h.p.l.c.) was carried out using Waters or Gibson systems 
and prepacked Waters u—Bondapak—C18 and Waters p—Bondapak—NH2 analy­
tical columns. Samples were detected by their UV absorptions at 
214, 254 or 313nm. Bio-Rad AG 50WX2 resin (200-400 mesh, H+ form) 
was used for ion exchange chromatography.
Reagents were purchased from Fisons, Sigma, Aldrich, Fluka and 
Eastman Kodak and were routinely recrystallized or redistilled before 
use. [13C]—paraformaldehyde (90 atom% 13C) was obtained from Merck, 
Sharp and Dohme and DL— [15N]—valine (95 atom% 15N) from the Commiss­
ariat a L'Energie Atomique (CEA). Diphenyldiazomethane was made by
533an adaption to the literature procedure . Typically, benzo- 
phenone hydrazone (1.96g, lO.Ommol), anhyd. Na2 S0l( (2.84g, 20.0mmol), 
Yellow HgO (4.33g, 20.0mmol) and K0H sat. EtOH (1ml) were added to a 
100ml pressure bottle containing dry n-hexane (30ml). The flask 
was sealed, shaken vigorously for 5h and the solution filtered.
Evaporation of the filtrate afforded a dark red crystalline solid, 
diphenyldiazomethane (1.94g, 100%). Solvents were dried and re­
distilled by standard procedures and organic extracts dried over 
MgSO,,, K 2C03 or Na2S01(.
Melting points were determined using a Reichert hot-stage micro­
scope and are uncorrected. Optical rotations were obtained using a 
Perkin-Elmer 141 Automatic Polarimeter and elemental analyses on a 
Perkin-Elmer 240 Elemental Analyser. UV/visible spectra were 
recorded on a Varian DMS90 spectrophotometer and infra-red (i.r.) 
spectra on Perkin-Elmer 298 and Perkin-Elmer 781 spectrophotometers. 
Unless otherwise stated, liquid samples were analysed as neat films 
and solid samples as solutions in CC1,, or CHC13. The i.r. spectra 
were calibrated with the 1603cm 1 absorption of polystyrene.
Nuclear magnetic resonance (n.m.r.) spectra were recorded on Varian 
EM360, Varian XL100, Varian CFT20, Bruker WP200SY, Bruker WM300WB 
and Bruker WH360 spectrometers. Spectra were measured on the 6 
scale with internal or external tetramethylsilane at 0.006, CHC13 
at 7.256 or 13CDC13 (centre peak) at 77.006. Mass spectra and 
exact mass measurements were recorded on an AEI MS902 spectrometer 
(electron impact (El) at 70 eV) or a Kratos MS80RF-DS55 spectro­
meter using a fast atom bombardment (FAB) source.
Antibiotic titres were measured using a "hole" plate bioassay 
with Bacillus subtilus or Staphylococcus aureus as test organisms.
The B. subtilus system was more sensitive to low concentrations of 
antibiotic but in practice proved less reliable for quantification of 
antibiotic levels. The Staph, aureus system was used to obtain quan­
titative data (limit of detection ca 10 units/ml of isopenicillin N).
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Isopenicillin N was assumed to have an activity of 80 units/mg
and cephalosporin C an activity of 10 units/mg against S ta ph , a u r e u s .
Typically aliquots (lOOpl) of test solutions and cephalosporin C*
or penicillin G standard solutions (lOOpl) were pipetted into the
hole of the "hole" plate bioassay. The plates were allowed to stand
at room temperature for 30min then incubated at 37°C for 16h. Clear
inhibition zones were measured and test results determined from the
linear In dose - response graphs obtained from the standard solutions.
Results were normally expressed as mg/ml cephalosporin C equivalents
or as yg/ml of isopenicillin N. A 1 mg/ml solution of cephalosporin 
352C* was assumed to equal 90 ug/ml of isopenicillin N.
The Dyno-Mill used in the preparation of the cell-free systems 
was supplied by Willy A. Bachofen AG Maschinenfabrik, Basle.
6.2 AMINO-ACIDS AND AMINO-ACID PRECURSORS
Diethyl Acetamidodimethylaminomethylmalonate
Paraformaldehyde (l.OOg, 33.3mmol), dimethylamine hydrochloride 
(2.84g, 35.0mmol) and diethyl acetamidomalonate (7.59g, 35.0mmol) 
were suspended in H20 (10ml) and 3 drops of IM-aq. HC1 added. The 
suspension was heated to 100°C in a sealed flask until a clear solu­
tion was obtained and then for a further 30min. When cooled the 
solution was saturated with NaCl and adjusted to pH12 with 20%-aq.
NaOH. The aqueous solution was extracted with ether (3x30ml), the 
extracts dried over Na2S04 and evaporated to leave crude diethyl 
acetamidodimethylaminomethylmalonate which was crystallized from
*The cephalosporin C was 72% pure as judged by h.p.l.c. using the 
system of Miller and Neuss ^
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ether/n-hexane (6.18g,67%), m.p. 62-66°C; <5 (60MHz,CDC13) 1.30H
(6H,t ,77.0Hz,2xCH2C/7 3), 2.08 (3H,s,C0CH 3) , 2.28 (6H,s,(CH3 )2N), 3.30 
(2H, s , NC/72C) , 4.29 (4H, q,77.OHz , 2xC7/2CH3 ) and 7.12br (lH.s.Ntf).
Diethyl Acetamidodimethylamino— [13C]—methylmalonate
The above procedure was repeated using [13C]—paraformaldehyde
(1.OOg,33.3mmol) to give crude diethyl acetamidodimethylamino— [13C] —
methylmalonate (2.21g,25%), <5U (60MHz,CDC13) 1.30 (6H,t,77.0Hz,H
2xCH2C/7 3) , 2.08 ( 3H, s , C0G/73 ) , 2.30 ( 6H, d,75. 0Hz , (C//3) 2N 1 3C) , 3.30 
(2H, d,7131.0Hz ,N1 3C/72C) , 4.29 (4H, q,77.0Hz, 2xQ¥2CH3) and 7.03br 
(1H,s ,N/7). The material was used without further purification.
Diethyl Acetamidodimethylaminomethylmalonate Methyl Iodide
Diethyl acetamidodimethylaminomethylmalonate (6.18g,22.6mmol) 
was dissolved in dry ether (40ml) and iodomethane (14.00ml,150.9mmol) 
added. The solution was stirred at 40°C for 24h then chilled to 
5°C for 12h to precipitate the crude product as a colourless solid 
(8.54g,91%), m.p. 160-170°C. Crystallization from MeOH/ether 
afforded diethyl acetamidodimethylaminomethylmalonate methyl iodide
(8.18g,59% from paraformaldehyde), m.p. 171-173°C (lit.4^ ,  m.p.
535174-175°C; lit. , m.p. 171-173°C); 5 (60MHz,D20) 1.38 (3H,t,H
77.0Hz ,CH2C//3 ) , 1.40 ( 3H, t ,77.0Hz ,CH2C/73 ) , 2.27 ( 3H , s , C0C//3 ) , 3.33 
(9H,s , ( CH 3 )3 N+), 4.46 (2H,q,77.0Hz, OH 2CH3), 4.48 (2H,q,77.0Hz, CH2 CH3) 
and 4.47 (2H,s,+NQ¥2C).
Diethyl Acetamidodimethylamino -[13C]-methylmalonate Methyl Iodide 
Repeating the above procedure using diethyl acetamidodimethyl­
amino— [ 1 3 C ]—methylmalonate (2.21g,8.0mmol) and iodomethane (5.00ml, 
53.9mmol) afforded crude diethyl acetamidodimethylamino— [13C]—methyl­




Sodium ethoxide (1.22g,17.9mmol) was dissolved in dry ethanol 
(20ml) and benzyl mercaptan (1.48ml,12.6mmol) added. The solution 
was left for 5 min and diethyl acetamidodimethylaminomethylmalonate 
methyl iodide (4.99g,12.Ommol) added. The solution was refluxed 
under a N2 atmosphere for 10 days, evaporated to dryness and the 
residue dissolved in CHC13 (20ml). The organic layer was washed 
with H20 (10ml), sat. aq. NaCl (10ml) and dried over K2C03. Eva­
poration left a yellow oil which was mixed with conc. aq. HC1 (40ml) 
and refluxed for 5h. The solution was filtered through celite and 
evaporated to an off-white solid which was precipitated by dissolv­
ing in hot H20 (20ml), adjusting to pH 5.4 with dil. aq. NH3 and 
adding EtOH (40ml). The precipitate was washed with EtOH and dried
to leave S-benzyl-DL-cysteine (1.72g,68%), m.p. 188-190°C (lit.480,
536m.p. 209-211°C; lit. , m . p .215-216°C) ; <5 (60MHz , TFA) 2.78br (2H,m,H
cys3H), 3.42 (2H, s , SC//2Ph) , 3.70br (lH,m,c3s2H) and 6.90 (5H,s,ArH) .
A small sample was crystallized from boiling H20, m.p. 207-209°C.
5~Benzyl—DL— [3— 13 C]—Cysteine
A repeat experiment using NaOEt (0.66g,9.7mmol), benzyl mercap­
tan (0.80ml,6.8mmol) and diethyl acetamidodimethylamino— [13C]—methyl- 
malonate (2.71g,6.5mmol) in EtOH (10ml) gave S~benzyl—DL— [3— 13C]— 
cysteine which was recrystallized from boiling H20 (0.91g,66%), 
m.p. 205°C.
Attempted Synthesis of /V-Acetyl-S-Benzyl-DL-Cysteine
S~benzyl—L—cysteine (0.85g,4.Ommol) and Ac20 (1.23ml,13.Ommol) 
were added to AcOH (10ml) and the mixture warmed at 60°C until a
160-170°C.
clear solution was obtained. The solution was stirred a further 15 
min at 60°C, cooled to room temperature and evaporated to a clear 
oil which was vigorously shaken with H20 (20ml) for 30 min. Ethanol 
was added to give a clear solution from which a colourless solid was 
obtained by evaporation. The solid was dissolved in dry acetone, 
filtered through celite and crystallized from acetone/ether/n-hexane 
to afford A/—acetyl-5—benzyl—L-cysteine (0.94g,92%). A small quan­
tity of material was recrystallized from acetone/ether/n-hexane,
537m.p. 141-144°C (lit. , m.p. 143.5-145.5°C); [a]D-43.0° (cl.O.EtOH)
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[iit. ,[a]D-46.1°(cl.0,95%Et0H) ; 6H(60MHz,CD3C0CD3) 1.58 (3H,s, 
W 3C0), 2.42 (2H,AB of ABX,6^ 2.47,602.37,J 3 .5,1.5Hz, cys3H), 3.37 
(2H,s,SC//2Ph) , 4.25 (lH,m,cys2H) and 5.92 (5H,s,Ar#).
(V—Acetyl—S—Benzyl—DL—Cysteine
In an identical experiment to above, refluxing the Ac0H/Ac20
solution for 5 min and repeating the isolation procedure gave /V-
acetyl—5—benzyl—DL—cysteine (0.70g,69%), m.p. 155-157°C (lit.477,
m.p. 157°C); «h (60MHz,CD30D) 1.67 (3H,s,Ctf3C0), 2.48 (2H,AB of ABX,
<5A2,53’6B2,42,‘/4-0,2,0Hz’cy s3H) > 3-43 (2H,s,SCtf2Ph), 4.27 (lH,m,cys 
2H) and 6.98 (5H,s,An7).
IV—Acetyl—S—Benzyl—DL—[3-13C~|—Cysteine
5—benzyl—DL— [3-13C]—cysteine (0.85g,4.0mmol) and Ac20 (1.23ml,
13.0mmol) in AcOH (10ml) were stirred at 60°C, as described above,
and worked up by the same procedure to give /V-acetyl-S-benzyl-DL-
[3-13C]—cysteine (0.92g,90%), m.p. 158-160°C; 6 (60MHz,CD30D)H
1.67 (3H, s , CH 3 CO) , 2.48 (2H, AB of ABMX, <5 2.53,6 2.42, /142.0,A B 1




/V—acetyl—S—benzyl—DL—cysteine (1.01g,4.Ommol) was dissolved in 
H20 (100ml), adjusted to pH 7.5 with lM-aq. NH3 and hog kidney acy- 
lase I (0.10g,1845 units/mg) added. The mixture was rocked gently 
at 37°C for 24h, the pH re-adjusted to 7.5 and hog kidney acylase I 
(0.08g,1845 units/mg) added. After a further 24h at 37°C the solu­
tion was heated to boiling for 5 min, cooled, and the denatured 
protein removed by filtration through celite. The filtrate was 
added to an ion-exchange column (3x20cm) and eluted with H20 (600ml) 
followed by lM-aq. NHS (400ml). The basic eluate was evaporated to
give S—benzyl—L-cysteine (0.40g,95%) which was crystallized from
4.77H20/Et0H (0.15g, 3 5%) , [a^-15.50 ( cl. 0, 5N-aq .HC1) [lit. . M q“ 
19.5° (5N-aq.HC1)]; [a^+24.3 (cl.0,lN-aq.NaOH) [lit.477,[a ]d +25.5 
(cl.0,lN-aq.NaOH)].
S—Benzyl—L—[3-13C]—Cysteine
/V— acetyl-5—benzyl—DL—[3-13C]—cysteine (0.89g,3.5mmol) was
treated in an analagous manner to yield S—benzyl—L— [3-13C]—cysteine
(0.31g,84%) which was crystallized from H20/Et0H (0.15g,40%), [a ]D~
16.7° (cl.0,5N-aq.HC1); 6 (300MHz,D20/Na0D) 2.08 (2H,AB of ABMX,H
5 2.12,6 2.04,7140.7,140.3,13.5,5.3,6.7Hz,cys3H), 2.72 (lH.ddd,/
Pi IJ
5.3,6.7,4.8Hz,cys2H), 3.12 (2H,d,/3.8Hz,S(V/2Ph) and 6.65-6.75 (5H, 
m,ArH) ; <5 (75MHz,D20/Na0D) 36.73 (t,cysC3).
¿V-Acetyl-D—Valine
DL-valine (1.00g,8.5mmol) was dissolved in Ac0H(40ml), Ac20 
(20ml) added and the solution refluxed for 30 min. Water (300ml) 
was added and the solution evaporated to give a colourless solid 
which was suspended in H20 (60ml). The pH was adjusted to 7.3
with lM-aq. NH3, hog kidney acylase I (30mg, 1845 units/mg) added, 
and the mixture gently rocked at 37°C for 2 days. The pH was re­
adjusted to 7.3, a further aliquot of hog kidney acylase (20mg, 1845 
units/mg) added, and rocking continued for 24h. The solution was 
boiled for 5 min, the denatured protein removed by filtration and 
the filtrate applied to an ion-exchange column (3x20cm). Elution 
with H20 (700ml) gave a crude product which was crystallized from
acetone/ether to afford¿V—acetyl—D—valine (0.41g,60%), m.p. 168-170°C
A r~}'7 S3fl PS(lit. , m.p. 168°C); [a]D+19.2° (c0 .8,H20)[lit. ,[a] +20.0°
(H20)] ; 6 (60MHz,D20) 0.82 (6H,d,76.5Hz, v a l4,4'H), 1.83-2.30 (1H,
m ,v a l 3H) , 1.90 (3H, s, C//3 CO) and 4.07 (1H, d,76.0Hz ,v a l 2H) .
/V-Acetyl—D—[ 15 N] -Valine
DL—[15N]—valine (1.OOg,8.5mmol) was treated in a similar manner 
to give A/—acetyl—D—[15 N] -valine (0.46g,68%), m.p. 170-171°C; [a]D+
18.8° (c0.3 H20); 6u (60MHz,D20) 0.82 (6H,d,76.5Hz,valA,4'H),H
1.78-2.20 (lH,m,vai3H), 1.90 (3H,d,7l . 5Hz,CH3 CO15N) and 4.03 (lH.dd,
76.0,1.5Hz,v a l2 H ).
D-Valine
/V-acetyl—D—valine (0.32g,2.0mmol) was refluxed in conc.aq. HC1 
(10ml) for 2h and evaporated to dryness. The residue was dissolved 
in H20 (0.8ml) and EtOH (3.2ml) and the pH adjusted to 4.5 with ani­
line. Chilling the solution to 5°C for 5h yielded a colourless
solid, D-valine (0.20g,85%), 6U (60MHz,D20) 1.02 (3H,d,77.0Hz, va I4H),H
1.06 (3H,d,77.0Hz,va/4H) , 2.00-2.53 (1H,m,va/3H) and 3.59 (lH,d,
74.5Hz, val^U).
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/V-acetyl—D—[1sN]-valine (0.40g,2.5mmol) was refluxed in conc.aq.
HC1 (13ml) and worked up as above to yield D— [ 15N]-valine (0.26g)88E£),
538[ct]D-30.3° ( c1.0,6N-aq.HCl) [lit. ,[a]D~29.4° (6N-aq. HC1) ] ;
(360MHz,D20/DC1) 0.34 (3H,d,J 7.0Hz,va74H), 0.38 (3H,d,/7.0Hz,va/4H).
1.65 (lH.ddsept.,/7.0,4.4,3.3Hz,val3H ) and 3.14 (1H,d,M .4Hz, va l2H);
<5c (25MHz,D20/DC1) 18.18 (q,vai4C), 18.94 (q,i/ai4C), 30.35 (d,va/3C), 
60.44 (dd,76.0Hz,va/2C) and 173.85 (s.vailC).
5-Benzyl—L—Cysteine Methyl Ester Hydrochloride Salt
5-benzyl—L—cysteine (1.00g,4.7mmol) was dissolved in HC1 satur­
ated methanol (50ml) and refluxed for lh. The volume of the solu­
tion was reduced to 25ml by evaporation and a colourless solid pre­
cipitated by addition of ether. Crystallization of the crude pro­
duct from MeOH/ether gave S-benzyl—L—cysteine methyl ester hydro-
539chloride salt (0.99g,80%), m.p. 150-152°C (lit. , m.p. 151-152°C);
6h (60MHz ,CDC13 ) 3.28br (2H,m , cys3H) , 3.82 (2H, s ,SC//2 Ph) , 3.92 (3H, 
s,C02C//3), 4.53br (1H,m, cys2H) , 7.40 (5H,s,ArH) and 9.07br (3H,s,NH*) .
5-Benzyl—L—Cysteine Benzhydryl Ester 4—Toluenesulphonic Acid Salt
5-benzyl—L—cysteine (0.21g,1.Ommol) and 4-toluenesulphonic acid
monohydrate (0.21g,1.lmmol) were dissolved in DMF (10ml) and heated
to 60°C. A solution of diphenyldiazomethane (0.29g,1.5mmol) in
DMF (5ml) was added over 15 min to leave an orange solution which
was evaporated to afford an off-white solid. Crystallization from
acetonitrile/ether afforded 5-benzyl—L—cysteine benzhydryl ester
4-toluenesulphonic acid salt (0.17g,31%), m.p. 156.5-158°C; [a]^-
22.9° (c7.9,MeOH) (Found:C ,65.62; H.5.80; N,2.49. C30H31NO5S2
requires C.65.55; H,5.68; N,2.55%); 6„ (300MHz,CDC1, ) 2.21 (3H,s,H
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D— [15N]-Valine
CH 3) , 2.86 (2H,m,cys3H), 3.40 (2H, AB, <5. 3 .47, 6 3.34 ,/13. 3Hz , SC//2Ph) ,
r \  jD
4.36 (lH,t,/5.6Hz,cys2H), 6.77 (1H,s ,C//Ph2), 6 . 8 8 (2H,d,78.1Hz,Ar//) , 
7.04-7.23 (15H,m,ArH ) , 7.62 (2H, d ,/8. 1Hz , Ar//) and8.42br (3H,s,NH+3) ; 
v(CDC13) 3010 (C-H), 2925 (C-H) and 1753 (C=0) cm'1; m/z (El) 376 
(<1%), 210 (7%), 167 (100%) and 91 (100%).
/V— 4—Methoxybenzyloxycarbonyl—5—Benzyl—L—Cysteine Dicyclohexylamine Salt
S—benzyl-L—cysteine (2.llg,lO.Ommol) was suspended in H20 (20ml),
the pH adjusted to 9.0 with 2M-aq. NaOH and a solution of 4—methoxy-
benzyloxycarbonylazide in dioxan (20ml) added dropwise over lh at
room temperature. The solution was adjusted to pH 8.5 by addition
of 2M-aq. NaOH and then stirred for 24h. The volume of the solution
was reduced by evaporation and the solution washed with ether (50ml).
The pH of the aqueous solution was adjusted to 1 by addition of 5M-aq.
HC1 and the solution extracted with EtOAc (3x50ml). The EtOAc
extracts were dried over MgSO., and evaporated to give a yellow oil.
Dicyclohexylamine (2.10ml,10.5mmol) was added and a colourless solid
crystallized from EtOH/EtOAc, /V— ■4—methoxybenzyloxycarbonyl—S— benzyl—
L—cysteine dicyclohexylamine salt (3.95g,71%), m.p. 137-138°C; [a lp~
13.3° (cl.0,MeOH) (Found: 0,66.67; H.7.35; N.4.93. C3tH„ „ N20SS
requires 0,66.88; H.7.97; N,5.03%); 6„ (200MHz,CDCl, ) 1.07-2.03H
(22H,m,c y c l o h e x y l H ), 2.83-3.00 (4H,m,cys3H and N//̂ ) , 3.71 (2H,s,
SC//2Ph), 3.77 (3H,s,C//3 0) , 4.24-4.27 (1H,m ,cys2H), 5.03 (2H,s,OCtf, Ar), 
5.90 (lH,d,/5.8Hz,Ntf), 6.85 (2H,d,78.7Hz,ArH) and 7.16-7.32 (7H,m,ArH).
D—Valine Benzyl Ester 4—Toluenesulphonic Acid Salt
D—valine (1.17g,lO.Ommol) and 4-toluenesulphonic acid monohydrate 
(2.09g,11.Ommol) were dissolved in a mixture of dry benzene (30ml) 
and benzyl alcohol (2.59ml). The solution was refluxed under an
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argon atmosphere for 5 days in a Dean-Stark apparatus. Addition of
ether (50ml) to the reaction mixture precipitated a colourless solid,
D-valine benzyl ester 4-toluenesulphonic acid salt (3.70g,98%), m.p.
490160-162°C (lit. ,m.p. 158-160°C for L-isomer); [<*1̂ +3.0° (c2.0, 
r 491EtOH) [lit. , [a ]^-3.5° (c2.0,Et0H) for L-isomer]; 5^ (60MHz,
CDC13) 0.88 (3H,d,77.0Hz,vai4H) , 0.91 (3H,d,77.0Hz,va/4H), 1.97-2.60 
(lH,m,va/3H), 2.32 (3H,s,CH3) , 3.85-4.08 (lH,m,va/2H), 5.08 (2H,AB 
pattern,0C//2Ph) , 7.11 (2H,d,78.0Hz, Ar//) , 7.30 (5H,s,Ar//) , 7-84 (2H, 
d ,78. 0Hz, Ar//) and 8.27br (3H,s,N//*).
A small sample was converted to the hydrochloride salt v ia  the
540free amine, m.p. 141-143°C (lit. ,m.p. 138°C for L-isomer); 5H
(200MHz,CDCI3 ) 1.06 (3H,d,/5.4Hz,va/4H), 1.09 (3H,d,75.3Hz, v a l4H),
2.43 (lH ,m ,v a l3H), 3.94 (lH,d,73.5Hz,va/2H), 5.21 (2H,AB,5 A5.27,5 _A B
5.16,712.1Hz,0C//2Ph) and 7.30-7.40 (5H,m,Ar//); 6 c(20MHz,D2 0) 17.79
(q ,va/ 4C), 18.00 (q,va/4C), 30.18 (d,va/3C), 59.15 (d,va/2C), 69.34 
(t,0C//2 Ph), 129.68,129.84,135.51 (5xArC) and 170.47 (s,C=0).
/V—Benzyloxycarbonyl—L—a—Aminoadipic Acid 1— (4—Nitrobenzyl) Ester
/V—benzyloxycarbonyl-L-a—aminoadipic acid (2.06g, 7.0mmol)
was dissolved in DMF (5ml), triethylamine (1.02ml, 7.4mmol) added 
and the solution cooled to 0°C. 4-nitrobenzylbromide (1.59g, 7.4 
mmol) was added in aliquots over 5h and the reaction mixture allowed 
to come to room temperature overnight. Saturated aqueous NaCl 
(25ml) was added, the solution adjusted to pHl with conc.aq. HC1 
and extracted with EtOAc (4x30ml). The extracts were dried over 
MgSO,,, evaporated to a yellow oil and subjected to chromatography 
on silica (200g) with EtOAc:n-hexane (7:3) as eluant. The crude 
product was crystallized from Et0Ac/n-hexane to yield /V—benzyloxy-
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carbonyl-L-a-aminoadipic acid 1— (4—nitrobenzyl) ester (1.22g,50%), 
m.p. 101-104°C; [a]^-8.0° (c2.0, acetone) (Found: C,58.38; H,5.08;
N,6.46. Cn Hz; N20e requires 0,58.60; H,5.15; N,6.51%); ¿^(60MHz,
CDC13 ) 1.45-2.05 (4H,m, am in oa d ipyl 3,4H), 2.37 (2H,t,7 5.5Hz, am in o-
a d ip y l 5H) , 4.18-4.70 (lH,m, am in oa d ipyl 2H), 5.12 (2H, s ,0C//2 Ar) ,
5.23 (2H,s, OCH2 Ar) , 5.40 (lH,m,N//), 7.32 (5H,s,Ar//), 7.43 (2H,d,
79.0Hz , Ar/7) , 8.13 (2H,d,79.0Hz, Ar//) and8.75br (1H, s ,C02//) ; m/z (El)
430 (<1%) (M), 306 (2%), 250.1091 (19%,C ^3H t6N0„ requires 250.1079), 
206.1168 (37%,C !2H x6N02 requires 206.1181) and 91 (100%).
/V-benzyloxycarbonyl-DL-a-aminoadipic acid 1— (4—nitrobenzyl) 
ester was prepared in an analagous manner, m.p. 80-88°C.




N—benzyloxycarbonyl—DL—a—aminoadipic acid 1— (4—nitrobenzyl) 
ester (lOOmg, 0.23mmol) was dissolved in dry benzene (10ml), S0C12 
(36.3pl, 0.50mmol) added and the solution stirred for 4h. Evapora­
tion left an oil which was dissolved in dry CH2 Cl2 (5ml) and added 
dropwise to a solution of S~benzyl—L—cysteine methyl ester hydro­
chloride salt (69mg, 0.26mmol) and pyridine (41.3pl, 0.51mmol) in 
dry CH2 Cl2 (5ml) at 0°C. The solution was stirred overnight at 
room temperature, washed with sat. aq. NaHC03 (10ml), H20 (10ml), 
lM-aq. HC1 (10ml), H20 (10ml), sat. aq. NaCl (10ml) and dried over 
Na2 S0^. Evaporation to a colourless solid and crystallization 
from EtOAc/n-hexane yielded N—benzyloxycarbonyl—1— (4—nitrobenzyl)—
6— (DL—a—aminoadipyl)—5—benzyl—L—cysteine methyl ester (45mg, 30%),
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m.p. 76-84°C remelting at 112-116°C; 6R (200MHz, CDC13) 1.70-1.95 
(4H, m ,am inoadipyl 3, 4H) , 2.16-2.27 (2H,m, ami noad i p y  15H) , 2.86 (2H,
AB of ABMX pattern, cys3H) , 3.67 (2H,s ,SC//2Ph) , 3.71 (3H,s, C02C//3) , 
4.41-4.44 (lH,m,a m in o a d ip y l2H), 4.76 (1H,dt,/7.7,5.4Hz, cys2H),
5.10 ( 2H, s , 0C//2 Ar) , 5.23 (2H, s ,0C//2 Ar) , 5.43-5.47 (lH,m,N//), 6.09-
6.15 (lH,m,N//), 7.22-7.33 (10H,m , Ar//), 7.48 (2H, d,78.3Hz, Ar//) and
8.19 (2H,d,78.3Hz , Ar//) ; m/z (El) 637 (<1%) (M) , 546 (7%) (M-91),
502 (7%), 208 (33%) and 91 (100%).
/V-Benzyloxycarbonyl-1— (4—Nitrobenzyl)—6-(DL-a—Aminoadipyl)—5~Benzyl—
L—Cysteine Benzhydryl Ester
S—benzyl—L—cysteine (0.42g, 2 .0mmol) was converted to its benz­
hydryl ester 4—toluenesulphonic acid salt as previously described.
The crude yellow oil obtained following evaporation of the DMF sol­
vent was taken up in EtOAc (40ml), washed with sat. aq. NaHC03 
(2x40ml), sat. aq. NaCl (40ml) and dried over Na2S0„. Evaporation 
left a yellow oil which was added to a solution of 1 -hydroxybenzo- 
triazole hydrate (0.28g, 2.1mmol) and /V—benzyloxycarbonyl—DL—ct—amino- 
adipic acid 1— (4—nitrobenzyl) ester (0.88g, 2.0mmol) in EtOAc (20ml). 
Dicyclohexylcarbodiimide(0.43g, 2.1mmol) was added and the mixture 
stirred overnight at room temperature. Oxalic acid dihydrate (13mg) 
was added and stirring continued a further lh. The precipitated 
dicyclohexylurea was filtered and the filtrate washed with lM-aq.
HC1 (30ml), H20 (30ml), sat. aq. NaHC03 (30ml), H20 (30ml), sat. aq. 
NaCl (30ml) and dried over MgSO,, . Evaporation afforded an oil which 
was chromatographed on silica (150g) with EtOAc:n-hexane (6:4) as 
eluant. Initial fractions yielded benzophenone azine, m.p. 167°C
(lit. , m.p. 164-165°C); 6U (60MHz,CDC13), 7.20-7.33 (20H,m,Av H ) .ri
Later fractions gave a semi-solid, crystallized from EtOAc/n-hexane
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to yield /V-benzyloxycarbonyl—1— (4-nitrobenzyl) — <5— (DL-a-aminoadipyl) — 
5-benzyl—L—cysteine benzhydryl ester (0.99g, 63%), m.p. 73-77°C 
(Found: C,66.73; H,5.59; N,5.25. C „H „ 3N 30 9S requires C.66.90;
H.5.49; N,5.32%); & (60MHz,CDC13) 1.65-2.03 (4H,m ,a m in oa d ip y l 3 ,
4H) , 2.13-2.37 (2H,m,am inoad ipy 1 5H), 2.82-2.98 (2H,m,cys3H) , 3.63 
(2H,s,SC//2Ph) , 4.30-4.56 (1H,m ,am in oad ipyl 2H) , 4.86-5.03 (lH,m, c y s  
2H) , 5.15 (2H,s,0C//2Ar) , 5.27 ( 2H, s , 0C//2Ar) , 5.55 (1H, d, J 7 . 5Hz , NH) ,
6.26 (1H,d ,/8 .0Hz,N//), 6.95 (1H,s,CHPh2), 7.32-7.58 (22H,m,ArH) and
8.24 (2H,d,/8.5Hz,Ar//); v(CH2C12) 3425 (N-H), 3035 (C-H), 2940 
(C-H), 1730 (0=0) and 1675 (C=0)cm_1; m/z (El) 698 (<l%) (M-91),
622 (4%) (M-167), 578 (2%), 167 (100%) and 91 (100%).
iV-Benzyloxycarbonyl—1— (4—Nitrobenzyl)—<S — (L-a — Aminoadipyl)—5-Benzyl—
L—Cysteine Benzhydryl Ester
5—benzyl—L—cysteine (0.42g, 2 .0mmol) was converted to its benz-
hydral ester and coupled with N—benzyloxycarbonyl—L-a—aminoadipic
acid 1— (4—nitrobenzyl) ester (0.88g,2.0mmol), as described above
for the DL-mixture, to give N— benzyloxycarbonyl—1— (4—nitrobenzyl) —
5— (L-a—aminoadipyl)—5—benzyl—L—cysteine benzhydryl ester (l.Olg,
64%), m.p. 122-127°C; [a] -5.6° (cl.0,CH2 Cl2) (Found: C.66.90;
H,5.58; N,5.10. C9 9H9 3N309S requires C.66.90; H,5.49; N,5.32%);
6 h (360MHz,CDC13 ) 1.68-1.90 (4 H ,m ,a m in oa d ip y l3 ,A h), 2.15-2.26 (2H,
m,a m in o a d ip y l5H), 2.85 (2H,AB of ABX,S 2.91,6 2.79,713.9,4.7,6.4t\ 1J
Hz , cys3H) , 3.58 (2H,AB,6 3.62,6 3. 54,/13.4Hz , SG7/2 Ph) , 4.41 (lH,m,A D
am in oa d lp y12H), 4.90 (1H,M of ABMX,/4.7,6 .4,7.9Hz,cys2H), 5.09
( 2H, AB , 6 5.12,<5 5.06,/12.2Hz, OC/72 Ar) , 5.21 (2H, AB ,6 A 5. 24,6 5.19,/ A d  A B
13 . 6Hz , 0CH2 Ar) , 5.47 (1H, d ,/7 . 9Hz , N/7) , 6.19 (1H, d ,/7 . 8Hz, NT/) , 6 . 8 6  
(1H , s , C7/Ph2 ) , 7.18-7.41 ( 20H, m , Ar/7) , 7.46 (2H, d ,/8 . 5Hz , Ar//) and
8.17 ( 2H, d , / 8 . 5Hz , Ar/Z) ; m/z (El) 698 (<1%) (M-91), 622 (<1%)
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(M-167), 578 (<1%), 167 (100%) and 91 (100%).
IV—Benzyloxycarbonyl—1— (4—Nitrobenzyl) —6 — (L-g —Aminoadipyl)—5—Benzyl—
L—[ 3—1 3 C] —Cysteine Benzhydryl Ester
5—benzyl—L—[3— 1 3C]—cysteine (0.15g, 0.71mmol) was converted to
its benzhydryl ester and coupled with IV—'benzyloxycarbonyl—L-a—amino-
adipic acid 1— (4-nitrobenzyl) ester (0.36g, 0.84mmol),as previously
described, to give (V—benzyloxycarbonyl— 1— (4—nitrobenzyl)—6— (L-a—
aminoadipyl)-S—benzyl-L—[ 3—1 3 c]—cysteine benzhydryl ester (0.36g,
64%), m.p. 120-122°C; 6 h (300MHz,CDC13 ) 1.69-1.92 (4H,m,a m in oa d ip y l
3,4H), 2.16-2.26 (2H,m ,a m in o a d ip y l5H), 2.85 (2H,AB of ABMX.S 2.91,
A
6 2.79,7143.0,140.8,13.8,6.4,4.6Hz,cys3H) , 3.57 (2H,AB of ABX ,6
D A
3.62,6 3. 54,/13.4,4.1,3.7Hz,SC//2 Ph) , 4.41 (1H,m ,aminoadipy!2H) ,
4.85-4.89 (lH,m,cyS2H) , 5.09 (2H,AB,6 .5.12,5 n5.06, /12. 2Hz , 0C//2 Ar) ,
A B
5.21 (2H,AB,6 5.24,6 5.19,/13.4Hz,OCAAr), 5.48 (1H, d ,/8 . 1Hz , N//) ,
A B
6.20 (1H, d ,/7. 6Hz , N//) , 6.85 (1H, s , C//Ph2 ) , 7.17-7.36 (20H, m , Ar//) ,
7.46 (2H,d,/8.5Hz,Ar//) and 8.17 (2H, d ,/8 . 5Hz , Ar//) ; m/z (El) 699 
(<1%) (M-91), 623 (6%) (M-167), 579 (4%), 167 (100%) and 91 (100%).
/V—Benzyloxycarbonyl—S—Benzyl—L—Cysteinyl—D—Valine Benzyl Ester 
D-valine benzyl ester 4—toluenesulphonic acid salt (0.42g, 
l.lmmol) was converted to the free base by suspension in EtOAc 
(20ml) and extraction with sat. aq. NaHC03 (20ml). The D-valine 
benzyl ester so obtained, N—benzyloxycarbonyl-S—benzyl—L—cysteine 
(0.35g, l.Ommol) and 1-hydroxybenzotriazole (0.15g,1.lmmol) were 
dissolved in EtOAc (15ml). Dicyclohexylcarbodiimide (0.22g, 
l.lmmol) was added in one portion and the solution stirred at room 
temperature overnight. Oxalic acid dihydrate (25mg) was added, 
the mixture stirred a further lh and filtered. The filtrate was 
washed with lM-aq. HC1 (10ml), sat. aq. NaHC03 (10ml), sat. aq. NaCl 
(10ml) and dried over MgSO,, . Evaporation afforded a colourless
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solid which was chromatographed on silica (30g) with an EtOAc:n-
hexane (5:5) — EtOAc:n-hexane (7:3) gradient as eluant. The crude
product was crystallized from EtOAc/n-hexane to yield /V-benzyloxy-
carbonyl—5-benzyl—L—cysteinyl—D—valine benzyl ester (0.47g, 87%),
451m.p. 101-102°C (lit. , m.p. 99.5-101°C); [otj^-15.10 (cl.O, acetone)
451[lit. , [aj^-15.10 (cl.O, acetone)] (Found: C,67.14; H,6.24;
N,5.14. C 30H 3 „N20 5S requires C,67.39; H,6.41; N,5.24%); 6U (200H
MHz ,CDC1 3) 0.82 (3H,d,76.9Hz,vai4H), 0.88 (3H, d ,76. 9Hz , va]4H) , 2.15
(lH,dsept.,76.9,4.8Hz,vai3H), 2.81 (2H,AB of ABX,6A2.88,6n2.73,714.1,A B
5.7,7.0Hz, cyS3H), 3.73 (2H,s,SC//2Ph), 4.29 (lH,m, cys2H), 4.56 (1H,
dd,74. 7 , 8 .8Hz , va/2H) , 5.12 (2H, s ,0C//2Ph) , 5.15 (2H, AB , 6.5.19 , <5_5.11,A B
7L2. 2Hz ,0C//2Ph) , 5.58 (1H, d,7 7.0 Hz , cysHH) , 6.64 (1H,d,78.9Hz , valNH) 
and 7.19-7.38 (15H,m,Artf) ; m/z (El) 534 (2%) (M), 443 (13%), 399 
(22%), 335 (43%), 292 (53%) and 91 (100%).
A/—4—Methoxybenzyloxycarbony1—5-Benzyl—L—Cysteinyl—D—Valine Benzyl 
Ester
/V- 4—methoxybenzyloxycarbonyl—5—benzyl—L—cysteine dicyclohexyl- 
amine salt (1.39g, 2.5mmol) was converted to the free acid by sus­
pension in EtOAc (40ml) and extraction with lM-aq. HC1 (40ml). The 
N - 4—methoxybenzyloxycarbonyl—5—benzyl—L—cysteine so obtained, D- 
valine benzyl ester (0.54g, 2.6mmol) and 1-hydroxybenzotriazole 
(0.35g, 2.6mmol) were dissolved in EtOAc (40ml) and dicyclohexyl- 
carbodiimide (0.54g, 2.6mmol) added. The solution was stirred over­
night at room temperature, oxalic acid dihydrate (15mg) added, and 
stirring continued for a further lh. The dicyclohexylurea precipi­
tate was filtered and the filtrate washed with lM-aq. HC1 (25ml),
H20 (25ml), sat. aq. NaHC03 (25ml), sat. aq. NaCl (25ml) and dried 
over MgSOi, . Evaporation left a crude solid which was filtered
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through silica (5g) and crystallized from EtOAc/n-hexane to yield
N—4—methoxybenzyloxycarbonyl—S—benzyl—L—cysteinyl—D—valine benzyl
ester (1.31g, 93%), m.p. 117-118°C; [a]D-6.0° [cl .0, EtOH: CH..C12
(1:1)]; [a] 3 6 s-23.0° [cl.O,EtOH:CH2Cl2(l:l)] (Found: C.66.17;
H.6.28; N.5.15. C 3lH 36N 206S requires C,65.94; H.6.43; N,4.96%);
6h (200MHz, CDCl^ ) 0.82 (3H , d.,76. 9Hz ,va/4H) , 0.89 (3H, d ,76. 9Hz ,v a l 4H) ,
2.17 (lH.dsept.,76.9,4.8Hz,ua/3H), 2.80 (2H,AB of ABX,6A2.87,S02.74,A B
714.1,5.7,6.9Hz,cys3H), 3.72 (2H,s,SC//2Ph) , 3.79 (3H,s,0CH 3) , 4.31 
(lH,m,cys2H), 4.56 (lH,dd,78.8,4.8Hz,va/2H), 5.05 (2H,s,0Q72Ar), 5.15 
(2H,AB,<5A5.19,<5B5.10,7l2.2Hz,0G£/2Ar) , 5.59 (1H,d,77.3Hz,cysW )  , 6.69 
(1H, d,78. 7Hz ,v a lW i) , 6.87 (2H, d,78.7Hz , Ar//) and 7.22-7.33 (12H,m,Ar//) ;
6C (20MHz,CDCI3) 17.38 (q,vai4C), 18.80 { q , v a l 4 C ) , 31.06 (d,va/3C),
33.75, 36.33 (t,t,cys3C and SCH2Ph), 54.06 (d,cys2C), 55.08 (q,0CH3), 
57.12 (d,vai2C), 66.89 (t,2xOCH2Ar), 113.78, 127.08, 127.65, 128.18, 
128.31, 128.45, 128.81, 129.84, 135.11, 137.69, 155.78 (18xArC),
159.51, 169.93 and 171.14 (3xC=0); m/z (El) 473 (<1%) (M-91), 399 
(23%), 292 (2%), 210 (4%), 121 (100%) and 91 (75%).
/V-Benzyloxycarbonyl—1— (4—Nitrobenzyl)-g-(L-q-Aminoadipyl-S-Benzyl-L- 
Cysteine
/V-benzyloxycarbonyl— 1— (4—nitrobenzyl)— 6— (L—a—aminoadipyl)—S— 
benzyl—L—cysteine benzhydryl ester (0.40g, 0.51mmol) was dissolved 
in 0.2N-HC1 MeN02 and stirred at room temperature for l-2h or until 
the reaction was judged to be complete by analytical t.l.c. Eva­
poration afforded a crude solid which was chromatographed on silica 
(lOg) with an EtOAc-EtOAc:HOAc (99:1) gradient as eluant. Initial 
fractions afforded chlorodiphenylmethane, 6^ (60MHz, CDC13) 6.08 
(1H, s , C/jPh2) and 7.18-7.40 (10H,m , Ar//) . Later fractions gave crude
A7-benzyloxycarbonyl-l-(4-nitrobenzyl)—5— (L—a-aminoadipyl) — S-benzyl—
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0.31g, 98%) crystallized from EtOH/Et2O/n-hexane (0.24g, 
9-81°C ; [ct] -16.6° [cl .0,CH2 Cl2 :MeOH( 1:1) ] (Found:
,5.44; N.6.49. C3 3H3 3N309S requires C,59.70; H,5.33;
- (300MHz,CDC13) 1.69-1.87 (4H,m ,a m in o a d ip y l3,4H),
H,m,am in oa d ip y  15H), 2.83-2.90 (2H,m,cys3H), 3.66 (2H,s, 
-1-4.42 (lH,m,2H) , 4.69-4.71 (lH,m,2H) , 5.07 (2H,AB,6A 
,/12.0Hz,0C//2 Ar) , 5.18 (2H, AB , 6 . 5.20 ,6 5.16, /14 . 3Hz ,A D
5 (lH,d,77.9Hz,N//) , 6.57 (1H, d ,77. 2Hz , N//) , 7.17-7.30 
, 7.42 (2H, d,78. 5Hz, Ar//) and 8.15 (2H, d, 78. 5Hz , Ar//) ;
(<1%), 429 (<1%), 322 (4%), 294 (6%), 249 (27%), 107 
(1 0 0%).
ysteinyl—D—Valine Benzyl Ester Hydrochloride Salt and 
phonic Acid Salt
■hoxybenzyloxycarbonyl—S—benzyl—L—cysteinyl—D—valine 
(lmg) was dissolved in HC1 saturated MeN02 (50pl) at 
:ture. After 2 min the solvent was removed in a stream 
gen and the crude product crystallized from CH2Cl2/n- 
_ ford S'—benzyl—L—cysteinyl—D—valine benzyl ester hydro- 
t, m.p. 147-149°C; m/z (El) 400 (3%) (M, free base),
•2 (18%), 263 (12%), 166 (6 6%) and 91 (100%).
nalagous procedure addition of 4-toluenesulphonic acid 
leq.) to the MeN02 solution, evaporation and crystall- 
EtOH/ether gave S—benzyl—L—cysteinyl—D—valine benzyl 
?nesulphonic acid salt (71%), m.p. 200-205°C (Found:
■ ■3.58; N,4.85. C2 9H3 6N206S2 requires 0,60.82; H,6.34;
! (200MHz,CDC13) 0.81 (3H,d, 6 .8Hz , v a l4H), 0.82 (3H,d,
2.11 (1H, dsept. ,76.8,5.6Hz ,t/ai 3H) , 2.24 (3H,s,C H3) , 
pattern, cys3H) , 3.64 (2H, AB,6ft3.69, 603 . 59 ,712.9Hz ,SC//2Ph) ,
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L-cysteine (0.31g, 98%) crystallized from EtOH/Et2O/n-hexane (0.24g,
76%), m.p. 79-81°C; [a]D-16.6° [cl-0,CH2 Cl2 :MeOH(1:1)] (Found:
0,59.59; H,5.44; N,6.49. C3 1 H3 3N30,S requires 0,59.70; H,5.33;
N ,6 .74%); 6 (300MHz,CDC1,) 1.69-1.87 (4H,m ,a m in o a d ip y l3,4H),
2.16-2.23 {2 U ,m ,a m in o a d ip y l5 H ), 2.83-2.90 (2H,m ,cys3H), 3.66 (2H,s,
SC//2 Ph) , 4.41-4.42 (lH,m,2//) , 4.69-4.71 (lH,m,2//) , 5.07 (2H,AB,6A
5 .1 0 , 6  5.04,712.0Hz, 0C//2 Ar), 5.18 (2H,AB,6.5.20,6D5.16,/14.3Hz, d A d
0C//2 At), 5.65 (1H, d ,77.9Hz , N//) , 6.57 (1H, d ,77. 2Hz , N//) , 7.17-7.30 
(10H,m , Ar//) , 7.42 (2H,d ,78. 5Hz , Ar//) and 8.15 (2H, d,78. 5Hz , Ar//) ; 
m/z (El) 481 (<1%), 429 (<1%), 322 (4%), 294 (6%), 249 (27%), 107 
(96%) and 91 (100%).
5-Benzyl—L—Cysteinyl—O-Valine Benzyl Ester Hydrochloride Salt and 
4—Toluenesulphonic Acid Salt
/V—4—methoxybenzyloxycarbonyl—5—benzyl—L—cysteinyl—D—valine 
benzyl ester (lmg) was dissolved in HC1 saturated MeNQ2 (50)jl) at 
room temperature. After 2 min the solvent was removed in a stream 
of dry nitrogen and the crude product crystallized from CH2Cl2/n- 
hexane to afford S—benzyl—L—cysteinyl—D—valine benzyl ester hydro­
chloride salt, m.p. 147-149°C; m/z (El) 400 (3%) (M, free base),
383 (2%), 292 (18%), 263 (12%), 166 (6 6%) and 91 (100%).
In an analagous procedure addition of 4-toluenesulphonic acid 
monohydrate (leq.) to the MeN02 solution, evaporation and crystall­
ization from EtOH/ether gave S—benzyl—L—cysteinyl—D—valine benzyl 
ester 4-toluenesulphonic acid salt (71%), m.p. 2Q0-205°C (Found: 
0,60.61; H,6.58; N,4.85. C2 9H 3 6N206S2 requires 0,60.82; H.6.34;
N ,4.89%); (200MHz,CDC13) 0.81 (3H,d, 6 .8Hz , v a l4H), 0.82 (3H,d,
7 6 . 8Hz ,v a l 4H) , 2.11 (1H, dsept. ,76.8 , 5. 6Hz ,v a l 3H) , 2.24 (3H,s ,C//3),
3.01 (2H,AB pattern, cvs3H) , 3.64 ( 2H , AB , 6 „ 3 . 69 , 6D3 . 59 ,712 . 9Hz , SC//2 Ph) ,A d
4.42 (lH,dd,75.6,8.4Hz,va/2H), 4.64br (1H,t,76.3Hz, cys2H), 5.00 (2H,
AB, 6 5.08, 6 4.91, 712.3Hz, 0C//2Ph) , 7.02 ( 2H, d , 78 . 0Hz , Ar//) , 7.11-7.28 A D
(10H,m , Ar//) , 7.71 (2H, d,78.OHz, Ar//) and 8.13 (1H, d ,78.4Hz,N//) ; m/z 
(El) 400 (3%) (M, free base), 383 (4%), 309 (2%), 292 (14%), 263 
(11%) and 91 (100%).
¿V-Benzyloxycarbonyl—1— (4—Nitrobenzyl)—<S— (DL—a—Aminoadipyl)— 5—Benzyl— 
L—Cysteinyl—D—Valine Benzhydryl Ester
/V-benzyloxycarbonyl—1— (4—nitrobenzyl)—5— (DL—a—aminoadipyl) - S -  
benzyl—L—cysteine (63mg, O.lOmmol) was prepared as described for the 
LL-species. D-valine (12mg, O.lOmmol) and 4-toluenesulphonic acid 
monohydrate (22mg, O.lOmmol) were dissolved in DMF (1ml) and heated 
to 50°C. Diphenydiazomethane (31mg, 0.16mmol) in DMF (1.5ml) was 
added dropwise over lh to afford crude D-valine benzhydryl ester 
4-toluenesulphonic acid salt. The DMF was removed in  v a cu o , the 
residue dissolved in EtOAc (4ml) and washed with sat. aq. NaHC03 
(2x4ml), sat. aq. NaCl (4ml) and dried over Na2S0,, . The crude 
D-valine benzhydryl ester, so obtained, the crude A^-benzyloxycarbon- 
yl—1— (4—nitrobenzyl)— ¿>— (DL-a-aminoadipyl)—5-benzyl—L—cysteine and 
1—hydroxybenzotriazole (14mg, O.lOmmol) were dissolved in EtOAc (2ml) 
and dicyclohexylcarbodiimide (22mg, O.llmmol) added. The mixture 
was stirred at room temperature overnight, oxalic acid dihydrate 
(lmg) added and after a further lh the dicyclohexylurea filtered.
The filtrate was washed with lM-aq. HC1 (2ml), H20 (2ml), sat. aq.
NaHC03 (2ml), H20 (2ml), sat. aq. NaCl (2ml) and dried over NajSO,,. 
Evaporation to an oil which was chromatographed on silica (lOg) 
with EtOAc:n-hexane (6:4) as eluant gave a crude solid crystallized 
from CH2Cl2/ether/n-hexane to yield /V-benzyloxycarbony1—1— (4—nitro­
benzyl )-£>-(DL-a— aminoadipyl )—S—benzyl—L—cysteinyl—D—valine benzhydryl
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ester (65mg, 72%), m.p. 75-80°C (Found: C,66.36; H,6.15; N,6.03.
C,9H 5 2N,O10S requires C,6 6 .20; H.5.90; N,6.30%); (300MHz,CDC13)
0.75 (3H,dd,76.9,1.1Hz,vai4H), 0.87 (3H,d,J 7.0Hz,valA tt), 1.68-1.85
(4H,m,a m m o a d ip y l3 , 4H), 2.10-2.26 (3H,m ,aminoadipyl'oW and v a l3H),
2.74 (2H,AB of ABMX,6ft2.80,6g2.6 8 ,/14.0,6 .0,7.0,1.8 ,2.1Hz, cys3H),
3.72 ( 2H, s , SC//2Ph) , 4.36-4.41 (lH,m,2H) , 4.55-4.66 (2H, m , 2x2//) , 5.09
(2H, AB , 6 5.11, 6 5.06,711.9Hz,0C//2 Ar) , 5.20 ( 2H, AB , 6 A5. 23, 6D5.16 , J A d  z A d
13. 7Hz , 0C//2Ar) , 5.72-5.76 (lH,m,N//), 6.48-6.51 (lH,m,N//), 6.87 (1H, 
s,C//Ph2), 6.91-6.98 (lH,m,N//), 7.17-7.38 (20H,m,Ar//) , 7.41-7.45 (2H, 
m , Ar//) and 8.16 (2H,d,J8 .9Hz , Ar//) ; m/z (El) 797 (<1%) (M-91), 752 
(<1%), 721 (<1%) (M-167), 309 (4%), 167 (84%) and 91 (100%).
N—Benzyloxycarbonyl— 1— (4—Nitrobenzyl)—<s— (DL—ct—Aminoadipyl)— S~ Benzyl—
L—Cysteinyl—D— (3R)— [4-1 3C ] —Valine Benzhydryl Ester
D-valine (llmg, 0.09mmol), mixed with (2R, 3R)— [4-1 3C]—valine 
(lmg) was converted to its benzhydryl ester and coupled with ¿V— ben­
zyloxycarbonyl— 1— (4—nitrobenzyl)—<5— (DL—a—aminoadipyl)—5—benzyl—L— 
cysteine as described above to yield ¿V— benzyloxycarbonyl— 1— (4—nitro­
benzyl )—5— (DL—a—aminoadipyl)—S—benzyl—L—cysteinyl—D— (3R)— [4-13C]— 
valine benzhydryl ester (56mg, 62%), m.p. 76-80°C; 6  ̂ (20MHz,
CDC13) 17.14 (va lA C), 18.94 (v a lA C ), 21.14 (am in oa d ip ylA C), 30.99,
31.30, 33.25, 35.04, 36.42 (v a l3 C , cyS 3C , am inoadipyl3C and 5C and 
SCH2Ph), 52.03, 53.70, 57.25 ( v a l , cys and a m in oa d ipyl 2C), 65.38,
66.98 (2x0CH2Ar), 77.91 (CHPh2), 123.70, 126.41, 126.79, 126.99,
127.28, 127.36, 127.64, 127.95, 128.05, 128.38, 128.84 (24xArC),
136.03, 137.87, 139.25, 139.42, 142.33, 155.94 ( 6 x quaternary ArC) , 
159.87, 170.06, 170.54, 171.77 and 172.20 (5xC=0).
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/V-Benzyloxycarbonyl—1— (4—Nitrobenzyl)— 6 — (L—a— Aminoadipyl)— 5-Benzy 1— 
L—Cysteinyl-D—Valine Benzhydryl Ester
D-valine (0.26g, 2.2mmol) was converted to its benzhydryl ester 
and coupled to /V-benzyloxycarbonyl—l— (4—nitrobenzyl)—<5 — (L-a— amino­
adipyl )—S-benzyl-L—cysteine (l.25g, 2.0mmol) as described above for 
the DL-a-aminoadipyl derivative to yield /V-benzyloxycarbonyl—1— (4— 
nitrobenzyl)-G— (L-a -aminoadipyl)—S-benzyl—L—cysteinyl-D—'valine benz­
hydryl ester (1.16g, 65%), m.p. 77-80°C remelting at 133-135°C;
[a ] 4 3 6 -11.9° (cl.O, acetone) (Found: C,66.41; H.5.81; N.6.02.
C „ H 5 2 N,O10S requires C,66.20; H.5.90; N,6.30%); 6 U (200MHz ,CDC13 )
0.75 (3H,d,/7.0Hz,va/4H), 0.87 (3H,d,/6 .8Hz, v a l m ), 1.67-1.90 (4H,m, 
a m in o a d ip y l3,4H), 2.15-2.27 (3H,m,am inoadipyl5U and va/3H), 2.74 
(2H,AB of ABX, 6 2.84,602.65,714.0,5.6,7.3Hz,cys3H), 3.74 (2H,s, 
SC//2Ph), 4.35-4.54 (2H,m, a m in oa d ip y l and cys 2H), 4.61 (1H,dd,/4.5,
8 .7Hz,va/2H), 5.09 (2H,AB pattern,0C//2Ar), 5.21 (2H,s,0CH 2Ar), 5.33 
(1H, d, J l . 9Hz , N//) , 6.22 (1H, d, J 7. 1Hz, NH) , 6.70 (1H, d, 78. 7Hz , valNH) ,
6 . 8 8  (1H, s , C//Ph2 ) , 7.17-7.33 (20H, m , Ar//) , 7.45 (2H, d, 78. 5Hz , Ar//) and
8.17 (2H,d,/8.5Hz,Ar//) ; <5 (25MHz ,CDC13 ) 17.18 (va/4C), 18.95 (v a lL»
4C), 21.17 (a m in oa d ip y l4C), 30.99, 31.34, 33.36, 35.07, 36.48 (va l3C, 
cy s 3 C ,a m in o a d ip y l3C and 5C and SCH2Ph), 52.07, 53.76, 57.29 { v a l ,  
c y s and a m in oa d ip y l2C), 65.39, 66.96 (2xOCH2Ar), 77.94 (CHPh2),
123.69, 124.27, 125.37, 125.47, 125.62, 125.75, 126.02, 126.15,
126.42, 126.81, 127.26, 128.06, 128.37, 128.80 (24xArC), 136.05,
137.89, 139.28, 139.43, 142.34, 155.95 ( 6 x quaternary ArC), 159.85,
170.03, 170.49, 171.76 and 172.12 (5xC=0); m/z (El) 797 (<1%) (M-91), 
752 (<1%), 721 (<1%) (M-167), 167 (61%) and 91 (100%).
/V—Benzyloxycarbony1—1— (4—Nitrobenzyl) - 6 — (L-a —Aminoadipyl)—5~Benzyl—
L— f3-1 3C ]—Cysteinyl—D— [1 5N|—'Valine Benzhydryl Ester
D— [1 SN]—■valine (57mg, 0.48mmol) was converted to its benzhydryl
ester and coupled with /V—benzyloxycarbony1—1— (4—nitrobenzyl)— 6— (L—a— 
aminoadipyl)—5—benzyl—L— [3-1 3C]—cysteine [prepared from IV—benzyloxy­
carbony 1— 1— (4—nitrobenzyl)— 6— (L—a—aminoadipyl)—S~benzyl—L— [3-1 3C ]— 
cysteine benzhydryl ester (360mg, 0.46mmol)] as described above.
The crude product was purified by column chromatography on silica 
(30g) with EtOAc:n-hexane (6:4) as eluant and crystallized from 
CH2C12/ether/n-hexane to afford N— benzyloxycarbony1—1— (4—nitrobenzyl)
— 6— (L—a—aminoadipyl)—S—benzyl—L— [3-1 3C]—cysteinyl—D— [1 5N ]—valine 
benzhydryl ester (222mg, 55%), m.p. 130-135°C; 6U (300MHz,CDC1,)
0.74 (3H,d,/6.9Hz,va/4H), 0.86 (3H,d,76.7Hz,valA H), 1.67-1.85 (4H,m, 
a m in oa d ipy  1 3 ,4H), 2.15-2.24 (3H, m ,a m in oa d ip y l 5H and v a l 3H) , 2.73 
(2H ,AB of ABMX.5 2.83,6B2.64,7l42.5,141.0,14.0,5.4,7.2Hz,cys3H),
3.74 (2H, d ,73. 4Hz , SC//2Ph) , 4.39-4.50 (2H,m, a m in oa d ip y l and cys2H) ,
4.62 (1H,dd,78.5,4.2Hz,va/2H), 5.09 ( 2H, AB , <5 A 5.11, <$D5.06,712 . 1Hz ,A D
0C//2Ar), 5.21 (2H,AB,6A5.24,6B5.18,7l3.4Hz,0Qi72Ar), 5.56 (lH,d,77.8 
Hz.N//), 6.24 (lH,d,77.1Hz,N//) , 6.72 (1H, dd ,791. 3 , 8 . 5Hz , 1 5 N//) , 6.87 
(lH,s,Q7Ph2) , 7.18-7.31 (20H,m , Ar//) , 7.46 (2H, d,78.4Hz , Ar//) and 8.18 
(2H,d,78.4Hz, Ar//) ; <$c (75MHz , CDC13 ) 33.38 (t,cys3C); m/z (El) 799




benzyl—L—cysteine (69mg, O.llmmol), D-valine benzyl ester hydro­
chloride salt (30mg, 0.12mmol), triethylamine (17.1pl, 0.12mmol),
1—hydroxybenzotriazole (17mg, 0.13mmol) and dicyclohexylcarbodiimide 
(25mg, 0.12mmol) were dissolved in EtOAc (5ml) and stirred at room 
temperature overnight. Oxalic acid dihydrate (2mg) was added, 
stirring continued for a further lh, and the dicyclohexylurea
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precipitate filtered. The filtrate was washed with lM-aq. HC1 (5ml),
H20 (5ml), sat. aq. NaHC03 (5ml), H20 (5ml), sat. aq. NaCl (5ml) and 
dried over MgS0H . Evaporation afforded a colourless solid which 
was dissolved in the minimum of CH2C12, filtered and crystallized 
from CH2Cl2/ether to yield /V—benzyloxycarbony1—1— (4—nitrobenzyl)— 6—
(L-a-aminoadipyl)—5—benzyl-L—cysteinyl—D—valine benzyl ester (56mg,
62%) .
Alternatively 5—benzyl—L—cysteinyl—D—valine benzyl ester [pre­
pared from S—benzyl—L—cysteinyl—D—valine benzyl ester 4-toluene- 
sulphonic acid salt (172mg, 0.30mmol)], /V—benzyloxycarbony1—L—a— 
aminoadipic acid 1— (4—nitrobenzyl) ester (136mg, 0.32mmol), 1—hydroxy- 
benzotriazole (43mg, 0.32mmol) and dicyclohexylcarbodiimide (65mg, 
0.32mmol) were dissolved in EtOAc (20ml) and stirred overnight at 
room temperature. Oxalic acid dihydrate (4mg) was added, stirring 
continued a further lh and the solution filtered. The filtrate was 
washed with lM-aq. HC1 (20ml), sat. aq. NaHC03 (20ml), sat. aq. NaCl 
(20ml) and dried over MgSO,,. Evaporation left a colourless solid 
which was chromatographed on silica (25g) with EtOH:CH2Cl2 :EtOAc: 
n-hexane (1:1:7:3) as eluant. The crude product was crystallized 
from CH2Cl2/ether/n-hexane to yield /V—benzyloxycarbony1—1— (4—nitro­
benzyl )—6— (L-a-aminoadipyl)-S-benzyl-L—cysteinyl-D—'valine benzyl 
ester (188mg, 77%), m.p. 136-137°C; [aJ^-13.60 (cl.0, acetone)
(Found: C.63.27; H,5.78; N , 6 . 90 . C„ 3 H, 8 N„ 03 „ S requires C , 63 . 53 ;
H,5.95; N,6.89%); 6 (200MHz,CDC13) 0.83 (3H,d ,J 6 .9Hz, v a l4H) ,H
0.89 (3H,d,76.9Hz,i/a/4H) , 1.69-1.87 { AW, m ,am inoad ipyl 3,4H) , 2.12-
2.21 (2H,m,am inoad ipy 1 5H and v a l 3 U ) , 2.75 (2H,AB of ABX.6^2.85, 
<5B2.66,7l4.0,5.8,7.2Hz,cys3H) , 3.76 ( 2H, s , SQ72 Ph) , 4.45-4.54 (3H,m, 
a m in oa d ip yl , cys and v a l 2H), 5.10 (2H,s ,0(?/2 Ar) , 5.11 (2H,AB,
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6 5.16, 6^.06,/12.2Hz,0C//2Ar) , 5.23 (2H, s , 0C//2Ar) , 5.62 (1 H , d,/8 . 2Hz,
N H) , 6.24 (1H, d , /7 . 3Hz , N/7) , 6.73 (1H, d, /8 . 7Hz , N//) , 7.21-7.36 (15H,m,
Ar H) , 7.47 (2H,d,/8.5Hz,Ar//) and 8.18 (2H, d,/8 . 5Hz, Ar//) ; 6 ( 50MHz ,
CDC13) 17.57 (va/4C), 18.96 ( v a l 4C), 21.42 { am inoad ipyl^C ) , 31.06,
31.42, 33.46, 35.23, 36.64 [v a l3 C ,am inoadipyl3C and 5C,cys3C and 
SOl2Ph), 52.20, 53.93, 57.47 (c y s ,v a l and a m in oa d ip y lZ C ), 65.48,
67.07 (3x0CH2Ar), 123.78, 127.24, 128.02, 128.14, 128.29, 128.32,
128.47, 128.54, 128.64, 128.93 (19xArC), 135.27, 136.21, 138.01,
142.48, 147.87 (5x quaternary A r C ) , 156.05, 170.18, 171.33, 171.88 
and 172.31 (5xC=0); m/z (El) 335 (3%), 292 (5%), 249 (6%), 214 
(14%), 166 (17%) and 91 (100%).
/V-Benzyloxycarbonyl-l-(4-Nitrobenzyl )-<5— (L-a-Aminoadipyl)— g-Benzyl- 
L—Cysteinyl—D—Valylglycine Benzyl Ester
/V-benzyloxycarbonyl-l-(4—nitrobenzyl)— <5— (L-a—aminoadipyl)~S~
benzyl-L—cysteinyl-D-valine benzhydryl ester (200mg, 0.23mmol) was
dissolved in 0.2N-HC1 MeN02 for l-2h. Evaporation left an oil
which was chromatographed on silica (lOg) with Et0Ac:H0Ac (99.5:0.5)
as eluant to yield crude /V-benzyloxycarbonyl— 1— (4—nitrobenzyl)— 6—
(L—a—aminoadipyl)—S-benzyl—L—cysteinyl—D—valine. This crude product
was dissolved in THF (3ml), pyridine (20.0pl, 0.25mmol) and ethyl
chloroformate (23.8pl, 0.25mmol) added and the solution stirred at
0°C for 15 min. A solution of glycine benzyl ester 4-toluenesul-
phonic acid salt (84mg, 0.25mmol) and pyridine (20.0pl, 0.25mmol)
in CH2Cl2(3ml) was added and the mixture allowed to come to room
temperature overnight. The solvent was evaporated and the residue
dissolved in EtOAc (15ml). The EtOAc solution was washed with 1M-
aq. HC1 (10ml), H20 (10ml), sat. aq. NaCl (10ml) and dried over
MgSO,,. Evaporation left a semi-solid which was purified by pre­
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parative t.l.c. on silica with CH2Cl2:MeOH (19:1) as eluant and
crystallized from CH 2Cl2/EtOH/n-hexane to afford /V-benzyloxycarbonyl—
l-(4-nitrobenzyl)— 5— (L-a-aminoadipyl)—S~benzyl-L—cysteinyl—D—valyl-
glycine benzyl ester (90mg, 46%), m.p. 155-158°C; [a]D-7-4° [cl.O,
CH2C12:MeOH (1:1)] (Found: C.61.86; H.6.13; N.7.79. C„SH 5 1N 5
0 U S requires C,62.13; H.5.91; N,8.05%); 6H [ 300MHz, CDC13: CD 30D
(1:1)] 0.88 (3H,d,/6.8Hz,vai4H), 0.91 (3H,d,/6.8Hz,vai4H), 1.66-1.85
{4H ,m ,a m m oa d ip y l3 ,4H ) , 2.13-2.23 (3H,m ,am in oa d ipy 15H and v a l3H) ,
2.68 (2H,AB of ABX,6ft2.74,<5g2.63,/l3.8,7.4,6.5Hz,cys3H), 3.69 (2H,s,
SCH2Ph), 4.24 (lH,m,2H), 4.30 (lH,m,2H), 4.46 (lH,m,2H), 5.06 (2H,
AB , 6  5.09,6 5.03,/l2.2Hz,0Cf/2Ar), 5.11 (2H,s,0G¥2Ar), 5.20 (2H,AB,
<5.5.23, 65.17,/l3. 5Hz , 0C//2 Ar) , 7.20-7.35 (15H, m, Ar//) , 7.45 (2H,d,A d
/8 .6Hz,Arf/) and 8.15 (2H, d,/8 . 6Hz , Ar//) ; m/z (El) 350 (<1%), 108 
(53%) and 91 (100%).
6— (L-a-Aminoadipyl)—L—Cysteinyl-D—Valine
.'V—benzyloxycarbonyl— 1 — (4—nitrobenzyl)— 6— (L—a—aminoadipyl)—S— 
benzyl—L—cysteinyl—D—valine benzhydryl ester (lOOmg, O.llmmol) was 
dissolved in refluxing liquid ammonia (1 0ml) under a nitrogen atmos­
phere and small pieces of sodium metal added until the blue colour 
persisted for 5 min. Ammonium acetate (ca lOOmg) was added, the 
ammonia evaporated in a stream of dry nitrogen and the residue 
desiccated over cone. H 2S0.,. The product was isolated as follows:-
Procedure A: The residue was dissolved in 5% aq. HOAc (5ml), fil­
tered and a 10% (w/v) solution of Hg(0Ac) 2 in 5% aq. HOAc added 
dropwise to precipitate the tripeptide sulphide. The precipitate 
was separated by centrifugation and washed sequentially with de­
gassed water (4x5ml), MeOH (2x5ml) and ether (5ml). The dried
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tripeptide sulphide was resuspended in degassed water (2ml) and a 
stream of H2S passed through the suspension for 15 min. The black 
HgS was separated by centrifugation, washed with degassed water (1ml) 
and the combined supernatant and washings filtered through celite.
The filtrate was lyopholized to afford a mixture of 6— (L—a—amino­
adipyl )—L—cysteinyl—D—valine and its disulphide as a colourless
powder (32mg, 78%) (Found: 0,44.75; H,6.85; N.11.10; ash,4%.
475Cll(H2SN306S requires 0,46.30; H,6.87; N,11.57%); free thiol
75%; m/z (FAB) 364 (100%) (M+H) .
Procedure B : The residue was dissolved in 5% aq. HOAc (5ml), ex­
tracted with ether (2x2ml) and the aqueous layer lyopholized. The 
product was dissolved in water (5ml), adjusted to pH8 with dil. aq.
NH3 and the solution aerated for 2h. The solution was freeze dried, 
the residue dissolved in water and applied to an ion-exchange column 
(1.5x18cm) with a H20—1M—aq. pyridine gradient as eluant. The nin- 
hydrin-positive fractions were lyopholized to give 6— (L—a—amino­
adipyl )—L—cysteinyl—D—valine as its disulphide (39mg, 96%), m.p.
449200-203°C (decomp.); [a] -9.5° (c2.0,2M-aq.HCl) [lit. ,[a ]D-9.50
(C2.0,2M-aq.HC1); lit.4 5 0 ,[a] -11 - 0° (c2.0,2M-aq.HCl)] (Found:
0,46.18; H,6 .37; N.11.02. C2 6H„8N603 2S2 requires 0,46.40; H,
47S6.67; N,11.59%); free thiol 4%; 6^ (300MHz,D20) 0.31 (3H,d,
J 7 .2Hz,val4H), 0.34 (3H,d,77.9Hz,val4H), 1.08-1.30 {AH,m,aminoadipyl
3,4H) , 1.53-1.60 (lH.m.vai 3H) , 1.76-1.81 (2H ,m ,am inoadipyl'5H), 2.48
(2H,AB of ABX.6„2.58,6 2.39,714.1,5.7,8.4Hz,cys3H), 3.17br (lH,t,A D
J 5.8Hz , am in oa d ipyl 2H) and 3.59 (1H, d ,7 5. 8Hz ,va l 2H) ; <5 c (75MHz,D20)
17.14 { v a l A C ) , 18.52 [va l 40), 20.70 {am in oad ipyl 40) , 29.57, 30.07 
{va l and am in oa d ipyl 30) , 34.56 {am in oa d ip yl 50) , 38.49 (cys30),
52.43, 59.51 and 59.77 {am in oa d ip yl , cys and v a l 20); m/z (FAB)
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725.2861 (100%) (M+H ,C 28H „9N 60 l 2S 2 requires 725.2850).
<5 — (L—ct—Aminoadipyl)—L— [3- 13C ]—Cysteinyl—D~ [ 1 5N ]—Valine
/V-benzyloxycarbonyl—1— (4—nitrobenzyl) — 6— (L—cc-aminoadipyl)—S~ 
benzyl—L— [3- 1 3C ]—cysteinyl-D— [1 SN ]—valine benzhydryl ester (212mg, 
0.24mmol) was deprotected as described above and purified by proced­
ure B to afford 6— (L-a — aminoadipyl)—L—[ 3- 1 3 C] —cysteinyl—D—[ 1 5 N] — 
valine as its disulphide (48mg, 55%), m.p. 195-200°C (decomp.);
6 (200MHz, D20) 0.94 (3H,d ,J 7 .8Hz,v a l4H), 0.98 (3H,d ,J 7 .0Hz, v a l4H),rl
1.64-2.01 (4H,m ,a m in o a d ip y l3,4H), 2.10-2.22 (1H,m, v a l3H), 2.37-2.51
(2H, m,a m in oa d ip y l 5H) , 2.80 (2H, AB of ABMX,6 A2.90,<5 D2.70,7193.9,12. 3,A B
3.6,6.9Hz,cys3H), 3.36-3.48 (lH,m,cys2H), 3.80 (1H,t,76.0Hz ,a m in o -  
a d i p y l2H) and 4.16 (1H,d,75.6Hz , v a l2H); 5 (50MHz,D20) 39.17 (t,
cys3C) ; m/z (FAB) 729 (100%) (M+H) and 728 (45%).
<S — (L—a—Aminoadipyl )—L—Cysteicyl—D—Valine
6— (L-a—aminoadipyl)—L—cysteinyl—D—valine and/or its disulphide 
(13mg, 0.04mmol) was dissolved in HC03H (1.5ml) and stirred at 0°C 
for lh. Water was added and the solution freeze dried. The re­
sidue was purified by ion-exchange chromatography with water as 
eluant to yield 6— (L-a—aminoadipyl)—L—cysteicyl—D—valine (14mg, 95%),
6 [ 90MHz,D20:H20 (2:1),pH 10.5] 17.00 {va l AC) , 18.69 {va l AC) , 21.12
{am in oa d ip yl AC ) , 30.65 {va l C3), 32.17 {am inoad ipyl 3C) , 35.01 {am ino­
a d ip y l 5C) , 50.82 (cys2C andcys3C), 54.74 {am inoadipyl 2C) and 60.66 
{va l 2C); m/z (FAB) 412 (100%) (M+H).
<5 — (DL-a— Aminoadipyl)— L—Cysteicyl—D— (3R)—[ 4- 1 3 C] —Valine
/V— benzyloxycarbonyl—1— (4-nitrobenzyl ) S  -(DL-a -aminoadipyl ) S ~  
benzyl—L—cysteinyl—D— (3R)-[ A -13C]—valine benzhydryl ester (8 6mg,
O.lOmmol) was deprotected as described above and purified by pro-
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cedure A. The tripeptide was oxidized with HC03H and purified by 
ion-exchange chromatography with water as eluant to yield 6— (DL—a— 
aminoadipyl)— L-cysteicyl—D-(3R) — [4- 1 3C]—valine (14mg, 35%), <5 
[90MHz,D20:H20 (2:1),pHIO.5] 17.00 { val AC)  , 18.68 { v a l A C ) , 21.05 
{a m in o a d ip y l4C), 30.63 { v a l3C), 31.57 {a m in oa d ip y l3 C), 34.92 {am ino­
a d ip y l 5C), 50.83 (cys2C and cy s 3 C ), 54.73 {a m in oa d ip y l2C) and 60.67 
{ v a l 2C); m/z (FAB) 412 (100%) (M+H).
6— (L-a—Aminoadipyl)—L—Cysteinyl—D—Valylglycine
N—benzyloxycarbonyl—1— (4—nitrobenzyl)— 6— (L—a-aminoadipyl)—S— 
benzyl—L—cysteinyl—D—valylglycine benzyl ester (54mg, 0.06mmol) was 
dissolved in refluxing liquid ammonia (5ml) and treated with sodium 
metal as described for the synthesis <5— (L-a—aminoadipyl )—L—cysteinyl—
D—valine. Purification using procedure B gave <5— (L-a-aminoadipyl) —
L—cysteinyl—D—valylglycine as its disulphide (19mg, 73%), m.p. 230- 
235°C (decomp.) (Found: C,46.05; H.6.21; N.12.32. C3 2H 5^N80!„S2
requires C.45.81; H,6.49; N,13.36%); (300MHz, D20) 0.25 (3H,d,
J 7 .5Hz, valAW), 0.28 (3H,d,77.5Hz,va/4H), 1.00-1.22 {A H ,m ,am inoadipyl 
3,4H), 1.44-1.52 (1H,m,v a l3H), 1.70br (2H,t,76.7Hz,a m in o a d ip y l5H) ,
2.40 (2H,AB of ABX,6 2.48,62.33,713.9,7.4,5.8Hz,cys3H), 3.07br (1H,A D
t ,J 5 .6 H z ,a m in o a d ip y 1 2 H ), 3.20 (2H,s,g7y2H) and 3.54 (1H,m,v a l2H); 
m/z (FAB) 839 (69%) (M+H) and 421 (100%).
6.4 /V-[6— (L—a—AMINOADIPYL)—L—CYSTEINYL]-/V-HYDR0XY—D—VALINE
D—Valine Benzyl Ester 4—Methoxybenzaldimine
D-valine benzyl ester 4-toluenesulphonic acid salt (1.14g,
3.0mmol) was converted to the free base, added to a solution of 
4-methoxybenzaldehyde (0.38ml, 3.1mmol) in dry benzene (30ml) and
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MgSO „ (ca5g) added. The mixture was stirred for 12h at 30°C, fil­
tered and evaporated to yield D-valine benzyl ester 4—methoxybenz- 
aldimine (0.96g, 98%), 6̂  (60MHz,CDC13) 0.95 (6H ,d,77.0Hz,va/4,41H), 
2.13-2.68 (lH,m,va/3H), 3.68 (lH,d,77.0Hz,va/2H), 3.77 (3H,s, 0 ) ,
5.22 (2H,s,0C//2 Ph), 7.02 (2H,d,78.5Hz,Ar//) , 7.35 (5H,s,ArH ) , 1 .IQ  
(2H, d,78. 5Hz , Ar//) and 8.20 (1H,s,C//=N) ; u (film) 2960 (C-H) , 1738 
(C=0), 1635 (C=N), 1605 and 1510cm-1.
Attempted Synthesis of /V—Hydroxy—D—Valine Benzyl Ester Hydrochloride 
Salt
D-valine benzyl ester 4—methoxybenzaldimine (0.96g,3.Ommol) was 
dissolved in CH2C12 (15ml) and cooled to 0°C. A solution of 3-chlo- 
roperbenzoic acid (82% pure) (0.69g ,4 .Ommol) in CH2Cl2(15ml) was 
added dropwise over 15min and stirring continued at 0°C for a further 
15min. The solution was filtered and the filtrate washed with sat. 
aq. NaHC03 (2x30ml), sat. aq. NaCl (30ml) and dried over Na2S01< . 
Evaporation left a crude orange oil. Treatment of the crude oil 
(222mg,0.6 8mmol) with 1M HCl-H20:Me0H (1:9) or 2M HCl-H20:Me0H (1:4) 
and crystallization of the product from EtOH/ether/n-hexane afforded 
D-valine benzyl ester 4—methoxybenzaldimine N~ oxide (94mg, 40%) re­
crystallized from EtOH/ether/n-hexane (75mg, 32%), m.p. 100-102°C,
[a ]q+20.0 (cl•0,MeOH) (Found: 0,70.25; H,6 .8 6 ; N,4.12.
C2 0 H2 3 NO, requires 0,70.36; H,6.79; N,4.10%); 6 ^ (60MHz,CDC13 )
1.04 (6H ,d,7 6 .5Hz,va 7 4,41H), 2.40-2.90 (1H,m ,v a l3H), 3.82 (3H,s,
C//3 0), 4.30 (lH,d,/10.0Hz,vai2H) , 5.20 (2H , s , OC7/2 Ph) , 6.90 (2H,d,
79.0Hz, Ar//) , 7.30-7.37 (6H,m,ArH and C//=N) and 8.21 (2H, d ,79 . 0Hz ,
Ar//) ; u (CC1, ) 2955 (C-H), 1740 (0=0) and 1608 cm-1 ; m/z (El) 341
(48%) (M), 206 (41%), 190 (8 6%), 151 (69%) and 91 (100%).
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/V-Hydroxy—D—Valine Benzyl Ester Hydrochloride Salt
In an identical experiment the crude orange oil was taken up in 
dioxane(50ml), 6M—aq. HC1 (50ml) added and the solution stirred at 
room temperature for lh. The solution was reduced in volume, ex­
tracted with ether (50ml) and evaporated to a semi-solid which was 
dessicated over P 20 5 and crystallized from EtOH/ether/n-hexane to 
afford /V-hydroxy—D—valine benzyl ester hydrochloride salt (0.40g,
52%), m.p. 118-126°C (Found: 0,53.99; H,6.69; N,5.16.
C 1 2H 1 8C1N03 requires 0,55.49; H,6.99; N,5.39%); 6 (200MHz,CDC13)H
1.02 (3H,d,76.9Hz,va/4H), 1.11 (3H,d,77.0Hz,va/4H), 2.57 (lH.dsept.,
75.2,6.9Hz,va/3H), 4.01 (1H,d,75.0Hz,val2H), 5.25 (2H,AB,5 5.30,r\
<5 5.21,7l2.1Hz,0C//2Ph) , 6.09br (3H, s, +N//2-0//) and 7.31-7.40 (5H,m,
Ar//) ; v (KBr disc) 3440, 2970 (C-H), 2770, 1735 (0=0), 1205, 908,
759 and 700cm-1; m/z (El) 223 (11%) (M.free base), 178 (7%) and 91 
(1 0 0%).
/V-Hydroxy—D—Valine Benzyl Ester
/V-hydroxy—D—v a lin e  benzy l e s te r  h y d ro c h lo r id e  s a l t  (0 .2 0g, 0.77
mmol) was suspended in EtOAc (10ml), washed with sat. aq. NaHC03
(2x5ml), sat. aq. NaCl (5ml) and dried over Na2S0^. Evaporation
to a colourless solid and crystallization from n-hexane afforded
/V-hydroxy—D—v a lin e  benzy l e s te r  (0.12g, 70%), m.p. 56-57°C; [a ] +
14.1°(cl.0,Et0H) (Found: 0,62.95; H,7.60; N,6.38. C1 2 H1 7 N03
requires 0,64.55; H,7.67; N,6.27%); 6 (360MHz,CDC13) 0.93 (3H,n
d,76.9Hz, valAH), 0.96 (3H,d, 76.9Hz, va/4H) , 2.02 (1H,dsept.,76.3,
6.9Hz, va/3H), 3.59 (1H,d,76.3Hz,va/2H), 5.22 (2H,AB,6 A5.24,6 g5.19,
J 12.3Hz,0C//2Ph) , 6.29br (2H,s,NH -qH ) and 7.29-7.38 (5H,m,Ar7/); $L/
[75MHz,CD3SOCD3 :H2 0(1:1)] 19.92 (q,va/4C), 20.58 (q,va/4C), 29.80 
(d , v a l30), 67.64 (t,0CH2Ph), 72.81 (d,va/2C), 129.58, 129.82 and
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130.04 (5xArC); m/z (El) 223 (22%) (M), 178 (8%) and 91 (100%).
/V-Hydroxy—D—Valine Benzyl Ester 4—Toluenesulphonic Acid Salt
/V~hydroxy—P—valine benzyl ester (69mg,0.31 mmol) and 4—toluene­
sulphonic acid monohydrate (64mg, 0.34mmol) were dissolved in meth­
anol (2ml), evaporated and crystallized twice from CH2Cl2/n-hexane 
to yield (V-hydroxy-P—valine benzyl ester 4—toluenesulphonic acid 
salt (106mg, 87%), m.p. 105-108°C; [a]D-3.4°(cl.O.MeOH) (Found:
C,57.84; H.6.36; N.3.43. C1 9H2 SN06S requires 0,57.70; H,6.37;
N, 3 . 54% ) ; 6 (60MHz,CDClj ) 0.93 ( 3H, d, /8 . 0Hz , va/4H) , 1.05 (3H,d,n
/6.0Hz, va U w ) , 2.15-2.60 (1H, m, va/3H) , 2.38 (3H,s ,C//3), 3.98 (lH,d,
/5.0Hz , valZH) , 5.22 (2H,s ,0C//2Ph) , 7.17 (2H,d,/8.0Hz,krH) , 7.35 (5H, 
s,Ar//) and 7.82 (2H,d,/8.0Hz,krH) ; m/z (El) 223 (3%) (M, free base), 
178 (3%), 172 (14%) and 91 (100%).
Attempted Syntheses of N— [IV— Benzyloxycarbonyl— 1— (4—Nitrobenzyl) —6 —
(L-a-Aminoadipyl)—S-Benzyl—L—Cysteinyl]-M— Hydroxy—D—'Valine Benzyl 
Ester
N— benzyloxycarbonyl— 1— (4—nitrobenzyl)—5 — (L-a —aminoadipyl)— S— 
benzyl—L—cysteine (255mg, 0.41mmol) was dissolved in dry THF (5ml) 
at 0°C and pyridine (0.33ml, 4.1mmol) and ethylchloroformate (0.39ml, 
4.1mmol) added. The solution was stirred for 15min, filtered and 
evaporated to yield an oil which was dissolved in CH2C1 2 (5ml) and 
added dropwise over lOmin to a solution of A/—hydroxy—D—valine benzyl 
ester (91mg, 0.41mmol) in CH2Cl2 (5ml). The solution was stirred 
at room temperature for 2h, washed with lM-aq. HC1 (10ml), H20 (10ml), 
sat. aq. NaCl (10ml) and dried over MgS09. Evaporation afforded a 
yellow oil which was chromatographed on silica (lOg) with EtOAc: 
CH2Cl2 :Me0H (500:500:1) as eluant to yield 0 — [/V-benzyloxycarbony1—
1— (4—nitrobenzyl )-<5-(L-a—aminoadipyl)—S— benzyl—L—cysteinyl}hV— hydroxy
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—D—valine benzyl ester (162mg, 48%).
Likewise, /V-benzyloxycarbonyl— 1— (4—nitrobenzyl )^6 — (L-ct — amino- 
adipyl)—5-benzyl—L-cysteine (60mg, O.lOmmol), A/—hydroxy—D—valine 
benzyl ester (23mg, O.lOmmol), 1—hydroxybenzotriazole (14mg, 0.10 
mmol) and dicyclohexylcarbodiimide (20mg, O.lOmmol) were dissolved 
in MeCN (2ml) and stirred at room temperature for 5h. The solution 
was filtered, evaporated and the residue purified by column chroma­
tography on silica (5g), with CH2CL,:MeOH (19:1) as eluant. Cryst­
allization of the product from CH30H/CH2Cl2/ether/n-hexane afforded 
O-iA^-benzyloxycarbonyl—l-(4—nitrobenzyl)-fi-(L-a—aminoadipyl)—5— 
benzyl—L-cysteinyl]-A(—hydroxy—D—valine benzyl ester (59mg, 74%), 
m.p. 81-84°C (Found: C.62.39; H.5.76; N.6.62. C H N O  S
’  ’ ’  ’ ’  * *3 **0 I I
requires C.62.31; H,5.84; N,6.76%); FeCl,-negative; s (60MHz,H
CDC13 ) 0.94 (6H, d,/ 6 . 5Hz ,va 7 4,41H), 1.57-1.85 (4H,m,a m in o a d ip y l3,4H), 
2.00-2.20 (2H,m,a m in o a d ip y l5H), 2.62 (2H,d,75.5Hz,cys3H), 3.57 (2H, 
s,SC//2 Ph), 3.60-3.65 (1H,m ,v a l 2 H ), 4.18-4.42 (1H,m,a m in o a d ip y l2H) ,
4.65br (lH,t,/5.5Hz,cys2H), 5.00 (2H,s,00% Ar), 5.08 (2H,s,00% Ar), 
5.52 (lH,d,/7.5Hz,N//) , 5.98 (1H,d,78.0Hz,N//) , 7.08-7.17 (15H,m,ArH) , 
7.38 (2H,d,/8.0Hz,Ar//) and 7.95 (2H, d, J 8. 0Hz, Ar/7) ; m/z (El) 721 
(<1%), 622 (<1%), 546 (<1%), 372 (9%), 322 (<1%), 249 (7%), 124 
(74%), 108 (38%), 107 (38%) and 91 (100%).
0— [/V-Benzy loxy carbonyl—5-Benzyl—L—Cysteinyl 1-/V-Hydroxy-D-Valine 
Benzyl Ester
/V-benzyloxycarbonyl—5-benzyl-L-cysteine (138mg, 0.40mmol), 
AT-hydroxy—D—valine benzyl ester (98mg, 0.44mmol), 1—hydroxybenzo­
triazole (59mg, 0.44mmol) and dicyclohexylcarbodiimide (91mg, 0.44 
mmol) were dissolved in CH3CN (4ml) and the solution stirred over­
night at room temperature. The precipitated dicyclohexylurea was
filtered and the filtrate evaporated to a yellow oil which was dis­
solved in EtOAc (10ml). The EtOAc solution was washed with lM-aq.
HC1 (5ml), H20 (5ml), sat. aq. NaCl (5ml) and dried over MgSO,̂ . 
Evaporation and chromatography on silica (30g) with EtOAc :r/-hexane 
(4:6) as eluant afforded 0 - [ N -benzyloxycarbonyl-S-benzyl-L—cysteinyl] 
-/V-hydroxy-D-valine benzyl ester as an oil (200mg, 91%), FeCl3-
negative; 6 (300MHz,CDCl3) 0.96 (3H,d,76.5Hz,vai4H) , 0.98 (3H,d,H
76.6Hz, vaMH), 1.96-2.07 (lH,m, va/3H), 2.69 (2H,AB of ABX,6A2.74,
6b2.65, 714.2, 5.1,6.4Hz, cys3H) , 3.23-3.65 (lH,m,vaM/), 3.63-3.73 
(lH,m, val2H) , 3.66 (2H, s , SC//2 Ph) , 4.48-4.54 (1H, m, cys2H) , 5.10 (2H,
AB,<S A 5.12, <S_5.07, 712.3Hz, 0C//2Ph) , 5.13 (2H, AB , 6 A 5.16,6 n5.10, 712 . 2Hz ,A d A d
0C//2 Ph) , 5.41 (1H, d, 78. 5Hz , cySUH) and 7.21-7.38 (15H,m,Ar H) ; utCCl^)
3430 (N-H), 2955 (C-H), 1735 (C=0), 1495 and 693cm-1 I m/z (El) 393
(52%), 304 (61%), 260 (72%), 205 (85%), 108 (89%) and 91 (100%).
Attempted Synthesis of /V-Benzyloxy—D—Valine Benzyl Ester
/V-hydroxy—D—valine benzyl ester hydrochloride salt (lOOmg,
0.39mmol), benzyl bromide (50.5pl, 0.42mmol) and Ag20 (98mg, 0.42 
mmol) were added to DMF (0.6ml) and stirred at room temperature for 
3 days. The mixture was filtered, evaporated and the residue dis­
solved in EtOAc (10ml). The EtOAc solution was washed with sat. aq. 
NaHC03 (2x5ml), sat. aq. NaCl (5ml) and dried over MgSO,,. Evapora­
tion left a clear oil which was chromatographed on silica (lOg), 
with a benzene-benzene:EtOAc (8:2) gradient as eluant, to yield 
unreacted /V-hydroxy—D—valine benzyl ester (24mg, 28% recovery) and 
/V-benzyl—/V-hydroxy—D—valine benzyl ester (34mg, 39% based on recov­
ered /V-hydroxy—D—valine benzyl ester), 6 (60MHz,CDCl ) 0.91 (3H,d,H J
77.0Hz,valAH), 1.04 (3H,d,77.0Hz,valAH), 1.95-2.52 (1H,m ,va/3H),
3.15 (lH,d,79.0Hz, val2H) , 3.87 (2H,s , NC/7, Ph) , 5.15 (2H,s ,OCtf Ph) ,
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5.30-5.52 (lH,s,0//) and 7.18-7.28 (10H, m , Ar//) ; u(CCl„) 3580 (0-H) ,
2965 (C-H), 1740 (C=0) and 695cm-1; m/z (El) 313 (41%) (M), 270 
(28%), 222 (44%), 178 (99%), 162 (99%) and 91 (100%).
/V-Chloroacetoxy—D—'Valine Benzyl Ester
/V-hydroxy-D—'valine benzyl ester hydrochloride salt (50mg, 0.19
mmol) and pyridine (32.7ul, 0.40mmol) were dissolved in CH2C12(1.9ml)
450and 4-nitrophenychloroacetate (44mg, 0.20mmol) added. The
solution was stirred at room temperature for 24h, washed with lM-aq.
HC1 (2ml), H 20 (2ml), sat. aq. NaCl (2ml) and dried over MgS0„. 
Evaporation left an orange oil which was purified by preparative 
t.l.c. on silica with CH2Cl2:MeOH (19:1) as eluant to afford AA-chloro- 
acetoxy—D—valine benzyl ester (36mg, 62%).
Alternatively, /V-hydroxy-D—valine benzyl ester (98mg, 0.44mmol), 
chloroacetic acid (38mg, 0.40mmol), 1—hydroxybenzotriazole (59mg,
0.44mmol) and dicyclohexylcarbodiimide (91mg, 0.44mmol) were dis­
solved in CH3CN (4ml) and the solution stirred overnight and filter­
ed. The filtrate was evaporated to an oil which was taken up in 
EtOAc (10ml), washed with lM-aq. HC1 (5ml), H20 (5ml), sat. aq.
NaCl (5ml) and dried over MgS0„. Evaporation and column chroma­
tography of the residue, on silica (lOg) with EtOAc:n-hexane (4:6) 
as eluant afforded /V-chloroacetoxy -D-valine benzyl ester as an oil 
(112mg, 93%), FeCl3-negative; 6^ (60MHz,CDC13) 0.98 (6H,d ,J 7 .0Hz, 
va/4,4'H), 1.73-2.27 (1H,m,va/3H), 3.58 (1H,d,/6.0Hz,va/2H), 3.47 
(2H,s,ClC//2 ), 5.08 (2H,s, 0C//2Ph), 7.15-7.48 (lH.m.Ntf), 7.20 (5H,s,
Ar//); u(CClJ 3230 (N-H), 2960 (C-H), 1765 (C=0), 1740 (C=0) and 
695cm-1.
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A/-[ /V-Benzyloxycarbony 1—5-Benzyl—L—Cysteinyl ]-A/-Hydroxy—D—Valine
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Benzyl Ester
/V-benzyloxycarbonyl— 5-benzyl—L—cysteine (276mg, 0.80mmol) and
/V-hydroxy—D—valine benzyl ester (196mg, 0.88mmol) were dissolved in
DMF (10ml). Dicyclohexylcarbodiimide (182mg, 0.88mmol) was added
and the solution stirred at room temperature for 24h. The dicyclo-
hexylurea precipitate was filtered, the filtrate added to 50% sat.
aq. NaCl (10ml) and the mixture extracted with EtOAc (3x15ml). The
EtOAc extracts were dried over MgSOi, and evaporated to a yellow oil
which was chromatographed on silica (30g) with a n-hexane—n-hexane:
EtOAc (4:6) gradient as eluant. Initial fractions afforded, as a
clear foam, /V-[/V-benzyloxycarbonyl—5-benzyl—L—cysteinyl]—/V,/V'—dicy-
clohexylurea (147mg, 33%), FeCl3-negative ; <5 (60MHz, CDC13 ) 1.03-H
1.95 (22H,m,c y c lo h e x y lU ), 2.68 (2H,AB of ABX pattern,cys3H), 3.60 
(2H, s , SCH2 Ph) , 3.93-4.17 (1H, m, cys2H) , 4.49 (1H, d,76. 5Hz ,N//) , 4.95 
( 2H, AB , 6^5 .07, 604.84 ,712. 0Hz ,0CH2 Ph) , 5.76 (1H, d, 76. 5 H z, N//) and 
7.12-7.16 (10H,m,Ar//) ; utCClJ 3430 (N-H), 3300 (N-H), 2930 (C-H), 
2855 (C-H), 1710 (C=0), 1663 (C=0), 1495, 1217 and 695cm-1; m/z 
(El) 551 (<1%) (M), 426 (5%), 335 (12%), 291 (10%), 184 (35%), 125 
(6%) and 91 (100%). Later fractions were FeCl3-positive. Eva­
poration afforded a colourless solid (129mg, 29%) which was crystal­
lized from Et.0Ac/n-hexane to yield /V— [/V—benzyloxycarbonyl—5~benzyl— 
L—cysteinyl]-TV—hydroxy—D—valine benzyl ester (72mg, 16%), m.p. 122- 
123°C; [a]D-39.0° (C1.0,CHC13) (Found: C.65.43; H,6.15; N.5.04.
^3i)H3iiN2 requires C.65.43; H,6.22; N,5.09%); FeCl3-positive;
6 ( 300MHz ,CDC13 ) 0.96 ( 3H,d,76.8Hz , valAW) , 0.97 (3H, d,76.8Hz ,va/4H),
2.34-2.46 (lH,m,vai3H), 2.77 (2H,AB of ABX,6A2.86,5D2.68,713.8,5.6,A D
7.3Hz,cys3H) , 3.75 (2H, s , SC//2 Ph) , 4.98 (1H, d ,77. 9Hz , v a l 2H) , 5.08 
( 2H, AB , 6 . 5.11, 6R5.04,712 . 2Hz ,0C//2Ph) , 5.11-5.19 (1H, m, cys2H) , 5.17r\ u
(2H.AB, 6 5.21, <5_5.13,712.2Hz,0C//2Ph) , 5.59 (1H, d ,78. 5Hz , N//) , 7.18-A D
7.42 (15H,m,ArH) and 7.91 (lH,s,0H)\ u(CHCl3) 3420 (N-H), 2960 
(C-H), 1717 (C=0), 1670 (C=0), 1495 and 692cm-1; m/z (El) 550 (29%)
(M), 489 (2%), 459 (2%), 276 (28%), 254 (38%), 137 (23%) and 91 
(100%).
Attempted Synthesis of /V-[/V-4-Methoxybenzyloxycarbonyl—S~Benzyl-L- 
Cysteinyl]—/V-Hydroxy—D—Valine Benzyl Ester
/V-4—methoxybenzyloxycarbonyl-S—benzyl—L—cysteine dicyclohexyl- 
amine salt (1.33g, 2.4mmol) was converted to the free acid and dis­
solved in DMF (30ml). /V-hydroxy—D—valine benzyl ester (0.54g, 2.4 
mmol) and dicyclohexylcarbodiimide (0.51g, 2.5mmol) were added and 
the solution stirred at room temperature for 20h. The precipitated 
dicyclohexylurea was filtered and the filtrate evaporated to an oil 
which was filtered through silica (lOg) and subjected to column 
chromatography on silica (200g) with an EtOAc:n-hexane (3:7)—EtOAc: 
n-hexane (7:3) gradient as eluant. Initial fractions afforded 
/V-[/V~4—methoxybenzyloxycarbonyl-S-benzyl—L—cysteinyl ]—/V./Vldicyclo- 
hexylurea (0.31g, 22%) as an oil, S (200MHz,CDC13) 1.12-1.40 
(8H,m ,c y c l o h e x y l H ) , 1.59-1.95 (14H,m,c y c lo h e x y lH ), 2.72 (2H,AB of
ABX,6 2.81,6 2.64,7l3.8,5.7,8.1Hz, cys3H), 3.66 (2H, s , SC//2Ph) , 3.79 A B
(3H,s,C//30 ), 4.08-4.21 (lH,m,NH) , 4.54-4.59 (1H,m ,cys2H), 5.00 (2H,
AB,6.5.07, 6 4. 94, 7ll .8Hz , 0C//2Ar) , 5.47 (1H, d, 76 . 3Hz , N//) , 6.87 (2H,A B
d, 78. 7Hz , Ar//) and 7.14-7.34 (7H,m,Ar //) ; m/z (El) 416 (<1%) (M-165),
365 (<1%), 291 (12%), 125 (11%), 121 (100%), 91 (48%) and 82 (47%).
Later fractions were FeCl3-positive and were evaporated to leave a 
colourless solid (0.29g, 21%) which was crystallized from EtOAc/ 
n-hexane to yield a mixture of /V-4-methoxybenzyloxycarbonyl— S- 
benzyl—L—cysteinyl—D—valine benzyl ester and N—[N—/\—methoxybenzyoxy-
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carbony1-5-benzyl—L-cysteinyl]-/V-hydroxy-D—valine benzyl ester 
(O.llg, 8%).
Attempted Synthesis of I\h [¿V-4-Methoxybenzyloxycarbonyl— 5~Benzyl-L- 
Cysteinyl]-/V-Benzyloxy—D—Valine Benzyl Ester
The mixture of N—4—methoxybenzyloxycarbony1—5-benzyl—L—cysteinyl 
-D—valine benzyl ester and N~[N~4—methoxybenzyloxycarbony1—5—benzyl— 
L—cysteinyl]-/V-hydroxy—D—valine benzyl ester (166mg) was dissolved 
in distilled DMF (16.6ml). Benzyl bromide (272pl, 2.3mmol) and 
Ag20 (265mg, l.lmmol) were added and the mixture shaken, under an 
argon atmosphere, at room temperature and in the dark for 2h. The 
mixture was filtered, evaporated and filtered through silica (2g). 
Evaporation of the filtrate to a yellow oil and column chromatography 
on silica (lOg) with EtOAc:n-hexane (2:8) as eluant afforded a mix­
ture of products. The mixture was separated and purified by column 
chromatography on silica (lOg) with toluene:n-hexane (1:9) as eluant 
to yield O-benzyl—2—oxoisovaleric acid oxime benzyl ester (6mg),
FeCl3-negative; 6H (200MHz,CDC13 ) 1.17 (6H,d,/7.OHz,va/4,4'H),
3.42 (1H,sept.,/7.0Hz,va/3H), 5.23 (2H, s ,0C//2 Ph) , 5.27 (2H, s ,00/7, Ph) 
and 7.29-7.40 (10H,m,ArH ) ; u(CC1„ ) 3035 (C-H), 2965 (C-H), 1732 
(C=0), 1605 and 695cm_1 ! m/z (El) 311 (4%) (M), 294 (8%), 181 (48%) 
and 91 (100%), and A/-benzyl-A/-hydroxy-D—valine benzyl ester (39mg), 
FeClj-negative; <5 (200MHz,CDCl ) 0.95 (3H, d,76.7Hz , vai4H) , 1.09 
(3H,d,/6.7Hz,vai4H), 2.28 (1H,dsept.,/6.7,8.9Hz,vai3H), 3.21 (1H,
d,/8.9Hz,i/ai2H) , 3.95 (2H,AB,6 4.00,6D3.89,/13.4Hz,NQ¥2Ph) , 5.25A D
(2H,AB,<5 5. 29,65.21,712.2Hz , 0C/72 Ph) , 5.58 (lH,s,Qtf) and 7.27-7.45 A D
(10H,m,AiT/); m/z (El) 313 (4%) (M), 270 (30%), 222 (4%), 178 (15%) 
and 91 (100%).
/V-[ A/-4—Me thoxybenzyloxy carbonyl—g-Benzyl—L—Cysteinyl] -A/—Benzyloxy-D- 
Valine Benzyl Ester
The mixture of A/—4—methoxybenzyloxycarbony1—S—benzyl—L—cysteinyl 
-D—valine benzyl ester and /V— [N—4—methoxybenzyloxycarbony1—S~benzyl—
L—cysteinyl]-A/—hydroxy—D—valine benzyl ester (150mg) was dissolved 
in non-distilled DMF (15ml) and benzyl bromide (153.6pl, 1.3mmol) 
and Ag20 (150mg, 0.65mmol) added. The mixture was shaken at room 
temperature, in the dark and under an argon atmosphere for 5h.
The mixture was filtered, the filtrate added to H 20 (15ml) and the 
aqueous layer extracted with EtOAc (4x30ml). The organic extracts 
were dried over MgSO^ and evaporated to a clear oil which was chroma­
tographed on silica (8g) with toluene:EtOAc (9:1) as eluant to afford 
N~[N—4—methoxybenzyloxycarbonyl—S—benzyl—L—cysteinyl ]-N —benzyloxy—D— 
valine benzvl ester (118mg, 68%), FeCl3-negative; (200MHz,CDC13)
0.92 (3H,d,/6.6Hz,va/4H), 0.98 (3H,d,76.7Hz,v a l4 H ), 2.51 (lH,m,v a l  
3H) , 2.61 (2H,AB of ABX,6A2.71,6?.51,713.9,4.9,8.8Hz, cys3H), 3.50A D
(2H,AB, 6 3.57, 5_3.43,713.lHz,SC//2Ph) , 3.79 (3H, s , C//30 ) , 4.70 (lH,d,A D
79.9Hz,v a l2H), 4.98 (2H,AB,6 5.07,64.89,79.4Hz,0C//2Ar), 5.10 (2H,A D
AB pattern,0C//2Ar), 5.16-5.23 (1H, m, cys2H) , 5.20 (2H, s,0C//2 Ar) , 5.56 
(1H,d,79.3Hz,NT/) , 6.88 (2H, d ,78. 6Hz, Ar//) and 7.02-7.50 (17H, m , Ar//) ;
6 (75MHz,CDC13) 19.49 { q , v a l A C ) , 19.72 (q,va/4C), 27.93 (d,va/3C),
33.63, 35.90 (t,t,cys3C and SCH2Ph), 50.59 (d,cys2C), 55.04 (q,CH30), 
65.74 (d,va/2C), 66.66 (t,0CH2Ar), 66.91 (t,0CH2Ar), 79.36 (t,
N0CH2Ph), 113.79, 126.74, 128.18, 128.24, 128.39, 128.57, 128.76,
128.96, 129.24, 129.52, 129.65, 133.77, 135.10, 137.44 (24xArC) ,
155.99, 170.09, 172.23 (3xC=0).
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N— [/V-4—Methoxybenzyloxycarbonyl— 5-Benzyl—L—Cysteinyl] — /V-Hydroxy-p—
Valine Benzyl Ester
N- 4 —methoxybenzyloxycarbonyl—5-benzyl—L—cysteine dicyclohexyl- 
amine salt (1.39g, 2.5mmol) was converted to the free acid, and 
dissolved in DMF (25ml). Dicyclohexylcarbodiimide (0.52g, 2.5mmol) 
was added and the solution stirred at room temperature for 5min. 
/V-hydroxy—D—valine benzyl ester hydrochloride salt (0.68g, 2.6mmol) 
and pyridine (0.20ml, 2.5mmol) were added and the solution stirped 
for 2h, reduced in volume to ca 15ml and stirred overnight. The 
precipitated dicyclohexylurea was filtered and the filtrate eva­
porated to a yellow oil which was taken up in EtOAc (30ml). The 
EtOAc solution was washed with lM-aq. HC1 (20ml), sat. aq. NaHC03 
(20ml), sat. aq. NaCl (20ml) and dried over MgSO,̂  . Evaporation 
left an oil which was filtered through silica (8g) and partially 
purified by chromatography on silica (30g) with EtOAc:n-hexane 
(5:5) as eluant. Initial fractions afforded N—[ /V-4—methoxybenzyl- 
oxycarbonyl-5-benzyl-L-cysteinyl] -/V,/V'— dicyclohexylurea (0. 32g, 22%) 
as an oil. The later FeCl3-positive fractions were combined, eva­
porated and chromatographed on silica (25g) with EtOAc:n-hexane:HOAc 
(37.5:60:2.5) as eluant to yield /V-[ ¿V-4-methoxybenzyloxycarbony1-5- 
benzyl— L—cysteinyl]-A/—hydroxy—D—valine benzyl ester (0.29g, 20%), 
m.p. 124-126°C (Found: 0,64.24; H,6.15; N,4.68. C3 1 H36N2 07 S
requires 0,64.12; H,6.25; N,4.82%); FeCl3-positive; 6H (200MHz,
CDC13 ) 0.96 (3H,d,J6.8Hz,va/4H), 0.98 (3H,d,/6.7Hz,vai4H), 2.31- 
2.48 (lH,m,va/3H) , 2.77 (2H,AB of ABX.6 ft2 .85, <502. 68 ,/13 .8, 4 .1, 7 . 1Hz , 
cys3H) , 3.75 (2H,s ,SCtf2Ph) , 3.78 (3H,s,Q530) , 5.02 (1H, d ,/10. 1Hz, 
va/2H), 5.11 (2H,AB, 6,5.22, <5_4.99,/12. 4Hz , 0C//2 Ar) , 5.08-5.19 (1H,A D
m,cys2H) , 5.16 (2H,s,0C//2Ar) , 5.50 (1H, d ,/8. 4Hz, W )  , 6.86 (2H,d,
/8.6Hz, ArH) , 7.20-7.35 (12H,m,Ant/) and 7.77 (lH,s,(W)> 5 (75MHz,
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CDC13) 19.18 (q,va/4C), 19.31 (q,va/4C), 28.82 (d, l/a/3C), 33.29,
36.33 ( t , t , c y s 3 C  and SCH2Ph), 50.14 (d,cys2C), 55.04 (q,CH30), 62.86 
(d,va/2C), 66.77 (t,0CH2Ar), 67.03 (t,0CH2Ar), 113.75, 126.88,127.01, 
128.13, 128.30, 128.42, 128.85, 129.70, 134.91, 137.67 (18xArC),
156.31, 159.40 and 170.84 (3xC=0); m/z (El) 580.2226 (<1%) (M, 
C 31H 36N207S requires 580.2243), 441 (8%), 335 (16%), 292 (16%), 263 
(15%), 121 (100%) and 91 (100%).
Attempted Synthesis of /V-[/V-Benzyloxycarbonyl—1— (4—Nitrobenzyl)—6—
(L—g—Aminoadipyl)— 5-Benzyl—L—Cysteinyl]—/V-Hydroxy—D—Valine Benzyl 
Ester
/V-benzyloxycarbonyl—1— (4—nitrobenzyl) — 6— (L—a—aminoadipyl)— 52- 
benzyl— L—cysteine (247mg, 0.40mmol) and /V-hydroxy—D—valine (98mg,
0.44mmol) were dissolved in DMF (5ml), dicyclohexylcarbodiimide 
(90mg, 0.44mmol) added and the solution stirred at room temperature 
for 24h. The dicyclohexylurea was filtered, the filtrate added to 
50% sat. aq. NaCl (5ml) and extracted with EtOAc (3x10ml). Eva­
poration left a yellow gum which was FeCl3-negative. The yellow 
gum was subjected to chromatography on silica (30g) with EtOAc:
/?-hexane (5:5) as eluant to afford /V-[/V-benzyloxycarbonyl— l-(4-nitro- 
b e n z y l ) — 6— (L-a-aminoadipyl) — 5-benzyl— L— cysteinyl ]-/V, N  -dicyclohexy­
lurea as the only isolable product (90mg, 27%), F e C l 3- n e g a t i v e ; 5^
[60MHz,CDC13:CD30D (1:1)] 0.82-2.22 (28H,m ,a m i n o a d i p y l ^,4,5H and 
cyclo h e x y lH), 2.62-2.80 (2H,m, cyS3H) , 3.65 (2H,s,SC//2Ph) , 4.00-4.50 
( 3H, m, cys 2H , a m i n o a d i p y  /2H and N H) , 5.03 (2H, s ,0C//2Ar) , 5.17 (2H,s, 
0C//2Ar) , 6.43 (1H, d, JQ. 0Hz , NH) , 7.17-7.43 (12H,m,Ar H) and 8.22 (2H, 
d,/8.0Hz, Ar//) ; m/z (El) 722 (<1%), 550 (<1%), 390 (1%), 279 (69%),
225 (14%), 224 (20%) and 91 (100%).
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Attempted Synthesis of ¿V~[/V~Benzyloxycarbonyl—1— (4—Nitrobenzyl)— 6 —
(L—«—Aminoadipyl)~S—Benzyl—L—Cysteinyl]-N — Hydroxy—D—Valine Benzyl 
Ester
Crude A/—[/V-benzyloxycarbonyl—S—benzyl—L—cysteinyl] -/V— hydroxy— 
D—valine benzyl ester (1.52g, 2.8mmol) was dissolved in trifluoro- 
acetic acid (20ml), refluxed for 40min and evaporated to a brown 
oil.
/V-benzyloxycarbonyl-L-a-aminoadipic acid 1— (4-nitrobenzyl) 
ester (1.31g, 3.0mmol), triethylamine (0.46ml, 3.3mmol) and ethyl— 
chloroformate (2.64ml, 27.6mmol) were dissolved in dry benzene 
(30ml). The solution was stirred at room temperature for lh, 
filtered and evaporated to a clear oil which was dissolved in 
CH2Cl2(40ml). The crude material from the trifluoroacetic acid 
deprotection and triethylamine (1.92ml, 13.8mmol) were added to the 
CH2CI2solution, and the mixture stirred at room temperature for 3%h 
to leave a golden yellow solution. The CH2C12 was removed in  
v a cu o , the residue dissolved in EtOAc (50ml), washed with lM-aq.
HC1 (30ml), H20 (30ml), sat. aq. NaHC03 (30ml), sat. aq. NaCl 
(30ml), and dried over MgSO,, . Evaporation left an orange oil 
which was chromatographed on silica (200g) with EtOAc: n-hexane 
(5:5) as eluant to afford a crude product. The crude material 
was further purified by column chromatography on silica (30g) with 
a benzene:Et0Ac (9:1)-benzene:EtOAc (6:4) gradient as eluant to 
yield an almost 50:50 mixture of two compounds. A small quantity 
of the mixture was separated by h.p.l.c., using a Waters y-Bondapak 
C18 analytical column and Me0H:H20 (72:28) as eluant, to yield 
/V~benzyloxycarbonyl—1—(4—nitrobenzyl)—6— (L—a—aminoadipyl)—S-benzyl 
—L—cysteinyl—D—valine benzyl ester, FeCl3-negative; 6 (200MHz,CDC13)
0.82 (3H,d,/6.9Hz,vai4H), 0.88 (3H,d,/6.8Hz,va l4H), 1.67-1.95
(4H, m , am m oa .d ipyl3, 4H) , 2.12-2.25 (3H, m, a m in o a d ip y l'^ and \/a/3H),
2.75 (2H,AB of ABX,62.84,S 2.66,/13.9,5.6,7.4Hz,cys3H), 3.76 (2H,s,A B
SC//2Ph), 4.39-4.55 (3H,m, a m in o a d ip y l, c y s and v a l 2H), 5.10 (2H,s,
0C//2Ph) , 5.11 (2H,AB,6.5.16,6D5.06,/12.2Hz,0C//,Ph), 5.23 (2H,s,A d  i
0C//2Ph) , 5.61 (1H,d,/8.2Hz,Ni/) , 6.23 (1H, d,/7 . 3Hz , N//) , 6.72 (lH,d, 
/8.7Hz, rtf/), 7.27-7.37 (15H, m, Ar//) , 7.47 (2H, d, /8. 6Hz , Ar//) and 8.18 
(2H,d,/8.6Hz,ArH) and N— [/V-benzyloxycarbonyl—1— (4-nitrobenzyl)—6—
(L-a-aminoadipyl)— S-benzyl-L-cysteinyl]-N —hydroxy—D-valine benzyl 
ester, FeCl3-positive; 6^ (200MHz,CDC13) 0.97 (6H,d,/6.5Hz,va/ 
4,4'H), 1.67-1.87 (4H,m,a m in o a d ip y l3,4H), 2.15-2.17 (2H ,m ,am ino­
a d ip y l  5U) , 2.41 (lH.dsept.,/7.8,6.6Hz,va/3H), 2.76 (2H,AB of ABX, 
6A2.86,<5B2.67,/l3.8,5.8,7.7Hz,cys3H) , 3.72 (2H, s , SC//2 Ph) , 4.38 (1H, 
m ,am in oa d ip y  12H) , 4.92 (1H, d,/7.8Hz , va/2H) , 5.05-5.31 (7H,m,3xOC//2 Ar 
and cys2H) , 5.54 (1H,d,/7.9Hz ,N//) , 6.21 (1H, d ,/7. 7Hz , N//) , 7.18-7.39 
(15H,m,Ar//) , 7.46 (2H, d,/8. 5Hz , An¥) , 8.20 (2H, d,/8 . 5Hz , Ar//) and 8.34 
(1H,s,OH) ; m/z (El) 369 (12%), 355 (11%), 263 (95%), 160 (40%), 114 
(63%) and 91 (100%).
N—[ /V—Benzyloxycarbonyl—1— (4—Nitrobenzyl)—6 — (L-g —Aminoadipyl)—5— 
Benzyl—L-CysteinylJ-A/-Benzyloxy-D—Valine Benzyl Ester
The mixture of /V—benzyloxycarbonyl—1— (4—nitrobenzyl)—6— (L-a — 
aminoadipyl)—S—benzyl—L—cysteinyl—D—valine benzyl ester and /V—[/V— 
benzyloxycarbonyl—1— (4—nitrobenzyl)—6 — (L-a —aminoadipyl)—S—benzy1— 
L-cysteinyl]-A/—hydroxy-D—valine benzyl ester (140mg) was dissolved 
in non-distilled DMF (14ml). Benzyl bromide (120.7pl, l.Ommol) 
and Ag20 (118mg, 0.51mmol) were added and the solution shaken at 
room temperature, in the dark, for 5h under an argon atmosphere.
The solution was filtered through celite, evaporated and chromato­
graphed on silica (25g) with an EtOAc :n-hexane (4:6)—EtOAc:n-hexane
(7:3) gradient as eluant to afford N—[ /V-benzyloxycarbony1— 1— (4— nitro­
benzyl )— <5-( L-a -aminoadipyl )-S-benzyl— L— cysteinyl] -/V-benzyloxy-D—  
valine benzyl ester (69mg) as an oil, [“ 1^— 9.8° (c3.0, acetone);
FeCl3-negative; <$„ (200MHz,CDC13) 0.91 (3H,d,/6.6Hz,va/4H), 0.97H
(3H,d,/6.7Hz,vai4H), 1.68-1.94 {AH,m, a m in oa d ip y l3 ,A H ), 2.21-2.27
(2H,m,a/??inoad2py/5H) , 2.41-2.75 (3H,m,cys3H and v a l3H) , 3.44 (2H,
AB, <5 ̂ 3.51,<5 ̂ 3.37,713. 2Hz , S CHZ Ph) , 4.41-4.43 (1H, m ,am inoadipyl2H ) ,
4.66 (lH,d,/9.8Hz,va/2H) , 5.06 (2H,AB,6 5.22,6 4.92,J 9 .3Hz,0C//2 Ar),
A B
5.10 (2H,AB pattern,0C//2 Ar) , 5.17 (2H, s ,0C//2 Ar) , 5.18 (2H, s ,0C//2 Ar) ,
5.36-5.41 (lH,m,cys2H), 5.71 (1H,d ,JQ.0Hz,W ), 6.38 (1H,d ,JQ.9Hz,
Nd), 6.98-7.16 (5H,m,ArH ) , 7.26-7.51 (17H,m,Ar//) and 8.15 (2H,d,
/8.6Hz,And); 6C (75MHz,CDC13) 19.56 { v a l A C ) , 19.79 { v a l A C ) , 21.32 
{a m in o a d ip y l4C), 28.09, 31.37, 33.73, 35.23, 36.10 (v a l3C,cys3C, 
a m in oa d ip y l 3C and 5C and SCH2Ph), 48.62 (crys2C), 53.95 {a m in oa d ip yl  
2C), 65.33 (0CH2Ar), 66.23 {v a l2 C ), 66.95, 79.38 (3xOCH2Ar), 123.63, 
126.81, 127.85, 127.97, 128.23, 128.33, 128.41, 128.56, 128.73,
128.92, 129.41 (24xArC), 133.90, 135.17, 136.23, 137.51, 142.42,
147.83 (6xArC), 155.89, 169.86, 171.74, 171.87 and 172.39 (5xC=0).




loxy—D—valine benzyl ester (120mg, 0.18mmol) was dissolved in HC1 
sat.—MeN02 (6ml) and stirred at room temperature for 5min. Eva­
poration afforded an oil which was subjected to column chromato­
graphy on silica (8g) with EtOAc:n-hexane:H0Ac (7:2:1) as eluant.
The ninhydrin-positive fractions were combined, washed with sat. aq. 
NaHC03 (30ml), H20 (30ml), sat. aq. NaCl (30ml) and dried over Na2S0,,. 
Evaporation yielded /V- [S-benzyl-L-cysteinyl] -/V-benzyloxy —D—valine
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benzyl ester (75mg, 83%), m.p. 128-130°C; (200MHz,CDC13) 0.97H
(3H,d,/7.0Hz,va/4H), 0.99 (3H,d,J 7.0Hz,v a l A H ), 2.36-2.44 (3H,m,vai
3H and -NHz ) , 2.94 (2H,AB of ABX,6 3.21,6 2.69,714.1,3.2,8.7Hz,cysA B
3H) , 3.75 (2H,s,SC//2Ph) , 3.82 (1H, dd, 78.7,3. 2Hz , cys2H) , 3.85br (1H,
d,va/2H), 4.67 (2H,s,0C//2Ph) , 4.92 (2H, AB , 6 „4 .97, 6D4 .86, 7l0. 5Hz ,A B
0C//2Ph) and 7.18-7.40 (15H,m,ArH ) .
The A/—[ S-benzyl—L—cysteinyl]-A/-benzyloxy—D—valine benzyl ester 
(75mg, 0.15mmol) was dissolved in EtOAc (10ml). //-benzyloxycarbonyl 
—L-a—aminoadipic acid 1— (4—nitrobenzyl) ester (69mg, 0.16mmol), 1— 
hydroxybenzotriazole (21mg, 0.16mmol) and dicyclohexylcarbodiimide 
(32mg, 0.16mmol) were added and the solution stirred at room tempera­
ture overnight. Oxalic acid dihydrate (1.5mg) was added, the sol­
ution stirred a further lh and filtered. The filtrate was washed 
with lM-aq. HC1 (10ml), sat. aq. NaHC03 (10ml), sat. aq. NaCl (10ml) 
and dried over MgSO,, . Evaporation afforded a complex mixture of at 
least seven products which could not be purified.
(V-[ /V—Benzyloxycarbonyl—1— (4—Nitrobenzyl)—<5— (L—a—Aminoadipyl)— S- 
Benzyl—L—CysteinylJ-/V— Hydroxy—D—Valine Benzyl Ester
IV—[A h4—methoxybenzyloxycarbonyl—S-benzyl—L—cysteinyl]—/V-hydroxy 
—D—valine benzyl ester (295mg, 0.51mmol) was dissolved in HCl-sat.
MeN02 (15ml) and stirred at room temperature for 3min. The solu­
tion was evaporated and the residue dissolved in EtOAc (20ml).
The organic layer was washed with 5% aq. NaHC03 (20ml), sat. aq.
NaCl (20ml) and dried over MgSO,, . The EtOAc was removed in  v a c u o  
to afford crude A/—[ S—benzyl—L-cysteinyl] -A/—hydroxy—D—valine benzyl 
ester.
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A?—benzyloxycarbonyl—L-a—aminoadipic acid 1— (4—nitrobenzyl)
ester (240mg, 0.56mmol), triethylamine (81.4pl, 0.58mmol) and ethyl- 
chloroformate (487Pi, 5.1mmol) were dissolved in dry toluene (20ml) 
and stirred at room temperature for 30min. The solution was fil­
tered, evaporated and the residue dissolved in CH2C12(10ml). The 
crude /V— [5-benzyl—L—cysteinyl ]-/V—hydroxy—D—valine benzyl ester and 
N— methylmorpholine (58.7pl, 0.53mmol) were added to the CH2C1solu­
tion and the mixture stirred at room temperature for 3}jh. The 
solution was washed with lM-aq. HC1 (15ml), sat. aq. NaHCO3 (15ml), 
sat. aq. NaCl (15ml) and dried over MgSO,,. Evaporation afforded 
a crude solid which was chromatographed on silica (25g) with EtOAc: 
n-hexane (5:5) as eluant. The FeCl3-positive fractions were com­
bined, evaporated and further purified by column chromatography on 
silica (25g) with EtOAc:n-hexane (6:4) as eluant to yield crude 
/V— [/V—benzyloxycarbonyl—1— (4—nitrobenzyl)— 6— (L—a—aminoadipyl)— 5— 
benzyl—L—cysteinyl]-/V—hydroxy—D—valine benzyl ester (159mg, 38%) 
which was crystallized from CHCl3/ether (120mg, 29%), m.p. 151-154°C 
[a] -15.3° (cl.O, CH2C12) (Found: 0,62.28; H,5.94; N.6.72.
C„3H,8N„0,,S requires 0,62.31; H,5.84; N,6.76%); 6U (200MHz,
CDC13) 0.97 (6H,d,/6.8Hz, v a U , 4' H) , 1.66-1.90 (4H,m, a m in oa d ip y l  
3,4H), 2.15-2.21 (2H,m , a m in o a d ip y l5H), 2.41 (1H,dsept.,J 7 .8,6.8Hz, 
va/3H) , 2.76 (2H,AB of ABX, <5 ̂ 2.86,6Q2. 67,713.8,5.7,7.7Hz , cys3H) ,
3.71 (2H,s,SC//2Ph), 4.35-4.44 (1H,m ,a m in o a d ip y l2H), 4.92 (lH,d,
J 7 . 8Hz , val 2H) , 5.03-5.31 (7H, m, 3x0CHz Ar and cys2H), 5.55 (lH,d,
J7 . 8Hz , N//) , 6.20 (lH,d,/7.5Hz,N//) , 7.20-7.36 (15H, m, Ar//) , 7.46 (2H, 
d,/8. 6Hz ,krH) , 8.18 (2H, d ,/8. 6Hz , Ar/Z) and 8.38 (1H, s ,NQtf) ; 6C 
(75MHz,CDC13) 19.27 (q,va/4C), 19.31 (q,va/4C), 21.33 (t, a m in oa d ip y l  
40), 28.68 (d,va/3C), 31.13 (t,a m in oa d ip y l4 C ), 32.74 (t,cys3C), 
34.91, 36.23 (t , t ,a m in o a d ip y l5 C  and SCH2Ph), 48.22 (d,cys2C), 53.75
(d, aminoadipylzc) , 63.10 (d,va/2C), 65.35, 66.97 (t,t,3xOCH2Ar),
123.64, 127.01, 127.90, 128.06, 128.15, 128.30, 128.39, 128.83 
(19xArC), 134.98, 136.09, 137.60, 142.43, 147.64 (5 x A r C ) , 156.06,
170.35, 170.55, 171.84 and 172.93 (5xC=0); m/z (El) 507 (<1%), 263 
(4%), 214 (6%) and 91 (100%); m/z (FAB) 867 (54%) (M+K), 829 (100%) 
(M+H), 813 (55%) and 696 (62%).
Attempted Synthesis of /V~[5— (L—a—Aminoadipyl)—L—Cysteinyl]—/V-Hydroxy 
—D—Valine
/V-[ /V-benzyloxycarbonyl—1—■( 4—nitrobenzyl)—6— (L-a—aminoadipyl ) - S -  
benzyl—L—cysteinyl]—/V-benzyloxy—D—valine benzyl ester (64mg, 0.07 
mmol) was dissolved in refluxing liquid ammonia (5ml) under a N2 
atmosphere. Small pieces of sodium metal were added until the blue 
colour persisted for 5min. Ammonium acetate (ca50mg) was added and 
the ammonia blown off in a stream of dry N2. The residue was dess- 
icated over H2S0,, for 2h and dissolved in 5% aq. HOAc (5ml). The 
aqueous solution was filtered, washed with ether (5ml) and adjusted 
to pH8.5 with lM-aq. NH3. Oxygen gas was bubbled through the solu­
tion for 2h. The solution was freeze dried and the residue applied 
to an ion exchange column (15xlcm) with a H20-2M-aq. pyridine gradi­
ent as eluant. The ninhydrin-positive fractions were combined and 
lyopholized to afford a mixture of two products which were separated 
by preparative scale electrophoresis at pH6.5 to yield /V— [6— (a—amino­
adipyl) cysteinyl]-/V—hydroxy valine (5mg, 19%), FeCl3-positive; m/z 
(FAB) 378.1327 (M-H,Cu H2,N30,S requires 378.1329) and 360.1226 
(M-H-HjO.C! ,,H2 2N306 S requires 360.1224) and its disulphide (6mg,
23%), FeCl3-positive; m/z (FAB) 755 (M-H), 378.
/V— [ 6 — (L-ct-Aminoadipyl)—L—Cysteinyl]~/V— Hydroxy—D—Valine
/V— [N— benzyloxycarbonyl-1— (4—nitrobenzyl)—<5— (L-a-aminoadipyl) —
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S~benzyl—L—cysteinyl]-/V-hydroxy-D—valine benzyl ester (60mg, 0.07 
mmol) was dissolved in refluxing liquid ammonia (20ml) under a N2 
atmosphere. Small pieces of sodium metal were added till the blue 
colour persisted for 3 min. Solid NHlt0Ac (calOOmg) was added to 
leave a clear solution which was evaporated in a stream of dry N2 
gas. The residue obtained was dissolved in 10% aq. HOAc (5ml) 
washed with ether(5ml) and lyopholized. The residue was purified 
by ion exchange chromatography (18xlcm column) with a H20-lM-aq. 
pyridine gradient as eluant to afford /V-[ 6— (L-ct—aminoadipyl)— L— 
cysteinyl]-iV-hydroxy-D—valine (26mg, 95%), m.p. 157-160°C (decomp.); 
M d-30.8° (CO.5, H20) ; [a] 5 „ e-33.6° (C0.5, H20) (Found: 0,44.18;
H ,6.70; N, 10.96. C11(H25N3 07 S requires 0,44.32; H,6.64; N,11.07%);
FeCl3-positive; 6 (200MHz, D20) 1.03 (3H,d,/6.8Hz,va/4H), 1.08 (3H,
d,/6.8Hz,va/4H), 1.68-2.02 (4H,m,a m in o a d ip y l3 , 4H), 2.34-2.50 (3H,m, 
am inoadipylSH and va/3H), 3.01 (2H,AB of ABX,6A3.09,6g2.93,/l4.0,
5.3,7.4Hz,cys3H), 3.82-3.87 (1H,m,a m in o a d ip y l2H), 4.66 (1H,d,J 8 .8Hz, 
val 2W) and 5.22 (1H,X of ABX,/5.2,7.3Hz,cys2H); <5 c (75MHz,D20,pH3)
19.57 (q,i/a/4C), 19.65 (q,va/4C), 21.73 (t,a m in oa d ip y l40) , 25.55 
(t,cys3C), 28.61 (d,vai3C), 30.55 (t,a w in o a d ip y l3 C ), 35.54 (t ,a m in o ­
a d ip y l  SC) , 53.13 {& ,a m in oa d ip y l2 C), 55.15 (d,cys2C), 66.62 (d,va/2C), 
174.94, 175.80 and 176.50 (3xC=0); m/z (FAB) 795 (35%) (M+K) and 
757 (100%) (M+H).
6.5 /V-BENZYLOXYCARBONYL—L—a—AMINOADIPIC ACID 1-BENZYL ESTER
CL
[\J —Benzyloxycarbonyl—L—Lysine Benzyl Ester 4—Toluenesulphonic Acid 
Salt
ci SI S/V —benzyloxycarbonyl—L—lysine ~ (23.83g, 85.0mmol) and 4—
toluenesulphonic acid monohydrate (16.98g, 89.3mmol) were dissolved
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in a mixture of dry benzene (90ml) and benzyl alcohol (30ml).
The solution was fitted with a Dean-Stark trap and refluxed under 
an Ar atmosphere for 18h. The solution was filtered, evaporated 
and the residue crystallized from EtOH/ether/n-hexane to afford
A/01—benzyloxycarbonyl-L-lysine benzyl ester 4—toluenesulphonic acid
542 543salt (43.95g, 92%) m.p. 111-113°C (lit. ,m.p. 113-115°C; lit.
m.p. 111-112°C); [a]D-17.9° (c2.0,Me0H) (Found: 0,61.77; H.6.11;
N, 5.39. C28H3l(N207S requires 0,61.97; H,6.32; N,5.16%);
(360MHz,CDC13) 1.16-1.25 (2H,m, /ys4H), 1.41-1.63 (4H,m,l y s 3 ,5H),
2.26 (3H,s, CH3), 2. 69br (2H,m,/ys6H), 4.24 (1H,m,/ys2H), 5.02 (2H,
AB,6A5.06,6B4.99,7l2.1Hz,0(y/2Ph) , 5.08 ( 2H, s , 0C//2Ph) , 5.68 (lH,d,
78.0Hz,N//) , 7.06 (2H,d,78.0Hz,Ar//), 7.25-7.28 (10H,m,Ar//) , 7.61 (3H,
s,-iW3) and 7.70 (2H, d,78.0Hz, Ar//) ; m/z (El) 370 (16%) (M.free base),
279 (<1%), 235 (1%), 206 (2%), 128 (18%) and 91 (100%).
A/—Benzyloxycarbonyl—L—a—Aminoadipic Acid 1—Benzyl Ester
AT-benzyloxycarbonyl-L-lysine benzyl ester 4—toluenesulphonic 
acid salt (1.68g, 3.0mmol) was converted to the free base and dis­
solved in t-Bu0H:H20 (2:1) (30ml). Potassium permanganate (0.63g, 
4.0mmol) and CaSO,, (2.45g, 18.0mmol) were added, the pH of the solu­
tion adjusted to 7 and the mixture heated to 60°C under an Ar atmos­
phere for 40min. A few drops of sat. aq. Na2S205 were added, the 
mixture filtered through celite and the filtrate reduced in volume.
Sat. aq. NaCl (20ml) was added, the pH adjusted to 1 with cone. aq.
HC1 and the solution extracted with EtOAc (3x30ml). The organic
extracts were washed with lM-aq. HC1 (30ml), sat. aq. NaHC03 (2x30ml),
sat. aq. NaCl (30ml) and dried over MgS0„. The EtOAc solution was
evaporated and the residue purified by filtration through silica (5g) 
and column chromatography on silica (25g) with EtOAc:n-hexane (5:5)
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as eluant. The crude product was crystallized from EtOAc/CH2Cl2/
n-hexane to afford /V-benzyloxycarbonyl—L—a—aminoadipic acid 1-benzyl
516ester (95mg, 8%) m.p. 87-89°C (lit. ,m.p. 87-89°C); [a] -13.1°
(c2.0, acetone) [lit. , [a] —13.3°(c2.0, acetone)] (Found: C,65.24;
H,6.02; N.35.2. C21H23N06 requires 0,65.44; H.6.02; N.3.63%);
6h (200MHz, CD3COCD3) 1.72-2.02 (4H,m ,aminoadipyl3,4H), 2.35-2.39 
(2H, m ,aminoadipyl 5H) , 4.30 (1H, m, aminoadipyl 2H) , 5.09 (2H,s,0C/:/2Ph) ,
5.18 (2H, s ,0Cf/2Ph) , 6.75 (1H, d,/8. 0Hz , W ) and 7.30-7.41 (10H, m , A rtf) .
6.6 CELL FREE SYSTEM FROM CEPHAL0SP0RIUM ACREMDNIUM CW19
6.6.1 Culture and Growth Conditions
Vegatative slopes of Cephalosporium acremonium CW19 (ATCC 36225)
were washed with sterile water (5ml) and 0.2ml aliquots aseptically
544transferred to each of twenty slopes of a defined sporulation agar
The slopes were grown at 26°C for 5 days. One slope was used to
544inoculate 50ml of seed medium in a 250ml flask. The cells were
grown for 3 days on a rotary shaker at 26°C and 240 r.p.m. and ca
5442ml of seed media used to inoculate 50ml of growth media in each
of forty 250ml flasks. The flasks were shaken on a rotary shaker
at 240 r.p.m. and incubated at 26°C for up to 7 days. A growth
518curve for the organism was determined . Four parameters were 
measured; the absorbance of the culture at 600nm, the dry weight 
of the mycelium, the pH of the culture medium and the concentration 
of cephalosporin C in the culture medium. In the range 72-84h the 
absorbance and dry weight reached a maximum and the pH dropped to a 
minimum. Cephalosporin C concentration increased from 96h onwards.
230
6.6.2 Preparation of Cell-Free System
Twelve 1000ml flasks containing 250ml of growth medium were 
inoculated with ca 10ml of a 3 day-old seed culture. The flasks 
were shaken at 250 r.p.m. and at 26°C for 3 days and the mycelial 
mass collected on Whatman 54 filter paper. The cell mass was 
thoroughly washed with morpholinopropanesulphonic acid (MOPS) buffer 
(50mmol, pH7.2), resuspended in the same buffer (400ml) and ground 
in a Dyno-Mill. The 300ml Dyno-Mill cell was cooled to 0°C and 
contained 240ml of glass beads. The tip of blade speed was lOm/s 
and the cell was fitted with a 0.03mm distance piece. The cell 
mass was pumped through the Dyno-Mill cell at 200ml/min. The 
homogenate was collected at 0°C, saturated to 50% with (NH,,)2S0^ 
and centrifuged at 20,000g for 30min. An oily film was removed 
from the surface of the supernatant and the supernatant 80% satur­
ated with (NH^)2S0^. The mixture was centrifuged at 20,000g for 
30min and the supernatant discarded. The pellet was gently mixed 
with MOPS buffer (50mmol, pH7.2) (10ml), applied to a Sephadex G25 
column (100ml) and eluted with MOPS buffer (50mmol, pH7.2).
Fractions were collected and tested for the presence of SO^by 
addition of sat. aq. BaCl2 to a small aliquot of each fraction.
The UV absorbance at 280nm was measured and those fractions which 
were SOif" -negative, and displayed the largest UV absorbance, were 
combined and stored at -20°C.
Occasionally the cell-free system was concentrated using an 
Amicon Ultrafilter fitted with a PM10 (molecular weight> 10,000
a.m.u.) filter under a nitrogen pressure of 56 p.s.i.
231
6.6.3 Co-Factor Requirements
The cell-free preparation (1.00ml) and LLD-ACV (lmg/ml solution 
in MOPS (50mmol, pH7.2) buffer) (0.25ml) were added to 10ml conical 
flasks. Various quantities of DTT and FeSO^ were added to the 
flasks to achieve final concentrations of between zero and ten milli- 
molar. The flasks were incubated at 26°C and shaken on a rotary 
shaker at 250 r.p.m. Aliquots (lOOyl) were removed from the incub­
ation mixtures and bioassayed against B . s u b t i l u s . The results
indicated a requirement for DTT with the optimum concentration in 
the range 2-5mmol. The requirement for ferrous ions by this system 
could not be accurately determined and appeared to vary from batch
to batch. A final ferrous ion concentration of lmmol was normally 
352used in subsequent feeding experiments. The optimum incuba­
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For the preparation of compound X see page Y
34 206 106 211
81 227 107 212
82 208 108 213
83 209 109 215
84 192 110 214
85 190 113 216
86 195 118 222
87 202 119 203
88 206 120 196
89 205 126 223
90 209 127 227
92 193 128 227
94 198 129 191
95 208 130 220
96 208 131 225
97 208 132 197
98 205 133 199
101 211 135 219
102 225 139 224
103 209 141 228
105 210 142 229
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Synthesis of 5-(L-a-Aminoadipyl)-L-cysteinyl-D-valine and 
s-(L-ot-Aminoadipyl)-L-cysteinyl-D-valylg!ycine
Gordon A. Thomson, A. Ian Scott * and Robert L. Baxter *
Chemistry Department, University o f Edinburgh, West Mains Road, Edinburgh EH9 3JJ
An e f f ic ie n t  s y n th e s is  o f  S - ( L - a t - a m in o a d ip y l ) - L - c y s te in y l- D -v a lm e  (ACV; 1) a n d  S - ( L - x - a m in o a d i-  
p y l ) - L - c y s te in y l - o - v a ly lg ly c in e  (ACVG; 2) via th e  p ro te c te d  t r ip e p t id e  /V - b e n z y lo x y c a r b o n y l- 1  - (p-  
n it r o b e n z y l)  -5 -  ( l -  x - a m in o a d ip y l)  - S - b e n z y l- L - c y s te in y l- D - v a l in e ,  b e n z h y d ry l e s te r  (3) is  d e s c r ib e d .
In  the course  o f  studies on the b iosynthesis o f  the penicillins 
and  the ir acyclic p recu rso r,1 8-(L-x-am inoadipyl)-L-cyste- 
inyl-D-valine (A C V ; l ) , f  we required  an efficient synthesis o f  
the tripep tide  w hich co u ld  be utilised for the p rep ara tio n  o f  
13C labelled iso topom ers. In ad d itio n  we w ished to  prepare 
8-(L-a-am inoadipyl)-L-cysteinyl-D -valylglycine (A C V G ; 2), 
for b iosynthetic  studies. A te trap ep tid e  w ith this sequence o f 
am ino-acids bu t o f  undefined stereochem istry  has been 
isolated from  a f}-lactam p roducing  Cephalosporium sp.1 bu t 
its significance in penicillin biosynthesis is as yet unknow n.
Five syntheses o f the A CV  tripep tide  have been reported  
previously in the lite ra tu re  3-4 each  o f  w hich utilise different 
strategies a n d /o r  p ro tec ting  g roups. T w o d istinct rou tes have 
been em ployed involving e lab o ra tio n  from  either the  valine 
carboxy  3-4 o r  the am in o -te rm inus.6 Since it was o u r in tention  
to p repare  iso topom ers labelled in the valine residue the 
overall yield from  D-valine was o f p a ram o u n t im portance  and 
necessitated an  ap p ro ach  using the second strategy. We 
report here a synthesis o f  A CV  (1) by a  rou te  em ploying 
benzyl-based an d  benzhydry l-based  pro tec ting  groups w hich 
offers the advan tage  o f  rem oval o f  the p ro tecting  groups by 
reduction  w ith sod ium  in liqu id  a m m o n ia 6 o r  selective 
depro tection  o f  the valine carboxy -g roup  to  afford, in a  single 
step, the acid  (4) as the in term ediate  fo r the synthesis o f 
A C V G  (2).
T rea tm en t o f  ¿V -benzyloxycarbonyl-L-x-am inoadipic acid  7 
(6a) w ith p -n itrobenzy l b rom ide and  one equivalent o f  tri- 
ethylam ine in d im ethy lfo rm am ide afforded  the ester (6b) in 
50% yield. C oup ling  o f  th is derivative w ith S-benzyl-L- 
cysteine, benzhydryl e s t e r '  (7) was carried  o u t w ith l- 
hydroxybenzotriazo le  and  d icyclohexylcarbodi-im ide ’ to  give 
the fully pro tec ted  d ipep tide  (8a). R em oval o f  the benzhydryl 
protecting  g ro u p  was achieved in v irtually  q u an tita tiv e  yield 
by m ild  acid  hydrolysis an d  the resulting  d ipep tide acid  (8b) 
coupled  w ith D-valine benzhydryl ester using 1-hydroxy- 
benzotriazo le  and  d icyclohexylcarbodi-im ide to afford the 
fully p ro tec ted  tripep tide  (3) in 22% overall yield from  (6a).
R eduction  o f  the p ro tec ted  ACV (3) w ith sod ium  in liquid 
am m onia  gave the u np ro tec ted  tripep tide (1). Iso lation  as the 
co rrespond ing  su lph ide follow ed by regeneration  w ith 
hydrogen sulph ide afforded  A CV  in apparen tly  77% yield. 
H ow ever e lem ental analysis o f  the freeze-dried p roduc t 
show ed it to  con ta in  ca. 4% inorgan ic  con tam in an ts .4 The 
p roduct w as show n to  be a 3 : I m ixture o f (1) and  the co r­
responding  d isu lph ide (9) by E tlm an ’s p rocedure 10 and  by 
paper elec trophoresis. T o  circum vent the inhom ogeneity  
in troduced  by the above procedure  the crude p roduc t from  the 
reduction  was oxidised by passing a ir th rough  an  aqueous 
so lu tion  an d  the resu ltan t d isu lph ide 5 (9) isolated by ion 
exchange ch ro m ato g rap h y . T he p ro d u c t ob ta ined  in this 
m anner, in 96% yield from  (3), was hom ogeneous by paper
t  a-Aminoadipyl = 5-amino-J-carboxypentanoyl
elec trophoresis, h .p .l.c ., and  t.l.c. and  p roved  free o f  inorgan ic  
con tam inan ts . C onfirm ation  th a t the p ro d u c t was the desired 
d isulphide (9) w as o b ta ined  from  the 13C n .m .r. spectrum  
w hich show ed a resonance a t 38.5 p .p .m . co rrespond ing  to 
C-3 o f the cystine residue. In  co n tra st the spectrum  o f  the 
m onom eric  tripep tide  show ed a  peak a t 26.1 p .p .m .4 fo r 
C-3 o f  cysteine. O x idation  o f  (9) w ith  perform ic acid  11 
afforded the su lphon ic  acid  ( I f )  w hich proved  to  be ch ro m ato - 
g raphically  and  spectroscopically  identical w ith m ateria l 
p repared  from  A C V  isolated from  Cephalosporium acre- 
m onium  N -2 .1
W ith the p ro tec ted  tripep tide  (3) in hand , synthesis o f  
A C V G  (2) cou ld  now  be carried  o u t in a  stra igh tfo rw ard  
m anner. D epro tec tion  o f  the valine carboxy-group  by m ild 
acid  hydrolysis afforded  the acid (4). C oup ling  o f  (4) w ith 
glycine benzyl ester using dicyclohexylcarbodi-im ide and  I- 
hydroxylbenzotriazo le  as above gave only  p o o r yields o f  the 
desired p roduc t, the m ajo r p ro d u c t being the co rrespond ing  
W-acyl u rea .12 In  co n tra st, trea tm en t o f  (4) w ith ethyl ch lo ro - 
fo rm ate in the presence o f  pyrid ine to  afford  a m ixed an h y ­
d ride and  subsequent reaction  o f  the anhyd ride  w ith glycine 
benzyl ester gave the desired p ro d u c t (5) in 46% yield from  (3). 
S o d ium -liqu id  am m o n ia  reduc tion  o f  (5) follow ed by o x id ­
a tion  and  purifica tion  o f  the p ro d u c t by ion-exchange ch ro ­
m atog raphy  as described fo r (9) above gave the te trapep tide  
d isulphide (10).
T he d isulphides (9) and  (10) w ere quan tita tive ly  reduced to  
the respective m onom ers (1) and  (2) w ith an  excess o f  ethane- 
th io l. T he overall yields o f  A CV  (A C V G ) from  D-valine an d  
S-benzyl-L-cysteine by the rou te  described were 68 (24%) and  
43 (15%) respectively, w hich com pare  favourab ly  w ith yields 
achieved in previous syn theses.3-4
Experimental
E lectrophoresis was carried  ou t a t 50 V/cm on  W h a tm an  
3M M  paper using the ap p a ra tu s  described by M ich l,13 pH  
2.1 and  3.5 buffers were p repared  as described by A m b le r.1* 
M erck silica G 60 (70— 230 m esh) w as used for colum n 
ch rom atog raphy  an d  p repara tive  t.l.c. was carried  o u t on 
200 x 200 x 1 m m  layers o f  M erck 60G F254 silica. T h io l 
de term inations were carried  o u t using E llm an’s p ro ced u re .10 
L-x-A m inoadipic acid  [x]D“  + £ 4 °  (c 2.0, 5m-HC1) ( lit.,15 
(a]D +-25’ ) was purchased  from  Sigm a C hem ical C o. Inc. 
Solvents were purified an d  dried  by s tan d a rd  procedures and  
organ ic  ex trac ts typically d ried  over M g S 0 4 o r N a2S 0 4. 
N .m .r. spectra  w ere recorded  on V arian  EM 360, B ruker 
W M 300, o r  B ruker W M 360 spectrom eters . M ass spectra  (e.i.) 
w ere recorded  on an  A E I MS901 an d  a K ra to s  M S50 using a 
FA B  source.
p-N itrobenzyl N -Bertzyloxycarbonyl-L-x-am inoadipate
(6b).— ¿V -B enzyloxycarbonyl-L-x-am inoadipic acid 7 (2.065 g, 
7.00 m m ol) was dissolved in d im ethy lfo rm am ide (5 cm 3),
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nh> A
H ' r r u R 4C 0 2 ‘
( 1 )  R 1 : R 2 = R 3 : R ‘ = H
( 3 )  R1 = P h C H 2OCO . R 2 = p - N 0 2 C 6 H 4 C H 2 
R 3 = PhCH2 , R 4 .  P h 2 CH2
( 4 )  R 1 = P h C H j O C O  . R 2 = p - N 0 2 C 6H 4 CH2, 
R 3 = P h C H 2 . R4 :  H
R NH
C 0 2 R 4 
( 2 ) R ' : R 2 : R 3: R 4: H
( 5 )  R 1 = P h C H 2 O C O , R 2 - p -  N 0 2 C 6 H 4 C H 2 , 
R 3 = P h C H 2 . R 4 = Ph  C H 2
C 0 2H




a  . R 1 = PhC H2OCO . R 2 =H 
b , R1 = Ph  C H2OCO .
R 2 = p -  N 0 2 C 6 H 4 C H 2
R 1 :  P h  C H 20  C 0  . R 2 = p  -  N 0 2 C 6Ha C H 2 . 
R 3 = P h C H 2 , R 4 r P h 2CH 
R 1 = P h C H 2OCO . R 2 = p - N 0 2 C5 H 4 C H 2. 
R 3 = P h C H2 . R 4 r H
trie thy lam ine  (1.02 cm 3, 7.35 m m ol) added , and  the o lsu tion  
cooled  to  0 °C. T o  the stirred  so lu tion , p -n itrobenzyl b rom ide 
(1.588 g, 7.35 m m ol) w as added  in a liquots du ring  5 h. T he 
reaction  m ixture was allow ed to  com e to  room  tem peratu re  
overn igh t, a fter which sa tu ra ted  aqueous N aC l (25 cm 3) was 
ad d ed ; the m ixture was then ad justed  to  pH  1 w ith 5m-HC1 
and  ex tracted  w ith E tO A c (30 cm 3 x 4). T he extracts were 
ev ap o ra ted  to  yield a yellow oil w hich was ch rom atog raphed  
on  silica (200 g) w ith E tO A c-n -h ex an e  (7 : 3) as e luan t to  
afford (6b) w hich crystallised from  E tO A c-n -h ex an e  (1.22 g, 
50%), m .p. 101 — 104 °C ; [a]D20 -  8.01° ( r  2.0, acetone) 
(F o u n d : C , 58.4; H , 5.1; N , 6.45. C 21H 22N 2O s requires C , 
58.60; H , 5.15; N , 6.51% ), 6(60 M H z, CDC13) 1.45— 2.05 
(4 H , m, 3, 4-H ), 2 .3 7 (2  H , t , . / 5 .5  H z, 5-H), 4 .18—4.70 (1 H, 
m, 2-H ), 5.12 and  5.23 (4 H , 2s, benzyl-H ), 5.4 (1 H , m, N H ), 
7.32 (5 H , s, A rH ), 7.43 and  8.13 (4 H , 2 d , J  9 Hz, A rH ),
' C 0 N H
C 0 2H
C 0 N H  I
COR
( 9 )  R = 0 H
(10) R = N H C H 2 C 0 2H
NH,
' C0 NH
C 0 2H H. Y ^ 5 0 SH
XCONH 
>
H C 0 ,H
(11 )
> r  SC H2Ph 
C 0 2 C H Ph 2
( 7 )
8.75 (1 H , s, C 0 2H ); m /z  430 (M  +), 306, an d  250.1091 
(C 23H ,6N 0 4 requires 250.1079), 206.1168 (C 12H I6N 0 2 requires 
206.1181).
N -Benzyloxycarbonyl-\-(p-nitrobenzy[)-& -(L-x-am inoadi- 
pyl)-S-benzyl-L-cysteine, B enzhydryl E ster  (8a).— S-Benzyl- 
L-cysteine (0.422 g, 2 m m ol) w as converted  in to  the co r­
respond ing  benzhydryl ester as p reviously  described .’ T he  
crude p ro d u c t w as added  to  a  so lu tion  o f  (6b) (0.88 g, 2.05 
m m ol) an d  1-hyd roxybenzo triazo le  h y d ra te  (0.284 g, 2.1 
m m ol) in E tO A c (10 cm 3). T o  th e  stirred  so lu tion , dicyclo- 
hexycarbodi-im ide (0.433 g, 2.1 m m ol) in E tO A c (5 cm 3) w as 
added  and  the m ixture stirred  overn igh t. A fter ad d ition  o f  
oxalic acid  d ihyd ra te  (13 mg) the so lu tion  w as stirred  fo r 1 h, 
filtered, an d  the filtra te  w ashed successively w ith aqueous HC1 
(1m; 30 cm 3), w ater (30 cm 3), an d  sa tu ra ted  aqueous N a H C 0 3 
(30 cm 3), w ater (30 cm 3) an d  sa tu ra te d  N aC l (30 cm 3). 
E vapo ra tion  afforded an oil w hich was ch ro m ato g rap h ed  on 
silica (150 g), w ith E tO A c-n -h ex an e  (6 : 4) as e luan t, to  give 
(8a) w hich w as crystallised from  E tO A C -n -h ex an e  (1.01 g, 
64%), m .p . 122— 127 °C ; [a]DJ0 - 5 .6 4 °  (c 1.0, C H 2C !2) 
(F o u n d : C, 66.65; H , 5 .6; N , 5.1. C ^ H ^ N ^ s S  requires C , 
66.90; H , 5.49; N , 5.32%), 5(360 M H z, CDC13) 1.68— 1.90br 
(4 H , m , am inoadipyl 3,4 -H ), 2.15— 2.26br (2 H , m, am ino- 
adipyl 5-H ), 2.85 (2 H , AB o f  A BX  8A 2.91, 5B 2.79, J  13.9, 
4.7, 6.4 H z, cys 3-H ), 3.58 (2 H , A B ; 5A 3.62, 5B 3.54, J  13.4 
Hz, S C //2Ph), 4.41 (1 H , m , am in o ad ip y l 2-H ), 4.90 (I H , 
M o f  A B M X , J  4.7, 6.4, 7.9 H z, cys 2-H ), 5.09 (2 H , A B ; 
8a 5.12, 8b 5.06, J  12.2 H z; O C tf2A r), 5.21 (2 H , AB, 8A 5.24, 
8b 5.19, J  13.6 H z, O C / /2A r), 5.47 (1 H , d, J  7.9 H z, N H ),
6.19 (1 H , d , J  7.8 H z, N H ), 6.86 (1 H , s, C / /P h 2), 7.18— 7.41 
(20 H , m , A rH ), 7.46 and  8.17 (4 H , 2 d , /  8.5 Hz, A rH ); 
m /z  698 (Af -  91), 622 ( M  -  167), 167, and  91.
N -B enzyloxy carbonyl-1 -(.p-nitrobenzy[)~b-(L-a.-amino- 
adipyl)-S-benzyl-L-cysteinyl-D -valine, B enzhydryl Ester (3)—  
T he protected  d ipep tide (8a) (0.59 g, 0.75 m m ol) was d is­
solved in 0.2m  H C l-n itro m e th an e  (19 cm 3) and  the so lu tion  
stirred  at room  tem pera tu re  fo r 5 h ; it was then evapora ted  
to  give an  oil w hich was subjected  to  co lum n ch ro m ato g rap h y  
on silica (30 g), w ith E tO A c-n -h ex an e -H O A c  (90 : 1 0 :0 .4 )  
as e luan t to  afford the free acid (8b) (0.46 g, 98%) as a co lo u r­
less foam .
T he acid  (8b) w as added to  a so lu tion  o f  1-hydroxybenzo- 
triazo le  hydrate  (0.11 g, 0.83 m m ol) and  D-valine, benzhydryl 
ester [prepared from  D-valine (97 mg, 0.83 m m ol) as des­
cribed  ’] in E tO A c (7.5 cm 3). D icyclohexylcarbodi-im ide
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(0.17 g) in E tO A c  (5 cm 1) was added, the reaction  m ix ture  
stirred  overn igh t, trea ted  with oxalic acid, an d  w ashed  as 
described above. E vapo ra tion  o f the organ ic  frac tion  affo rded  
crude (3) w hich w as purified by colum n ch ro m ato g rap h y  on 
silica (30 g), w ith E tO A c-n-hexane ( 6 : 4 )  as e luan t, and  
crystallised from  C H 2C l2-e the r-n -h ex an e  as colourless 
needles (0.47 g, 71%), m .p. 77— 80 °C rem elting a t 133—  
135 °C ; [ a W °  - 1 1 .9 °  (c 1.0, acetone) (F o u n d : C , 66.4; 
H , 5 .8 ; N , 6.0. C 49H 52N 4O 10S requires C , 66.20; H , 5.90; N , 
6.30% ); 8(300 M H z, CDC13) 0.75 (3 H , dd, /  6.9, 1.1 H z, 
val 4 -H ), 0.87 (3 H , d , /  7.0 Hz, val 4-H ), 1.68— 1.85 (4 H , m, 
am inoad ipy l 3, 4-H ), 2.10— 2.26 (3 H , m, am inoad ipy l 
5-H , val 3-H ), 2.74 (2 H , AB o f A B M X ;  8A 2.84, 8B 2.68, /  
14.0, 7.0, 6.1, 2.1, 1.8 H z, cys 3-H), 3.72 (2 H , s, S C //2Ph),
4.36— 4.41 (1 H , m , am inoadipyl 2-H), 4.55— 4.66 (2 H , m , 
cys 2 -H , val 2 -H ), 5.09 (2 H , A B; 5A 5.11, 5„ 5.06, /  II  .9 H z, 
O C H 2A t), 5.20 (2 H , A B ; 5A 5.23, 8B 5 .1 7 ,/  13.7 H z, O C H 2- 
A r), 5.74 (1 H , dd , /  4.1, 7.8 H z, N H ), 6.50 (1 H , dd, /  7.3,
4.3 H z, N H ), 6.87 (1 H , s, C H ? h 2), 6.95 (1 H , m , N H ), 
7.17— 7.37br (20 H , m , A rH ), 7.43 (2 H , m, A rH ), and  8.16 
(2 H , d, / ,  8.9 H z, A rH ); m /z  797 (M  — 91), 752, 721, 167, 
and  91.
'N-Benzyloxycarbonyl-l-(p-nitrobenzyl)-5-(i.-<x.-aniino- 
adipyl)-S-benzyl-L-cysteinyl-D -valylglycine, Benzyl Ester (5). 
T he benzhydry l ester (3) (0.2 g, 0.23 m m ol) was hydrolysed 
to  th e  free acid  (4) (0.16 g) as above and the p roduct dissolved 
in d ry  T H F  (3 cm 3). Pyridine (20.0 pi, 0.25 mm ol) was added , 
the so lu tion  cooled  to  0 °C and a solution o f ethyl ch lo ro - 
fo rm ate  (23.8 pi, 0.25 m m ol) in T H F  (2 cm 3) added  in one 
po rtio n . T h e  so lu tion  was stirred fo r 15 min at 0 °C w hen a 
so lu tion  o f  glycine benzyl ester, toluene-p-sulphonic acid salt 
(83.6 m g) an d  pyrid ine (20.0  pi) in C H 2C12 (3 cm 3) was added  
and  the m ix tu re  allow ed to w arm  to  room  tem peratu re  over­
n igh t. A fte r ev ap o ra tio n  o f  the solvent the residue was d is­
solved in E tO A c (15 cm 3), and the solution washed succes­
sively w ith  aq u eo u s HC1 (1m ; 10 cm 3), w ater (10 cm 3), and  
sa tu ra te d  aq u eo u s N aC l (10 cm 3) and then dried, and  ev ap o ­
ra ted . T he  residue was subjected to preparative t.l.c. on silica, 
w ith C H 2C l2-M e O H  ( 1 9 : 1 )  as eluant, and the purified 
p ro tec ted  A C V G  crystallised from  C H 2C l2-E tO H -n -h ex an e  
as a m icrocrysta lline  solid (90 mg, 46%), m .p. 155— 158 °C,
[a]D20 - 7 .4 °  [c 1.0, C H 2CI2-M eO H  ( 1 : 1 ) ]  (F o u n d : C , 61.85; 
H , 6 .15; N , 7.8. C45H 51N 50 , 1S requires C, 62.13; H , 5.91; 
N , 8.05% ), S[300 M H z, C D C i3 : C D 3O D  ( 1 : 1 ) ]  0.88 and  0.91 
(6 H , 2 d, /  6.8 H z, val 4-H ), 1.66—  1.85br (4 H , m, am in o ­
adipyl 3, 4 -H ), 2.13— 2.23br (3 H, m, am inoadipyl 5-H , 
va! 3-H ), 2.68 (2 H , AB o f ABX;  5A 2.74, 5B 2 .6 3 , /  13.8, 7.4,
6.5 H z, cys 3-H ), 3.69 (2 H, s, S C //2Ph), 4.24, 4.30, 4.46 
(3 H , 3 m , 3 x 2-H ), 5.06 (2 H , A B; 8A 5.09, 5B 5.03, / 12.2 
H z, O C / /2A r), 5.11 (2 H , s, O C / /2A r), 5.20 (2 H , A B ; 5A 
5.23, 8 a 5.17, /  13.5 Hz, O C H 2.\r ) , 7.20— 7.35 (15 H , m, 
A rH ), and  7.45 and  8.15 (4 H , 2 d, /  8.6 Hz, A rH ).
8-(L-z-Aniinoadipyl)-L-cysteinyl-D -ialine  (A C V ; I ).—
T ypically  the p ro tec ted  tripeptide (3) (100 mg, 0.12 m m ol) was 
s tirred  in liqu id  N H 3 u nder N 2 and small pieces o f  freshly 
cut N a  added  unti l  the blue co lour persisted for 5 min. Solid 
N H 4O A c (ca . 100 mg) was added , the N H 3 evaporated  under 
a s tream  o f  d ry  N 2, and  the residue desiccated over H 2S 0 4. 
T he p ro d u c t w as iso latad  as follows.
Procedure A . T he  residue was dissolved in 5% (v/v) aqueous 
H O A c (5 cm 3), the so lu tion  filtered and a 10°.0 (w/v) so lu tion  
o f H g(O A c)2 in 5% (v/v) aqueous H O A c added slowly to  the 
filtrate to  afford  a p recip itate o f the tripeptide sulphide. The 
p rec ip ita te  w as separated  by centrifugation  and w ashed 
sequentially  wi th degassed w ater (5 cm 3 >• 4), M eO H  (5 
cm 3 x 2), and  e ther (5 cm 3). The dried residue was resus­
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pended  in degassed w ater (2 cm 3) and  a s tream  o f  H 2S passed 
th ro u g h  the suspension fo r 15 m in. A fte r sep a ra tio n  by 
cen trifugation  the pellet o f HgS was w ashed  w ith w ater (1 cm 3) 
an d  the com bined su p ern a tan t liquid an d  w ashings filtered 
th rough  Celite. T he filtrate was degassed in vacuo a n d  lyoph- 
ilized to  afford a m ixture o f  (1) and  th e  co rresp o n d in g  d i­
su lph ide (9) as a colourless pow der (31.5 m g, 77%) (F o u n d ; 
C , 44 .75 ; H , 6.85; N , 11.1; ash , 4% . C u H ^ N ^ S  requires C , 
46 .30 ; H , 6.87; N , 11.57%). F ree  th io l 75% , m /z  (FA B S) 364 
[m onom er (A / +  1)].
Procedure B. T he residue w as dissolved in  5% (v/v) aqueous 
H O A c (5 cm 3), extracted  w ith e ther (2 cm 3 x 2), and  the 
aq ueous layer lyophilized. T he residue w as dissolved in w ater 
(5 cm 3), the pH  ad justed  to  8, and  the so lu tio n  ae ra ted  fo r 2 h. 
T he  so lu tion  was freeze dried , th e  residue  dissolved in w ater 
(100 pi) and  subjected to  ion exchange ch ro m ato g rap h y  on 
B io rad  A G  50 x 2 resin (200— 400 m esh, H  + , 18 x 1.5 cm ) 
w ith a w ater-1 M-pyridine g rad ien t as e lu an t. L yoph iliza tion  o f 
the n inhydrin  positive fractions gave A C V  d isu lph ide as a 
colourless pow der (39 mg, 96%), m .p. 200— 203 °C  (decom p.), 
r<x]D20 - 9 .5 °  (c 2.0, 2m-HC1) (lit.,3 [oc]D - 9 . 5 ° ;  lit.,5 [<x]D -1 1 .0 = ) 
(F o u n d : C , 46.2; H , 6.35; N , 11.0. C a H ^ O . j S ,  requires 
C , 46 .40; H , 6.67; N , 11.59%), 5(300 M H z, D 20 )  0.27 (3 H , 
d, / ,  6.9 H z, val 4-H ), 0.32 (3 H , d , / ,  8.5 H z, val 4-H ), 1.06—
1.27br (4 H , m, am inoad ipy l 3,4-H ), 1.54br (1 H , m , val 
3-H ), 1.76br (2 H , m, am inoad ipy l 5-H ), 2.40 (2 H , A B, cys 
3-H ), 3.18 (1 H , m, am inoad ipy l 2 -H ), an d  3.58 (1 H , m, 
val 2 -H ); 5C (75 M H z, D 20 )  17.14 and  18.52 (val 4-C), 20.70 
(am inoad ipy l 4-C), 29.57 and  30.07 (val and  am inoad ipy l 
3-C), 34.56 (am inoadipyl 5-C), 38.49 (cys 3-C), 52.43, 59.51, 
and  59.77 (3 x 2-C ); m /z  (FA B ) 725 ( M  +  1) an d  364.
5-(L-3.-Aminoadipyl)-L-cysteinyl-D-vaIy!glycine (A C V G \ 
2).— D epro tection  o f  the te trapep tide  derivative (5) (54 mg, 
0.06 m m ol) was carried  ou t in a  m an n er iden tical w ith th a t o f 
(3) above. Iso lation  using procedure  B afforded  A C V G  as 
its d im er (10), a colourless pow der (19.4 m g, 74%), m .p. 
230— 235 °C (decom p.) (F o u n d : C , 46 .05 ; H , 6 .2 ; N , 12.3. 
C 32H 54N 80 , 4S2 requires C , 45.8; H , 6 .5 ; N , 13.35%), 5(300 
M H z, D 20 )  0.25 and 0.28 (6 H , 2 d , /  7.5 H z, val 4-H ),
l . l Obr  (4 H, m, am inoadipyl 3,4 -H ), 1.48br (1 H , m , val 
3-H ), 1.63— 1.72 (2 H , m, am inoad ipy l 5-H ), 2.40 (2 H , AB 
o f A B X ; 5a 2.48, 5B 2.33, /  13.9, 7.4, 5.8 H z, cys 3-H ), 3.07 
(1 H , t, /  5.6 Hz, am inoadipy l 2-H ), 3.20 (2 H , s. gly 2-H ), 
and  3.54 (1 H, m, val 2 -H ); m /z  (F A B ) 839 (M  +  1) and  421.
Q uan tita tive  reduction  o f  (10) to  the m o n o m er (2) was 
carried  ou t by brief trea tm en t w ith 5% (v/v) aq ueous ethane- 
th io l. T he freeze-dried residue was hom ogeneous by e lec tro ­
phoresis and  t.l.c. R eduction  o f  (9) was carried  o u t in a sim ilar 
m anner.
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Synthesis and Biological Activity of 6-(L-a-Aminoadipoyl)-L-cysteinyl-/V-hydroxy- 
D-valine:t a Proposed Intermediate in the Biosynthesis of the Penicillins
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6 -(L -a -A m in o a d ip o y l ) -L -c ys te in y l - /V -h y d ro x y -D -v a l in e  (3a) has b een  p re p a re d  f ro m  the  a p p ro p r ia te ly  p ro te c te d  a m in o  
acids; (3a) w a s  no t  c o n v e r te d  in to  isopenic i l l in  N (2) using a ce ll- f ree  s y s te m  f ro m  Cephalosporium acrem onium  b ut  
inh ib ited  th e  fo r m a t io n  o f  (2) f r o m  6 -(L -a -a m ino a d ip o y l) -L -c y s te in y l-o -v a l in e  (1) by this system .
W hile it is now  genera lly  accep ted  tha t the cyclisation of the 
tr ip ep tid e , 6-(L-a-am in6adipoyl)-L -cysteinyl-D -valine (1) to 
isopenicillin N (2) is the final step  in the series o f reactions 
com m on to  pencillin  and  cephalosporin  b iosyn thesis ,1 the 
m echanism s by w hich the P-lactam  and th iazolidine rings of 
the penam  nucleus a re  e lab o ra ted  in vivo  rem ain  unexplained. 
O n the basis o f in vitro  analogy several m echanism s for the 
fo rm ation  o f  the ^-lac tam  ring have been  p ro p o sed .2 3 O ne 
such possib ility  involves enzym ic hydroxylation  at the n itro ­
gen of th e  D-valine res idue  of (1) to  genera te  a hydroxam ic 
acid (3a) fo llow ed by abstrac tion  of the cysteinyl 3-pro-S  
p ro ton  and  ring  closu re  w ith elim ination  of the N -hydroxy 
group  o r o f th e  acyl g ro u p  of an /V-acy! derivative (3b) to 
afford an enzym e bo u n d  P-lactam  derivative (4, R =  
e n z y m e ) . T h i s  ro u te  ap p ears  a ttrac tive  since a num ber o f 
m icrobial p ep tid e  hydroxam ic acids have been  iso lated4 and 
the feasib ility  o f  such a pa thw ay has been  dem onstra ted  by a 
m odel chem ical re ac tio n 3 (Schem e 1). W hile recent resu lts5 
have show n th a t th e  oxygen a tom s o f the a-am inoadipoyl




residue  o f (1) are  re ta in ed  in the enzym ic conversion  of (1) 
in to  (2), p rec lud ing  in term ediacy  of a th iazo linesu lphone  o r a 
th iazo line species, the re ten tion  of the 6 -carbonv l oxygen does
H
(1) r ' , s ! , h 
(3)0. r ' * H. R2«OH
b, R1 * enzyme. R = Oacyl or OH
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Scheme 1. R = 4-NO:C^H,SO:-.
not obv ia te  the possible role o f a linear A -hydroxy derivative 
such as (3a) as an in te rm ed ia te . T o test this hypothesis it was 
necessary to  p rep a re  the A -hydroxy tripep tide  (3a) and to 
evaluate it as a substra te .
A ttem p ts  to p rep a re  a p ro tec ted  derivative of (3a) directly 
by acylation of (5)h w ith the  p ro tec ted  d ipep tide (6 )7 afforded 
only the O -acyl derivative (7). S im ilarly, acylation of (5) 
with A -benzyloxycarbonyl-S -benzyl-L -cysteine (8a) u nder a 
variety of pep tide  coupling cond itions y ielded the O-acyl 
derivative (9) as the m a jo r p ro d u c t. Selective A -acylation 
of (5) with A -(4-m ethoxybenzyloxycarbonyl)-5-benzyl-L - 
cysteine (8b) to  give (10) and  su b sequen t e labora tion  to  the 
desired A '-hydroxytripeptide (3a) w ere carried  ou t as shown in 
Scheme 2.+
The A '-hvdroxytripeptide (3a), gave a positive colour 
reaction w ith ferric  ch loride in so lu tion  and exhibited  an ion at 
m z 378 [378.1327, (M  -  1) - ,  C u H ^ N iC T S  requires 
378.1329] in its negative ion m ass spectrum  (fast atom  
bom bardm ent). T he l3C  n. m. r .  spectrum  (75 M H z. D : 0 )  
exhibited resonances at b 19.57, 19.65 (val C-4, 4 ') . 21.73 (aaa 
C-4), 25.54 (cys C -3). 28.61 (val C -3). 30.55, 35.54 (aaa C-3. 
5), 53.13. 55.15 (cys C-2, aaa C -2), and  66.61 p .p .m . (val C-2). 
The observation  of the A '-hvdroxy-D -valine C-2 resonance at 
higher frequency  than  the chem ical shift o f the valine C-2 in 
the spectrum  of (1) (6 59.77 p .p .m .)7 appears diagnostic of the 
hydroxam ic acid s truc tu re  In the spectrum  of A-hydroxy-D- 
valine benzyl este r (5) in D ; 0  the a  carbon  resonance appears 
at 6 72.81 p .p .m . while in the spectrum  of (12) in CDC13 the 
corresponding  carbon  re so n a tes  at 6 63.10 p .p .m .
The A -hvd roxy tripep tide  (3a) was adm inistered  to a p a r­
tially purified  enzym e system  derived  from  hom ogenised cells 
of C. acrem onium  C W -19lb u n d er cond itions in which (1) was 
efficiently converted  in to  (2).§ T he resu ltan t incubation 
m ixture was assayed for isopenicillin  N production  using a 
hole-plate assay w ith S taphococcus aureus . 8 No significant 
antibiotic activity was d e tec ted  and  the A -hydroxytripep tide 
could be recovered  unchanged  from  the incubation  m ixture 
suggesting that the com pound  is not directly  involved as a free 
in term ediate  in the enzym atic  conversion  of (1) into (2).
t Satisfactory elemental analyses and concordant spectroscopic data 
were obtained for compounds described in Scheme 2.
§ Incubations were carried out at 25 °C on a gyrorotatory shaker at 210 
r p m. in 50mM 3-(A-morpholino)propanesulphonic acid buffer, pH 
7.2, containing 1.3 mM F eS 04 and 2.5 mM dithiothreitol with a protein 
concentration of 5.5 mg/ml and substrate concentrations of 
0.15— 3.0 mM. For 0 3 mM (1) conversions were typically in the range 








Sbz bocNH oV  "MA
H ' ' i  nbzO.C
co2h
OCO,Et
( 8 ) a . R * boc 
b; R = mboc
( 11)
Scheme 2. Reagents i. (8b)-dicyclohexylcarbodi-tmide (1 mol. 
equiv.j-dimethylformamide; ii, H CI-M eN 02; iii, (U )-A - 
methylmorpholine-CH-Cl;,; iv, Na-NH,. Protecting groups, boc = 
benzyloxycarbonyl; mboc = 4-methoxybenzyloxycarbonyl; bz = 
benzyl; nbz = 4-nitrobenzyl.
H ow ever, add ition  of the A -hyd roxy tripep tide , at a concen­
tration  of 50|i m , to  the crude enzym e system  was found to 
com pletely  inhibit fo rm ation  of isopenicillin  N from  (1).
Pep tide hydroxam ic acids and A -acyl-A -hydroxypeptides 
are know n to be pow erfu l active site specific inh ib ito rs o f a 
num ber o f zinc con ta in ing  m eta llo p ep tid ases .9 W hile even 
relatively sim ple hydroxam ic acids inhibit A ero m o n a s  am ino- 
pep tidase , hydroxam ic acids co rrespond ing  to  L-amino acid 
am ides w hich act as substra tes for the m etailoenzym e have 
been show n to be p o ten t in h ib ito rs .10 It m ay be significant that 
acetohydroxam ic acid also inhibits conversion  of (1) into (2) 
by the C. acrem onium  enzym e system  but only at concen tra ­
tions h igher than those requ ired  for inhib ition  by the 
A -hydroxytripeptide.H
1 A ceto h y d ro x am ic  acid at 1 mM and (3a) at 40 pM w ere req u ired  for 
50%  inh ib ition  o f the conversio n  ol ( I )  in to  (2).
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E R R A T A
Page 7 line 11 Read "penicillinase" for "pencillinase".
Page 52 . line 5 Read "phosphoenolpyruvate" for "phosphoenal- 
pyruvate".
Page 78 Figure 41 Read "piperidine-2-carboxylic acid" for 
"piperadine-2-carboxylic acid".
Page 90 line 7 Read "amide anion" for "amide amion".
Page 91 lines! 2-3 Read "analogous" for "analagous".
Page 95 lines 3-4 Read "sterically constrained" for "sterically 
contained".
Page 132 line 2 Read "(94)" for "(78)".
Page 140 line 12 Read "polyamide" for "polyacrylamide".
Page 161 line 22 Read "CaC03" for "CaSO,,".
Page 229 line 19 Read "CaC03" for "CaS0„".
Page 230 line 5 Read "N,3.52" for "N,35.2".
Page 236 ref. 52 Read "G. N. Rolinson" for "G. N. Robinson".
Page 237 ref. 59 Read "G. N. Rolinson" for "G. N. Robinson".
Page 237 ref. 68 Read "G. N. Rolinson" for "G. N. Robinson".
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